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“We have bigger houses, but smaller families. More conveniences, but less time. We have 
knowledge, but less judgments; more experts, but more problems; more medicines but less 












































Heart failure: disease and diagnosis 
Heart failure is a major public health issue worldwide that is associated with increased 
disability and mortality.1 Currently, the prevalence of heart failure in the Western world is 
estimated at 2-3% and there are over 23 million people suffering from heart failure 
worldwide.2-4 The prognosis of heart failure is poor, with only 25-35% of heart failure 
patients surviving beyond 5 years after diagnosis.5, 6 Due to the ageing of the population and 
the improved survival of heart failure patients, the number of heart failure patients is 
expected to increase even further in the future, placing a high burden on patients and their 
families as well as on society at large.7, 8 
 
Heart failure is a complex clinical syndrome which is characterized by an abnormality of the 
cardiac structure or function, leading to failure of the heart to deliver oxygen at a rate 
commensurate with the requirements of the metabolizing tissues.9 Common causes of heart 
failure include myocardial infarction, hypertension, valvular heart disease, viral infection, 
exposure to toxins, chemotherapy and cardiomyopathy. Some cardiomyopathies have 
genetic underpinnings, such as hypertrophic and non-compaction cardiomyopathy, while 
most others are acquired. The cardinal manifestations of heart failure differ based on the 
underlying cause and may include symptoms and signs such as dyspnea, fatigue, elevated 
jugular venous pressure, pulmonary crackles, and displaced apex beat.10  
 
Diagnosing heart failure can be difficult, especially in the early stages. Although symptoms 
alert patients to seek medical attention, many heart failure symptoms are non-specific and 
do therefore not help discriminate between heart failure and other conditions.10 Routine 
tests for diagnosing suspected heart failure are an echocardiogram, electrocardiogram, chest 
X-ray and routine laboratory tests. A laboratory test for heart failure which has emerged in 
the last 10-15 years is the measurement of cardiac hormones, such as natriuretic peptides. 
Natriuretic peptides are markers of neurohormonal activation which are secreted by 
cardiomyocytes when the heart is diseased or the load on any chamber is increased. The two 
most commonly used natriuretic peptides are B-type natriuretic peptide (BNP) and N-
terminal pro B-type natriuretic peptide (NT-proBNP).10-12 Increased BNP levels have been 
shown to be strong indicators for a poor prognosis, but also to be of value in guiding therapy 






Heart failure is usually a progressive disease, caused by cardiac remodeling of the wall of the 
left ventricle. Heart failure can be divided into different stages, with specific treatments 
being available at each stage to relieve symptoms, prevent hospital admission, and improve 
survival.1 Pharmacological therapy, including vasodilators, angiotensin-converting-enzyme 
inhibitor (ACE)-inhibitors and beta-blockers, are usually the first line of treatment, followed 
by more rigorous medical interventions such as a percutaneous coronary intervention, 
coronary artery bypass grafting, implantation of an implantable cardioverter defibrillator 
with or without cardiac resynchronization therapy (i.e. ICD or CRT-D), a left ventricular assist 
device (LVAD) or heart transplantation. 
 
ICD/CRT-D 
An ICD is a small battery-powered electrical impulse generator that constantly monitors the 
rate and rhythm of the heart and can deliver therapies by means of anti-tachycardia pacing 
or a low- or high-voltage electrical shock to abort potentially life-threatening arrhythmias.14 
The ICD is the first choice of treatment for the prevention of sudden cardiac death due to 
potentially life threatening ventricular arrhythmias, since clinical trials have demonstrated its 
superiority over anti-arrhythmic therapy.15-17 ICD therapy can be indicated as primary or 
secondary prevention. Secondary prevention is indicated in patients who survived an initial 
sudden cardiac arrest, while primary prevention is indicated in patients who did not 
experience prior life-threatening arrhythmias but who are considered at high risk. A 
reduction in mortality of 26% and 28% was found with ICD therapy compared to anti-
arrhythmic drugs for primary and secondary prevention, respectively.15, 17 
 Approximately one third of patients with heart failure suffer from a prolonged QRS 
duration (>120 ms), which leads to a disruption of the normal, coordinated and 
simultaneous distribution of the electrical signal to the two ventricles. For these patients, 
cardiac resynchronization therapy (CRT) may be indicated, which helps to restore left 
ventricular systolic function by correcting the electro-mechanical dyssynchrony, thereby 
facilitating that blood is pumped throughout the body more efficiently. In addition, CRT has 
been shown to improve exercise capacity and to reduce rehospitalization and mortality.16, 
18,19 A CRT device can be combined with an ICD, also called a CRT-D, combining the separate 























Left ventricular assist device (LVAD) 
Driven by the significant shortage of donor hearts and a simultaneous increase in the 
incidence of heart failure, LVADs are becoming an indispensible tool for patients with 
advanced heart failure whose medical treatment options have been exhausted.22 LVADs are 
mechanical circulatory implantable devices that are used to partially or completely replace 
the function of a failing heart by maintaining blood circulation and vital organ perfusion.23 
Some LVADs are intended for short term use, typically for patients recovering from a heart 
attack or heart surgery, while others are intended for long-term use (months to years and in 
some cases for life) for patients suffering from advanced heart failure. Long-term use of 
LVADs is either as a bridge to transplantation (BTT) in transplant candidates who show 
considerable clinical deterioration and are unable to wait any longer for heart 
transplantation, or as an alternative for heart transplantation (DT).24 In the Netherlands the 
use of LVAD therapy as BTT is expanding, however the use as DT is currently only allowed on 
a small scale with stringent criteria.         
 The first generation of LVADs are pulsatile pumps that mimic the natural pulsing 
action of the heart. These devices demonstrated to be superior with respect to survival 
compared to optimal medical treatment, with a reduction of 48% in mortality.25 However, 
due to their large volume and design a large dissection was required for implantation, with 
the result being that the device could not be implanted in patients with a small body size 
(Body Surface Area <1.5m2).          
            
12
In the last decade, several new devices have become available offering a greater 
durability and longevity. These devices are continuous flow pumps that can be subdivided 
into either centrifugal or axial flow pumps (Figure 2).26 To date, more than 6000 patients are 
implanted with a continuous flow pump. Among the continuous flow pumps, actuarial 
survival is 80% at 1 year and 70% at 2 years.27
Figure 2: Centrifugal LVAD pump (HeartWare®)22 and axial LVAD pump (HeartMate II®)28
The impact of heart failure on health status and psychological distress
Heart failure can have a tremendous impact on patients’ lives due to restrictions in 
functional capacity and a negative effect on social relationships, financial status and 
psychological well-being.29, 30 As a result, many heart failure patients report impaired health 
status.31,32 Health status is a multidimensional concept which assesses the patient’s 
perception of how a disease or treatment affects his/her symptoms and functioning.33  
Furthermore, patients with heart failure are disproportionately afflicted with 
psychological distress and psychiatric disorders, such as depression, anxiety and post-
traumatic stress.34 Depression is a mood disorder that interferes with a person’s ability to 
perform his or her day-to-day functioning, while anxiety is a negative affective state resulting 
from an individual’s perception of threat that is characterized by a perceived inability to 
predict, control, or gain the preferred results in given situations.34 The prevalence of 
depression and anxiety in heart failure patients ranges from 15-40%.35
Heart failure and its treatment options (i.e., CRT-D and LVAD) may also qualify as 











fear, persistence of painful intrusive memories, avoidance behavior and hyperarrousal, 
which is also known as post-traumatic stress disorder.36 In heart failure populations, 10-17% 
of patients suffer from post-traumatic stress.37       
 Symptoms of depression, anxiety and post-traumatic stress can be disabling, and are 
associated with increased risk for declines in physical health, mortality, higher medication 
costs, non-compliance with treatment, hospital readmissions and lack of adoption of 
secondary prevention behaviors, such as smoking cessation, physical activity, and cardiac 
rehabilitation.38         
Due to their potential impact on heart failure outcomes, health status and 
psychological distress are receiving increased recognition and are more often included as 
patient-reported outcomes in large clinical trials in addition to the clinical cardiovascular 
endpoints.39 Furthermore, there is a growing belief that patient-reported outcomes are as 
valid as the clinician’s perspective due to the acknowledgement that an illness and its 
treatment affect all domains of a patient’s life and not merely physical health.40 Information 
on patient-reported outcomes cannot be extracted from patients’ medical records or a proxy, 
emphasizing the importance of assessing PROs in their own right using self-report 
questionnaires. The questionnaires used for measuring patient-reported outcomes are 
either disease-specific or generic, thereby making it possible to compare outcomes with 
other heart failure patients, other disease groups, or healthy individuals, depending on the 
type of measure chosen.41 By measuring patient-reported outcomes in a structural manner, 
they may provide important additional information to health care providers and serve as 
targets for intervention in individual patients, with the potential to improve patient-centered 
care.39, 42 
 
The association between psychological distress and clinical outcomes of heart failure  
It is not well understood how psychological distress is linked to adverse clinical outcomes in 
patients with heart failure. Although some advocate that negative emotions may be a risk 
factor for heart failure, others suggest that heart failure may elicit psychological distress or 
that an interactional effect exists whereby negative emotions and heart failure affect one 
another in deleterious ways.34 Several mechanisms have been proposed that may explain 
the link between psychological distress and adverse clinical outcomes in heart failure 






mechanisms. Behavioral mechanisms include unhealthy lifestyle habits (e.g. smoking and not 
engaging in exercise) and poor medication adherence.43-45 Furthermore, impaired cognitive 
focus, reduced energy, and motivation associated with psychological distress might affect 
patients’ willingness and ability to follow through with treatment advice and to attend 
scheduled hospital appointments.46 Pathophysiological mechanisms constitute changes in 
cardiac rhythm, abnormal cardiac autonomic tone,47 increased platelet aggregation,48 
comorbidities and alterations in the hypothalamus-pituitary-adrenal (HPA) axis. In addition, 
inflammation is an acknowledged physiological mechanism through which distress may 
affect heart failure progression.49  
 
Inflammation 
Inflammation is part of the biological response of vascular tissues to harmful stimuli such as 
pathogens but also to distress and chronic illness.49 Important regulators of inflammation 
are called cytokines, which are soluble peptides that can mediate cell-to-cell interactions via 
specific cell surface receptors and regulate the activation, differentiation, death or 
acquisition of effector functions of the immune system. In addition, they mediate effects of 
the cells of the immune system on other cells and tissues.50 Through complex physiological 
pathways depression can stimulate pro-inflammatory cytokine release which exerts a 
deleterious effect on the heart by suppressing cardiac contractility, increasing the degree of 
atherosclerosis (plaque in artery walls) and by impeding cardiac remodeling.49, 51-53  The most 
common cytokines which are used as indicators of inflammation are tumor necrosis factor 
(TNF)-α, soluble TNF receptors 1 and 2 (sTNFr1 and sTNFr2), interleukin (IL)-6 and high 
sensitive C-reactive protein (hsCRP). Evidence has also been found for a reversed association 
in which inflammation is induced by heart failure, which can - when being exacerbated in 
duration and intensity - lead to a state of depression.54,55 This form of depression is 
characterized by somatic depressive symptoms56 and often referred to as sickness 
behavior.57 
 
Aims and outline of this dissertation 
The current dissertation focuses on health status and psychological distress, and their 
association with cardiovascular outcomes and inflammation, in different samples of heart 
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how psychological distress and health status are linked to prognosis via physiological and 
behavioral pathways that may be influenced by patient-related factors such as personality, 
socio-demographic and socio-economic characteristics and disease severity. 
 















Part one: Health status and psychological distress in patients with heart failure 
The first part of this dissertation addresses the health status and psychological distress of 
patients after implantation with an LVAD or in patients who are genetically predisposed for 
heart failure. Chapter 2 provides an overview of the knowledge on health status and 
psychological distress in patients implanted with a LVAD, thereby making a distinction 
between the first and second generation of devices. Chapters 3 and 4 elaborate on this topic 
and report on the results of a prospective multicenter study on health status and 






Chapter 5 examines the differential impact of genetic vulnerability versus disease severity in 
patients diagnosed with non-compaction cardiomyopathy, using a cross-sectional case-
control design. 
 
Part two: Psychological distress and clinical outcomes in heart failure 
Psychological distress is associated with increased risk for morbidity and mortality in patients 
with heart failure, but little is known about the mechanisms that may explain this link. It is 
also not clear whether treating psychological distress in heart failure patients, by means of 
psychological interventions, psychotropic medication or a combination thereof, will enhance 
survival. Chapter 6 examines the prevalence of anti-depressant use 5-years post heart failure 
diagnosis in a large sample of patients from the Danish heart failure registries. Furthermore, 
this chapter reports on the predictors of anti-depressant use and the relation between anti-
depressant use and all-cause mortality. Chapter 7 is a systematic review that evaluates the 
evidence for a link between psychological vulnerability, ventricular tachyarrhythmias, and 
mortality in patients with an ICD, and the physiological and behavioral pathways that may 
explain this link.  
 
Part three: Health status and psychological distress - the link with inflammation and 
cardiac hormones 
Cardiac hormones, such as brain natriuretic peptides, are markers of disease severity and 
valuable prognostic indicators in heart failure. Knowledge of the extent to which 
psychological distress in heart failure patients is associated with indicators of disease 
severity is important, as an association between both may indicate that psychological 
distress is confounded by disease severity and would then be a risk marker for prognosis 
rather than a risk factor. Chapter 8 examines the link between brain natriuretic peptide and 
the continuous and dichotomized scores of a broad range of psychological risk markers in a 
Danish cohort of heart failure patients.        
 Evidence suggests that inflammation is one of the mechanisms through which 
psychological distress may adversely affect clinical outcomes in heart failure patients, or vice 
versa. To examine the directionality of this association, Chapter 9 explores inflammation as 
one of the potential explanatory models for depression in heart failure, together with 











inflammation is not only linked to psychological distress, but also to positive measures of 
psychological and physical well-being in heart failure patients. Chapter 10 is based on the 
assumption that positive affect can act as a potential protective factor in the progression of 
chronic disease through a positive effect on inflammation. As there is an ongoing debate on 
the core characteristics of positive affect and how it should be measured, this chapter 
compares three different measures for positive affect and their association with 
inflammation in a sample of patients with chronic heart failure. Chapter 11 examines 
whether a significant clinical improvement after CRT-D implantation, based on an absolute 
increase in health status and decrease in echo parameters, is associated with a decrease in 
inflammation. 
 In Chapter 12 the main findings of this dissertation will be discussed and implications 
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Patient reported outcomes in left 
ventricular assist device therapy:
A systematic review and 
recommendations for clinical 
research and practice






Background: Technological advancements of left ventricular assist devices (LVAD) have 
created today’s potential for extending the lives of patients with end stage heart failure. Few 
studies have examined the effect of LVAD therapy on patient-reported outcomes (PROs) 
such as health status, quality of life and anxiety/depression, despite poor PROs predicting 
mortality and rehospitalization in heart failure patients. In this systematic review we provide 
an overview of available evidence on the impact of LVAD therapy on PROs, and discuss 
recommendations for clinical research and practice. 
Methods and Results: A systematic literature search identified 16 quantitative studies with a 
sample size n≥10 (mean±SD age=50.1±12.6 years) that examined the impact of LVAD 
therapy on PROs using a quantitative approach. Initial evidence suggests an improvement in 
health status, anxiety and depression in the first few months following LVAD implantation. 
However, PRO scores of LVAD patients are still lower with respect to physical, social, and 
emotional functioning as compared to transplant recipients. These studies had several 
methodological shortcomings, including the use of relatively small sample sizes, and only a 
paucity of studies focused on anxiety and depression. 
Conclusions: There is a paucity of studies on the patient perspective of LVAD therapy. To 
advance the field of LVAD research and to optimize the care of an increasingly growing 
population of patients receiving LVAD therapy, more well-designed large-scale studies are 



















Worldwide heart transplantation offers hope to approximately 3,500 advanced heart failure 
patients each year, but there are still over 15,000 patients on transplant waiting lists in 
urgent need of a donor heart.1 Driven by this significant shortage of donor hearts and a 
simultaneous increase in the incidence of heart failure, the first concepts of mechanical 
circulatory support from the early 1970s have been transformed into highly advanced 
devices capable of long-term support for patients with end stage heart failure. The most 
commonly used long-term devices are left ventricular assist devices (LVADs).2, 3 LVADs can be 
divided into 2 main types – (i) the pulsatile pumps that mimic the natural pulsing action of 
the heart and (ii) the continuous flow pumps which can be subdivided into either centrifugal 
pumps or axial flow pumps.4          
 The primary focus of the majority of LVAD studies has been on the clinical aspects of 
this therapy, including the efficacy of different device types, device settings, and alternative 
therapies (e.g., optimal medical treatment and heart transplantation) in enhancing survival 
and reducing complications. Only a subset of LVAD studies have examined the impact of 
LVAD therapy on patient reported outcomes (PROs), such as health status.5 This is 
unfortunate, because PROs can be used to assess the effectiveness of treatment, to enhance 
the quality of care and management of patients, and to help allocate resources to patients 
who need it the most.6,7 In addition, poor health status has predicted mortality and 
rehospitalization in patients with coronary artery disease and heart failure independent of 
traditional biomedical risk factors.8 This information cannot be extrapolated from 
information standardly available in patients’ medical records nor from a proxy.7, 9 In addition 
to health status, LVADs may also have an effect on psychological morbidity and feelings of 
worry and stress.10-14 Device type and settings might influence the level of psychological 
morbidity because patients receiving pulsatile LVAD therapy have a higher rate of 
complications, and are bothered by the clicking noise of the device.15  In other heart failure 
populations, psychological morbidity has been associated with poor treatment adherence, 
poor self-efficacy, and an unhealthy lifestyle.15,16 Yet, it is not known whether LVAD patients 
with psychological problems are identified and, hence, treated.  
In the future, LVAD therapy is likely to be indicated as bridge to transplant and as 
destination therapy worldwide, thereby providing much optimism for the treatment of more 











patients, we need to know the impact of LVAD therapy on patients from a patient 
perspective.12 Only with such knowledge are we able to improve the care after LVAD 
implantation and provide patients and families with all the necessary information that they 
need for effective decision-making regarding whether LVAD implantation is aligned with 
their own preferences and goals.  
Hence, the objectives of this systematic review are to provide a detailed overview of 
available evidence on the impact of LVAD therapy on PROs, and suggest recommendations 
for clinical research and practice. 
 
METHODS 
Literature search  
The first author (CB) performed a literature search on Pubmed in the period from January 
1980 to May 2011 using a combination of the following search terms: LVAD, left ventricular 
assist device, anxiety, depression, health status, quality of life, emotional distress, 
psychological distress, psychological morbidity and psychosocial. Only full-text, empirical 
studies with a sample size of n>10, examining the impact of LVAD therapy on PROs assessed 
by means of standardized clinical interviews or standardized and validated questionnaires 
were eligible for inclusion. Articles found by reference searching and articles for which 
inclusion was questionable were checked by the last author (S.S.P.), after which a consensus 
was reached between both authors (C.B. and S.S.P.). Of the 250 candidate articles, 26 
articles were identified which matched the inclusion criteria. Sixteen studies emanated 
largely from the same 4 cohorts, as reported on in 1 of the other articles.10-14, 18-28 From each 
cohort, only the most recent paper was included (i.e., papers with the most optimal study 
design and largest sample size), except for 2 extra papers that compared 2 groups of LVAD 
patients on 2 different devices.12, 18, 19, 25-27 Hence, the current review is based on 16 studies 
(Figure 1). 
 
Literature overview  
Detailed information on the 16 studies included in this review are presented in Table 1 and 
Table 2. The descriptives data are stratified by studies on pulsatile (Table 1) vs. continuous-
flow (Table 2) devices. Studies in which patients received therapy via both pulsatile and 






 For the pulsatile devices, the median number of patients included in the 7 studies 
was 30 (mean±SD, 36.0±27.2) with the number of patients receiving therapy via LVADs 
ranging from 10 to 78. The proportion of men ranged from 60% to 99%, and the mean age of 
study participants was 47.0±13.5 (range, 29-67) years. Three studies (42.9%) used a cross-
sectional study design, 29-31 4 studies (57.1%) a prospective (comparative) study design,12, 26, 
32, 33 of which 2 studies (28.6%) were a randomized controlled trial.33, 34 In most studies, the 
baseline assessment was conducted before hospital discharge, which varied between 1 and 
2 weeks12 to approximately 1 month post LVAD implantation.32 The 3 cross-sectional studies 
used a variety of assessment times ranging from <6 weeks after implantation29, 30 to up to 2 
months post LVAD implantation.31 Two studies26, 32 compared the PROs of LVAD patients 
with transplant recipients or patients receiving optimal medical treatment. Of all studies, 4 
studies (57.1%) focused on health status,12, 26, 32, 33  2 (28.6%) on anxiety,30, 32 and 5 (71.4%) 
on depression,26, 29-32 ; 2 (28.6%) studies focused on both anxiety and depression.30, 32  
 



























For the continuous-flow devices, the median number of patients included in the 9 
studies was 41 (mean±SD, 201±229.5) with the number of LVADs patients ranging from 17 to 
655. The proportion of men ranged from 76% to 100% across studies, and the mean±SD  age 
of study participants was 51.5±15.7 (range,  46-62.5) years. Two studies (22%) used a cross-
sectional study design,19, 35 1 study used a retrospective design (11%),36 and 6 studies (66.7%) 
a prospective (comparative) study design.18, 25, 27, 37-39 The prospective studies performed the 
baseline assessment within 1 month after LVAD implantation. The retrospective study 
assessed PROs at 12 months after LVAD implantation,36 and the cross-sectional studies 
included patients ranging from 2 to 135 months after LVAD implantation.19, 36 Two studies  
compared the PROs of LVAD patients with their partners or with transplant recipients.19, 37  
Of all studies, 8 studies (88.8%) focused on health status,18, 25, 27, 35-39  while one study (11%) 
focused on depression.19  
 
RESULTS 
PROs in studies on pulsatile devices 
The studies on the first generation of pulsatile LVADs (Thoratec TCI, Heartmate VE/IP 
[Thoratec Inc, Pleasanton, California, USA], Novacor LVAS [WorldHeart Inc., Oakland, 
California, USA], EXCOR [Berlin Heart AG, Berlin, Germany] or Toyobo LVAD [Toyobo 
Ventricular Assist Systems, Toyobo, Osaka Japan] assessed health status using a prospective 
design with a variety of instruments (Table 1). All studies found a significant improvement in 
the mean health status score (i.e. the Minnesota Living with Heart Failure Questionnaire 
[MLHFQ]) or in at least 2 subdomain scores (i.e., the Short Form Health Survey 36 [F-36], the 
Sickness Impact Profile, the LVAD stressor scale, and the Quality of Life Index [QoL Index]) at 
follow-up compared to baseline. The improvement in health status did seem to reach a 
plateau at ≈3 months after LVAD implantation. The results showed that, during this period, 
physical disability becomes less prominent and patients feel less fatigued and sleep better, 
thereby increasing the ability of self-care and ambulation.12 The impact of the degree of 
physical disability on health status was also indicated in a recent trial that randomized LVAD 
patients to an exercise-training programme versus usual care. The outcomes demonstrated 
that improvement in physical exercise capacity in patients in the treatment arm led to a 







Despite improvements in physical functioning, many patients may experience psychosocial 
problems and impaired psychological well-being, especially at around month after 
implantation.12, 21 The psychological symptoms seem to originate from feelings of sadness, 
helplessness, irritability, feeling useless to others and having a sense of loss of control over 
one’s life;12, 21 and seem to be associated with worrying about LVAD malfunction, 
complications, waiting for a donor heart and being away from family.12 Depression and 
anxiety are correlated with LVAD noise, driveline problems, and infection (P<0.05 for all).30 
The prevalence rates of anxiety and depression varied widely across the 6 studies that 
included a semi-structured diagnostic interview using the Diagnostic and Statistical Manual 
of Mental Disorders (4th Edition), the Symptom Checklist-90, the Beck Depression Inventory, 
or the Mini Mental State Examination. Some studies found that only 2% of LVAD patients 
experienced depression and only 4% experienced anxiety,20 whereas others found a 
considerable group of LVAD patients experiencing a depressive or adjustment disorder (21% 
and 37-50%, respectively).29, 31         
 In trials (i.e. the Randomized Evaluation of Mechanical Assistance in the Treatment of 
Congestive Heart Failure) comparing LVAD patients on pulsatile devices with patients using 
optimal medical treatment and transplant recipients, LVAD support was associated with a 
significant improvement in health status and depressive symptoms in contrast to medication 
alone (P<0.05 for both).26, 30, 32  However, LVAD patients do not seem to attain the same level 
of health status compared with transplant recipients, with transplant recipients experiencing 
more improvements in mobility, self-care ability, physical ability and social functioning than 
LVAD patients.13, 32 
         
Patient reported outcomes in studies on continuous-flow devices 
The most intensively studied continuous-flow device used in the studies included for the 
review was the HeartMate II (Thoratec Inc). Other devices included the Micromed DeBakey 
(Micromed Cardiovascular Inc., Houston, TX), INCORE (Berlin Heart AG), Jarvik 2000 (Jarvik 
Heart, Inc., New York, NY), or HVAD device (HeartWare Inc., Framingham, MA) (Table 2). 
Almost all studies on patients with a continuous-flow LVAD show significant improvements 
in mean health status scores, using the MLHFQ, Kansas City Cardiomyopathy Questionnaire 
(KCCQ), SF-36, and EuroQol EQ-5D (EQ-5D), from baseline up to 3-, 6- and 12-month follow-











improvement in health status using the SF-36 at the 6 month follow-up. Whether this was 
due to psychosocial problems or a lower physical exercise tolerance is not clear, because 
both may ultimately restrict patients’ opportunities to re-engage in professional and 
recreational activities, which are known predictors for long-term health status.37  
In recent years, several papers have been published on comparative studies between 
LVAD patients with different devices and in different clinical settings25, 27, 35, 39 or between 
LVAD patients and transplant recipients and healthy controls.37 The HeartMate II trial had 2 
arms that enabled the investigators to analyse the health status within and between 
patients groups supported by the HeartMate XVE or the HeartMate II. At 12-months follow-
up the health status of patients receiving therapy via continuous-flow LVADs was better 
compared with those receiving therapy via pulsatile devices (MLHFQ: P=0.03, KCCC-OSS 
[Overall Summery Score]: P=0.06, KCCQ-CSS [Clinical Summery Score]: P=0.12)), likely caused 
by the improved durability, decrease in complications, smaller size and silent operation of 
the continuous-flow device.27 Recently, the HeartMate II was also compared with the 
HeartMate XVE and Thoratec pVAD in a commercial setting to investigate the relative 
efficacy and risk profile, in patients enrolled in the Interagency Registry for Mechanically 
Assisted Circulatory Support. Health status appeared to improve equally for the 2 groups of 
devices (P<0.001) after 3 months to 1 year.39 Patients receiving therapy via pulsatile and 
continuous-flow devices were not significantly different on symptoms of anxiety, depression 
and post-traumatic stress disorder.19 The cross-sectional study of Meyer et al.35 found no 
significant differences in domain scores between 2 continuous-flow systems: the centrifugal-
flow pump Heartmate II and axial-flow pump HVAD.     
 From both arms of the HeartMate II trial, patients were also selected based on their 
device indication (i.e. bridge-to-transplant or destination therapy) and compared on paired 
health status scores. The group of LVAD patients indicated for destination therapy had a 
higher improvement in median health status scores between baseline and 6 months than 
the group of LVAD patients indicated for bridge-to-transplant therapy (MLHFQ, -40 vs. -29 
points; KCCQ-OSS, 39 vs. 28 points; KCCQ-CSS, 36 vs. 24 points, respectively).32 In this study, 
79% of the bridge-to-transplant patients and 92% of the destination therapy patients with 
paired data had achieved a clinically meaningful improvement of >5 points in their KCCQ-OSS 






Compared to transplant recipients and healthy controls, LVAD patients reported 
considerably poorer health status at baseline (P=0.0032) and at 6 months follow-up 
(P=0.016), especially with respect to mental health and physical functioning,35, 37 and with 
respect to the social functioning, role physical functioning, and role emotional functioning 
domains of the SF-36.35  
Overall, evidence on the impact of the duration of living with an LVAD, the initial 
diagnosis, and sex and age disparities in health status is scarce among LVAD patients. 
Women tend to have been underrepresented in LVAD studies to this date, with one study 
finding no significant gender differences among LVAD patients (MLHFQ, P=0.661; KCCQ-OSS,  
P=0.706; KCCQ-CSS, P=0.371).18   
 
DISCUSSION  
Summarizing the findings 
This review indicates that LVAD patients experience an improvement in health status, 
particularly in the first 3 months after LVAD implantation and discharge. This trend was 
visible irrespective of the type of device (pulsatile vs. continuous-flow devices) and clinical 
setting (destination therapy and bridge-to-transplant therapy). Results also indicated that 
LVAD patients supported by continuous-flow devices and destination therapy show the 
greatest improvements in health status after implantation.  
Few studies have examined the prevalence of anxiety and depression in LVAD 
patients, in particular in patients receiving therapy via continuous-flow LVADs. Patients 
supported by pulsatile devices showed relatively high mean depression scores just after 
LVAD implantation.26, 29, 31 The retrospective study of Bunzel et al.19, 20 found no significant 
difference in depression scores between patients receiving therapy via pulsatile vs. 
continuous-flow devices while patients supported by pulsatile devices were expected to be 
more vulnerable to psychological distress, based on the higher rate of complications and the 
characteristics of the device (e.g. short durability, large size, noise, and large batteries). 
Hence, these differences in findings could well be explained by sample size limitations in 
subtype of devices, and the time of collecting data. 
The LVAD patients report better health status and fewer symptoms of anxiety and 
depression when compared to their partners and to patients receiving optimal medical 











recipients, LVAD patients are recurrently reminded of their device due to the need to clean 
the driveline insertion site and change batteries frequently.15 Furthermore, organ recipients 
appear to redefine “normal” life and what it entails after transplantation.32  
Overall, there was a substantial difference between the studies in the handling and 
reporting of PROs, depending on whether PROs were assessed as primary or secondary 
outcomes. In Table 3, the details on the number of patients alive from baseline to end of 
follow-up, the estimated percentage of those patients having PRO data, and the cause of 
missing data were outlined for all prospective studies assessing health status in LVAD 
patients. Except for the Randomized Evaluation of Mechanical Assistance in the Treatment 
of Congestive Heart Failure trial,26 all studies on pulsatile devices assessed health status as a 
primary outcome, whereas this only holds true for 1 continuous-flow study.37 The 
percentage of PRO data obtained from the patients alive over time was 92% - 100% in the 
pulsatile device studies and 46%-91% in the continuous-flow device studies. At the end of 
the full study, this percentage was unchanged for the pulsatile device studies, and 49% - 89% 
for the continuous-flow device studies. In 2 continuous-flow device studies the follow-up 
period for the PROs was shorter than the follow-up period for the full study, causing an 
absence of PRO data at the final time points.18, 25 For those studies, the percentage of PRO 
data obtained was calculated based on the patients alive at the end of the PRO follow-up 
period rather than at the end of the full study. Most studies indicated similar reasons for the 
missing data (e.g. patient exclusion, deceased, too ill, HTx, dropout). None of the studies 
reported cognitive limitations or psychological distress as a reason for missing data. 
 
Limitations of the review  
Because of the different time era of the studies included in this review and the 
heterogeneity of the studies (differences in follow-up assessments, sample sizes and PRO 
assessment), it was not possible to perform a formal meta-analysis. Although increasing the 
statistical power by excluding studies with a small sample size (n<10), this resulted in fewer 
articles eligible for inclusion. In turn, this could have potentially created a bias towards 
results found in larger studies. The proportion of female patients across studies was 
relatively low; hence, it is not feasible to generalize the findings to women with an LVAD. 
 There was a considerable difference in the percentage of missing PRO data between 






that most of the pulsatile device studies assessed PROs as primary outcomes but also 
because of shorter follow-up times, thereby decreasing the chance of death, HTx and drop-
out. Only three studies18, 37, 38 reported how they dealt with the loss of data, which included 
comparing the baseline characteristics of patients for whom data were and were not 
available or by substituting the missing scores by the maximum negative score of the used 
instrument. Correcting for missing data did not affect the outcomes in these studies. Other 
studies calculated the percentage and significance of improvement by simply comparing the 
group total scores of patients with paired data between baseline and follow-up. However, 
the number of patients with paired data decreases significantly over time, which may 
increase the probability of finding a significant improvement since the sicker patients are 
usually lost to follow-up. More information is needed on intra-individual changes and the 
proportion of patients who experience a clinically relevant change.    
 Moreover, the instruments chosen for the study might not have been sufficiently 
sensitive to tap LVAD-related changes in health status, if present.37 Some instruments, such 
as the KCCQ, have also not been used optimally, since authors did not report subdomain 
scores. Finally, studies failed to examine key predictors of intra-individual changes in PROs 
over time or associations between PROs and other outcomes, such as mortality and number 
of hospitalizations 
 
The need for assessing patient reported outcomes in LVAD patients 
The importance of studying PROs, such as health status, is gaining increasing recognition 
because of the belief that an illness, its treatment, and complications affect all domains of a 
patient’s life, and that the patient perspective is as valid as that of the clinician when it 
comes to evaluating outcomes.40 In addition, information on PROs is important for future 
patients and families who have to make an informed decision regarding the option for LVAD 
therapy. Information on PROs cannot be extracted from patients’ medical records or a proxy 
and, therefore, PROs need to be assessed in their own right. Thus, PROs may provide 
important additional information to health care providers and serve as targets for 
intervention in individual patients.8, 9 Despite their importance, there is often a minor 
emphasis placed on PROs, and they are rarely included as primary outcomes in clinical LVAD 
trials.6 In particular studies on continuous-flow LVADs show a tendency to neglect anxiety 











suffer from depression,41, 42 40% from anxiety,16 and 10%-17% from posttraumatic stress 
disorder.43,44 Symptoms of depression and anxiety can be disabling,15 and are associated 
with an increased risk of declines in physical health,16 mortality, higher medication costs,15 
non-compliance with treatment, malignancies,45, 46 and hospital readmissions.8 The limited 
available evidence suggests that there may be a link between LVAD technology and the 
patient’s psychological adjustment.5  
 
Recommendations for future research and care of LVAD patients 
Because it has been widely established that LVAD therapy is capable of enhancing the 
survival of patients with end-stage heart failure, measuring PROs (e.g. functional status, 
quality of life and psychological distress) in these patients deserves a priority similar to 
survival in future LVAD studies. This review indicates that PROs improve over time, yet it also 
uncovers major shortcomings in their assessment, reflecting a considerable knowledge gap 
in the optimal care for these patients. More specific recommendations for future research 
and clinical practice in LVAD therapy are given in Table 4.  
In addition to the current inter-individual approach (comparing changes in mean 
group scores over time), PROs should also be analyzed using an intra-individual approach 
focusing on the proportion of patients who experience a clinical improvement or 
deterioration over time. Eventually, this will create the possibility to risk stratify patients and 
enhancing optimal clinical practice. Attention should also be given to the selection of PRO 
measures, with a distinct preference for disease-specific measures such as the KCCQ or 
MLHFQ. Patients are more likely to identify themselves in these instruments, thereby 
increasing the response rate. In studies on continuous-flow devices health status was 
predominantly measured with the KCCQ or the MLHFQ, with both measures showing similar 
results in various large-scale LVAD studies.18, 22, 23, 25, 27 This suggests that these measures are 
sensitive to detect LVAD-related changes in health status over time, if present. To capture 
psychological morbidity in LVAD patients, the Heart Failure Symptom Checklist or LVAD 
Stressor Scale could be used in addition to specific anxiety/depression measures. Given the 
paucity of studies on psychological functioning in LVAD patients, it is difficult to recommend 
a specific instrument to use. The Patient Health Questionnaire (PHQ-9) and the Generalized 






excellent psychometric properties. In addition, these measures are exempt from copyright 
and can be used free of charge. 
It is paramount that future studies comply with the Consolidated Standards of 
Reporting Trials [CONSORT] and the Strengthening the Reporting of OBservational studies in 
Epidemiology [STROBE] statements for reporting results of randomized trials and 
observational studies.47,48 These guidelines also stipulate reporting of missing data and 
clinical relevance, as has also been advocated by others.49, 50 This is needed because, for 
sufficiently large trials, it is possible to have a statistically significant difference that may not 
be clinically meaningful.50 In clinical practice, there needs to be a shift in LVAD rehabilitation 
programs from survival to also focus on coping abilities and health status of LVAD patients. 
These programs need to be tailored to the individual patient, and should account for the 
patient’s level of emotional functioning.  
 
CONCLUSION  
There is a paucity of studies on the patient perspective of LVAD therapy. Initial evidence 
suggests an improvement in health status, anxiety and depression in the first months after 
LVAD implantation. However, PRO scores of LVAD patients are still lower for physical, social 
and emotional functioning compared to transplant recipients. To advance the field of LVAD 
research and to optimize the management of an increasingly growing population of LVAD 
patients, more well designed large-scale studies on PROs are needed. By these studies, we 
will be able to further elucidate the psychological and social impact of LVAD therapy, 
thereby creating the opportunity to not only improve the care for patients after LVAD 
implantation, but also to provide important information that is needed by patients and 
families for effective decision-making regarding whether LVAD implantation is aligned with 
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Table 4: Recommendations for the incorporation of PRO assessments in clinical practice  







Purpose of incorporating 
PROs in clinical practice 
and research 
 PROs have unique prognostic 
value above and beyond 
physician-rated measures and 
information derived from 
patients’ medical status 
 Inclusion of the patient 
perspective; no proxy measure 
available from measures 
assessed in standard clinical 
setting 
 PROs may facilitate 
communication between 
patients and physicians 
 PROs may enhance 
identification of high-risk 
patients whose medical 
treatment should be optimized  
 PROs can be used as 
performance measures to 
evaluate the quality of care  
 Evaluate the impact of treatment, 
devices and device settings on 
PROs using both health status 
and anxiety/depression measures 
 Comparison of PROs between 
LVAD patients and other groups 
(e.g. patients on optimal medical 
treatment, HTx) is necessary for 
informed political and clinical 
decision-making 
 Compare the sensitivity of 
disease-specific and generic PRO 
measures to detect changes over 
time; if necessary develop new 
disease-specific measures e.g. to 
assess anxiety and depression 
Recommendations for 
PROs as primary 
outcomes in LVAD 
research and therapy 
 Enables more accurate tracking 
of changes in patient’s physical 
and psychological functioning 
over time, and better 
coordination of care (e.g. 
individually tailored 
rehabilitation programs ) 
 Is a no-risk, low-cost and low-
burden addition to clinical care 
 Examine the correlation between 
clinical variables and PROs and 
determine their relative 
importance for LVAD patient 
prognosis 
 Use both an inter- and intra-
individual approach in data 
analyses 
 Adhere to CONSORT and STROBE 
statement guidelines for 
reporting critical PRO data 
elements (e.g. missing data and 
clinical meaningful improvement) 
 Use of disease specific 
questionnaires (e.g. MLHFQ, 
KCCQ) in studies with LVAD 
cohorts only 
 Incorporate PRO instruments for 
anxiety and depression in studies 
on continuous-flow devices 
 Use prospective studies with 
large sample sizes 
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Psychological distress in patients 
with a left ventricular assist 
device and their partners: An 
exploratory study






Background: Left ventricular assist device (LVAD) therapy is increasingly used in patients 
with advanced heart failure, and may have a significant psychological impact on both 
patients and their partners. Hence, we examined the distress levels of LVAD patients and 
their partners. 
Methods: Anxiety, depression and post-traumatic stress (PTSD) were assessed at 3-4 weeks 
after implantation, and at 3  and 6 months follow-up in 33 LVAD patients (73% men; mean 
age=54±10years) and 33 partners (27% men;  mean age=54±11 years). 
Results: The prevalence of anxiety in LVAD partners was significantly higher compared to 
LVAD patients at baseline (48% vs. 23%, p=.03) and 3 months (44% vs. 15%, p=.02), but not 
at 6 months follow-up (p=.43).  No differences were found for depression and PTSD (ps>.05). 
Scores between the LVAD patients and partners showed only a significant correlation at 
baseline for the anxiety, depression and PTSD score of the patient and the depression score 
of the partner (ranx=.40, p=.04; rdep=.40, p=.04; rPSTD=.46, p=.05). Multivariate analyses 
showed no significant association between the role (patient vs. partner) and anxiety, 
depression and PTSD over time after correction for age, gender and clinical covariates. 
However, after correction for Type D personality and the use of psychotropic medication the 
LVAD partners showed significantly higher anxiety (F=6.95, p=.01) and depression (F=3.94, 
p=.04) scores over time compared to LVAD patients.  
Conclusion: LVAD partners had significantly higher levels of anxiety than LVAD patients. 
Emotional distress of LVAD partners should gain more attention, as partners are an essential 

















As donor hearts for transplantation continue to be extremely limited, the left ventricular 
assist device (LVAD) is becoming an indispensible tool for patients with advanced heart 
failure whose medical treatment options have been exhausted.1,2 With the increasing 
availability of the new generation axial and centrifugal pumps, the incidence of morbidity 
and mortality is decreasing and LVADs are becoming more patient friendly with respect to 
size and durability.1, 3 Despite these advances, LVAD therapy is a complex treatment with a 
trajectory that is often marked by intense physical rehabilitation, complications, frequent 
hospitalization and social isolation.4,5 As a consequence, quality of life has become an 
important complementary end-point in large clinical trials in addition to morbidity and 
mortality in this patient population.6, 7 
While the evidence on quality of life of LVAD patients continues to grow, this is not 
the case for evidence on psychological distress (e.g. anxiety and depression), which has only 
been adequately assessed in older studies during the era of pulsatile devices.8 This is 
surprising given that 15%-36% of patients with heart failure patients experience depression, 
40% anxiety,9 and 10%-17% posttraumatic stress disorder.10,11 Moreover, although the 
awareness of the partner’s and the family’s role in the patient’s adaptation to cardiovascular 
disease is increasing, only a few studies focused on the emotional well-being of partners and 
caregivers of LVAD patients.12-14,44-45 These studies found that LVAD partners experienced a 
greater caregiver burden in comparison to partners of heart transplant recipients, and that 
psychological distress of LVAD partners was mostly related to fear of stroke, device 
malfunction and infection.13 Studies on patients with heart failure and their partners show 
that partner levels of psychological distress are often on par with patient levels.15-17 Patients 
tend to score lower on physical health status as compared to their partners, but not always 
on mental health status.5,7,16,18 Furthermore, patients and partners score lower on mental 
health compared to the general population.4,15, 19 The level of psychological distress in heart 
failure patients and partners may be influenced by age, gender, disease severity and 
personality (i.e. Type D personality).15,16,20 However, it is unknown whether these same 
factors could play a role in the psychological distress levels of patients after LVAD therapy.  
Therefore, this study examined the prevalence of psychological distress (anxiety, 
depression and post-traumatic stress) in LVAD patients and their partners and compared the 












Study population and design 
This paper reports on a multi-center prospective observational study in which adults with 
advanced heart failure implanted with the axial-flow HeartMate II LVAD (Thoratec) or 
centrifugal-flow HVAD (HeartWare) as a bridge-to-transplant were eligible for study 
participation. Patients were recruited as a consecutively implanted cohort from the 
University Medical Center, Utrecht and the Erasmus Medical Center, Rotterdam, the 
Netherlands and the Heart Center at St. Paul’s hospital in Vancouver, Canada, between 
January 2011 and February 2013. Patients were eligible for inclusion if they had not 
undergone a previous LVAD implantation, were ≥18 years of age, were proficient in the 
Dutch or English language and had no history of severe psychiatric illness other than 
cognitive-affective disorders. Partners could consent to participate in the study only if the 
LVAD patients had consented to participate.  
Patients and partners were asked to complete a set of standardized and validated 
questionnaires at baseline (i.e. 3-4 weeks after LVAD implantation) and at 3 and 6 months 
follow-up. The baseline assessment was performed when patients were given the LVAD-
training while still being hospitalized, indicating that they had recovered sufficiently for 
study participation. The follow-up assessments were sent out by mail around the same time 
points as the visits to the outpatient clinic. The questionnaires were returned in a stamped, 
pre-addressed envelope. If the questionnaire was not returned within two weeks, patients 
and partners received a reminder telephone call or letter. The study was approved by the 
Medical Ethics Committee of the participating hospitals, and conducted in accordance with 
the Helsinki Declaration (2008).  
 
Measures 
Demographic and clinical variables 
Information on demographic variables comprised sex, age, marital status, and educational 
level and were collected both on patients and partners. Clinical variables for patients and 
partners included body mass index (BMI), medical comorbidity and use of psychotropic 
medication. Information on these demographic and clinical variables was extracted from 
purpose-designed questions in the questionnaires and from the patients’ medical records. A 






evaluates 17 different comorbidities with varying assigned weights. We used an abbreviated 
CCI score with the following comorbid conditions: myocardial infarction (MI), 
cerebrovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, 
peripheral vascular disease, liver disease, renal failure, and any malignancy excluding 
metastatic tumors.21           
 Other clinical variables for the patients included duration of hospitalization, etiology, 
left ventricular ejection fraction (LVEF), New York Heart Association (NYHA) functional class, 
prescribed medications (i.e., beta-blockers, aldosterone receptor antagonists, anticoagulants, 
ACE-inhibitors, statins and diuretics), previous cardiac events (i.e., myocardial infarction, 
coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI)) and the 
Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) score. The 
INTERMACS score was developed by the INTERMACS Coordinator’s Council as a result of the 
existing limitations for clinical characterization of mechanical circulatory support recipients. 
It is a valid score system that is increasingly used as a tool to assess the patient’s profile and 
predicts complications and mortality after LVAD implantation. Seven profiles have been 
defined for the INTERMACS registry ranging from crash-and-burn patients (INTERMACS 1) to 
patients with advanced NYHA III (INTERMACS 7).22-24 
 
Symptoms of anxiety and depression 
The 14-item Hospital Anxiety and Depression Scale (HADS) was used to assess symptoms of 
depression and anxiety.25-27 Items are answered on a four-point Likert Scale from 0-3 (range 
[0-21]). The HADS is a valid and reliable measure, which has strong psychometric 
properties25,26 and has shown to be an adequate measure of anxiety and depressive 
symptoms in cardiac patients.28 We used a cut-off of ≥8 to indicate the presence of 
symptoms of anxiety and depression, based on the optimal cut-off found in large-scale 
studies.29  
 
Post-traumatic stress disorder 
Symptoms of post-traumatic stress (PTSD) were assessed with the Posttraumatic Stress 
Diagnostic Scale,30 a 17-item self-report instrument that can be used to generate a diagnosis 
that is consistent with the diagnostic criteria for post-traumatic stress.31 To ensure that post-











patients were asked to rate each item according to the ‘LVAD implantation’. A similar 
approach has been used by others.32 To qualify for a diagnosis of post-traumatic stress, the 
respondent has to endorse at least: 1 re-experiencing symptom, 3 avoidance symptoms, and 
2 hyperarousal symptoms. Items are rated on a 4-point scale ranging from 0 (not at all) to 3 
(almost always). It is also possible to calculate a total PTSD symptom score by summing up 
the 17 items. The scale has good sensitivity and specificity with a high internal consistency 
(Cronbach’s α = .92) and test–retest reliability for a PTSD diagnosis (κ = .74).30 
 
Type D personality 
The Type D Scale (DS14) was used to assess the distressed (Type D) personality defined by a 
cut-off of ≥10 on both negative affectivity and social inhibition.33,34 Negative affectivity refers 
to the tendency to experience negative emotions, like anger, dysphoria and irritability. Social 
inhibition refers to discomfort in social interactions, reticence and lack of social poise. The 
negative affectivity and social inhibition scales showed to be internally consistent (alpha= 
0.88/0.86) and stable over a 3-month period (test-retest r= 0.72/0.82). Items are rated on a 
5-point Likert scale. The construct of Type D personality is stable when compared to the 
effect of gender on outcomes. The DS14 was administered at baseline.  
 
Statistical analyses 
The χ2-square test was used to examine differences on discrete variables and Student’s t-test 
for independent samples to examine differences on continuous variables. The correlations 
between the continuous anxiety, depression and PTSD scores between LVAD patients and 
partner were calculated using Pearson’s correlation coefficient. For the multivariate analyses, 
we used the linear mixed model procedure (covariance model: compound symmetry, 
maximum likelihood (ML) estimate) in SPSS version 19.0, which is comparable to a linear 
regression analysis except for the fact that the dependent variable is measured at multiple 
occasions over time. The mixed model procedure uses all the available time points available 
for each patient and partner, thereby limiting bias and preserving statistical power. The 
dependent variables included in this analysis were the continuous scores on anxiety, 
depression and PTSD at baseline, 3 months and 6 months. First, role (patient vs. partner), 
gender, age and time were entered into the model. By entering these variables we examine 






patients and partner, whether the scores changed significantly between baseline and 6 
months and whether differences between patients and partners were due to age and gender. 
In an additional model, we also added clinical variables (i.e. the length of hospitalization 
from baseline until discharge (in days), INTERMACS score, comorbidity) and psychosocial 
variables (Type D personality, use of psychotropic medication).  
 
RESULTS 
Of the 90 patients who met the inclusion criteria from all three centers, 20 patients refused 
participation, 16 patients died or were too ill at the time of inclusion and 3 were excluded 
due to inability to write and read English, low intellectual functioning or because they had a 
LVAD replacement, leaving a sample of 51 patients for analyses. The patients not 
participating in the study did not differ systematically on age, gender and type of LVAD 
compared to patients who participated (p>.05). 
Subsequently, the partners of these patients were asked to participate in the study. 
As this study was only focused on the psychological distress in LVAD patients and their 
partners, only the patients whose partner also participated in the study were used in the 
analyses. Eighteen partners refused participation leaving 33 patient partner dyads for 
analyses. Of the 33 LVAD patient-partner dyads, n=27 were included in the Netherlands and 
n=6 in Canada. 
 
Patient and partner characteristics 
Baseline characteristics stratified by LVAD patient versus partner status are presented in 
Table 1. Patients were more likely to be male (73% vs. 27%; p<.001), to have more co-
morbidities (p=.005), and to have a Type D personality (27% vs. 6%; p=.02). Further clinical 
information on LVAD patients is given in Table 2. 
There was a significant difference in the prevalence of anxiety between patients and 
partners at baseline (23% vs. 48%, p=.03) and 3 months follow-up (15% vs. 44%, p=.02) but 
not at 6 months follow-up (15% vs. 26%, p=.43). There was no significant difference between 
patients and partners in the prevalence of depression (28% and 39%, p=.37) and post-
traumatic stress (21% v. 12%, p=.32) at baseline, 3 months follow-up (23% vs. 32%, pdepr=.48; 












Patients using psychotropic medication (n=13) were more likely to have post-traumatic 
stress at baseline than patients not using psychotropic medication (n=9) (χ2=3.82, p=.05; 
data not shown).  There was no difference in the prevalence of anxiety, depression or post-
traumatic stress in the partners who used (n=6) or did not use (n=23) psychotropic 
medication, except for a higher prevalence of anxiety at 3 months follow-up for patients 
using psychotropic medication (n=6) (χ2=5.38, p=.02; data not shown).  
 


















*Results are reported as n (%) unless otherwise indicated 
1Higher education= secondary school and above; 2Comorbidity index= comorbidity was 
calculated using the abbreviated Charlson Comorbidity Index; 3Based on the standardized 





 LVAD Patients 
(n= 33) 
     Mean±SD          
         N (%) 
LVAD Partners 
        (n=33) 
     Mean±SD          
          N (%) 
p-value 
Demographics  
Male 24 (73) 9 (27) <.001 
Age (yrs), mean (SD) 54.7±10.6 53.6±10.7 .67 
Higher education1 29 (88) 31 (94) .39 
Employed 14 (42) 24 (73) .01 
Clinical   
Comorbidity Index2 
   0 
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 LVAD patients 
(n=33) 
        Mean±SD; N (%) 
Clinical  
Type of LVAD  
      HeartMate II 22 (67) 
      HeartWare 11 (33) 












    Ischemic      15 (45) 
    Dilated cardiomyopathy 13 (40) 
    Other (hypertrophic, myocarditis) 5 (15) 
Previous CABG 5 (15) 
Previous PCI 11 (35) 
Previous valve replacement 2 (6) 
Previous myocardial infarction 13 (40) 
Previous ICD/CRT-D implantation 24 (73) 
Previous CVA 5 (15) 
LVEF 18.5±7.8 
IABP 4 (12) 
ECMO 3 (9) 
Cardiac medication  
Amiodarone  21 (65) 
Beta-blockers 17 (53) 
Angiotensin-converting enzyme inhibitors 22 (69) 





CABG= coronary artery bypass graft; PCI=percutaneous coronary 
intervention; ICD= implantable cardioverter defibrillator; CRT-D= 
cardiac resynchronization therapy; CVA= cerebrovascular accident; 
NYHA= New York Heart Assocation; LVEF= left ventricular ejection 
fraction; IABP= intra-aortic balloon pump; ECMO=extracorporeal 
membrane oxygenation; INTERMACS= Interagency Registry for 











Correlation between psychological distress at baseline, 3 and 6 months in LVAD patients 
and partners 
Table 3 shows that patients’ and partners’ own psychological distress scores were strongly 
correlated at baseline, and at 3 and 6 months follow-up (p<.05). Scores between the LVAD 
patients and partners showed only a significant correlation at baseline for the anxiety, 
depression and PTSD score of the patient and the depression score of the partner (ranx=.40, 
p=.04; rdep=.40, p=.04; rPSTD=.46, p=.05). 
 
Psychological distress from baseline to 6 months follow-up in LVAD patients and partners 
Using mixed multivariate modeling, the average level of anxiety, depression and PTSD over 
time was examined for LVAD patients and partners (Table 4). Being a patient or partner was 
not significantly associated with higher anxiety (F=3.00, p=.08), depression (F=.55, p=.47) or 
PTSD (F=.01, p=.92) scores after correction for age and gender (Figure 1). Additional 
correction for comorbidity, INTERMACS gradation and duration of hospitalization did not 
alter these findings (anxiety, F=2.71 p=.11; depression, F=.66 p=.42; PTSD, F=.01, p=.93). 
However, after adding Type D personality and the use of psychotropic medication to the 
model, LVAD partners showed a significantly higher score on anxiety (F=6.95, p=.01) and 
depression (F=3.94, p=.04) as compared to LVAD patients. The averaged level of anxiety, 
depression and PTSD decreased significantly over time between baseline and 6 months in 
both LVAD patients and their partners (p<.01 for all). Patients and partners with a Type D 
personality showed significantly higher levels of anxiety (F=7.48, p=.008), depression (F=5.40, 
p=.02) and PTSD (F=19.45, p<.001) over time. Age, gender, duration of hospitalization, 
INTERMACS gradation and use of psychotropic medication were not significantly correlated 
with anxiety, depression and PTSD of LVAD patients and their partners over time. 
 
DISCUSSION 
The results of this study indicate that partners of LVAD patients may fare worse than LVAD 
patients with respect to psychological distress. At baseline, partners were more likely to be 
anxious than patients, and there was a trend towards a higher prevalence of depression.  
Comparing the outcomes of LVAD patients in our study to former studies is not 
straightforward given that majority of studies on psychological distress in LVAD patients 






or were retrospective.14 The REMATCH trial, and other more recent studies, found that 
depression and anxiety are prevalent in LVAD patients shortly after implantation, with 
prevalence rates ranging between 21-50%.36-39 These relatively high prevalence rates may be 
attributed to the challenges that patients face particularly shortly after implantation, such as 
complications, cardiac rehabilitation and medication-, driveline-, and device-training, which 
could make them vulnerable to distress. The prevalence of distress seems to decrease 
rapidly over the next 6 months, indicating that anxiety and depressive symptoms remit in 
the majority of LVAD patients following discharge from hospital. Studies on PTSD in LVAD 
patients are scarce, but studies in general cardiovascular patients show a prevalence of PTSD 
ranging between 0-22% in patients post MI, 1-15% in heart transplant recipients and up to 
24% in patients undergoing cardiac surgery.40-43 The latter prevalence is in line with our 
findings in LVAD patients.          
 There are only a few studies examining the psychological distress in LVAD patients 
and their partner, most of which have a qualitative study design.12, 39, 44, 45 One study of 
Bunzel et al., which uses a retrospective study design, found a higher prevalence of anxiety 
(23% vs. 4%), depression (19% vs. 2%) and PTSD (26% vs. 0%) in LVAD partners as compared 
to patients.14, 46 Although our study also found a higher prevalence of anxiety and depression 
in partners, there is a large discrepancy in the prevalence found in our sample as compared 
to those found by Bunzel et al. This large difference could be explained by the fact that those 
patients underwent LVAD implantation on average 6 years prior to assessment and were at 
that time already transplanted, thereby making it difficult to distinguish if their anxiety, 
depression and PTSD were LVAD or heart transplant-related. Most other studies on 
psychological distress in heart failure patients and their spouses found no significant 
differences15, 16, 47 or found that patients had significantly higher depression scores5, 7, 18 and 
a higher prevalence of PTSD than partners (10.5% vs. 7.7%).48 Differences in the findings of 
these studies and our findings suggest the psychological distress of partners might be LVAD-
specific and less related to the heart failure of the patient.12,39 Former studies found that 
psychological distress in LVAD partners originates from fear of the LVAD itself, of living with 
the LVAD and the knowledge and skills they need to obtain to become a good caregiver, but 
also from fear of complications.12, 39, 49  Yet, it seems that most partners find a way to accept 











months after implantation,45 which may explain the decrease in anxiety, depression and 
post-traumatic stress scores among the partners in our sample.   
 
Table 3: Correlations between anxiety, depression and PTSD scores in LVAD patients and 
their partners* 
Baseline 1    2   3     4    5 
1. Patient - Anxiety -     
2. Patient - Depression .76*** -    
3. Patient - PTSD .76*** .65*** -   
4. Partner - Anxiety .33 .28 .36 -  
5. Partner - Depression .40* .40* .46* .72*** - 
6. Partner - PTSD .27 .28 .26 .85*** .73*** 
3 months follow-up      
1. Patient - Anxiety -     
2. Patient - Depression .53*** -    
3. Patient - PTSD .79*** .68*** -   
4. Partner - Anxiety .36 .04 .11 -  
5. Partner - Depression .31 .07 .07 .42* - 
6. Partner - PTSD .10 -.23 -.03 .68*** .65*** 
6 months follow-up      
1. Patient - Anxiety -     
2. Patient - Depression .56*** -    
3. Patient - PTSD .78*** .81*** -   
4. Partner - Anxiety .07 -.11 -.10 -  
5. Partner - Depression .02 -.01 -.01 .71*** - 
6. Partner - PTSD .01 -.10 -.01 .81*** 85*** 
 
 
Interestingly, correlational analyses showed that the anxiety, depression and PTSD scores in 
LVAD patients and partners were not strongly related to one another, especially at 3 and 6 
months follow-up. One other study also found a significant correlation between the 
depression scores of heart failure patients and their partners,16 however not among younger 
patients and partners, while other studies found no correlation at all.5,15 Based on the 
**p <.05; ***p<.01 
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findings of the multivariate analyses, LVAD partners were more prone to experience 
symptoms of anxiety than LVAD patients. Furthermore, having a Type D personality 
significantly increased the likelihood of psychological distress in LVAD patients and partners, 
as was also found by Romppel et al.49 and Pedersen et al.50 in cardiac and MI patients.
SUMMARY
Overall, this is the first study examining the psychological distress in LVAD patients and their 
partner using a quantitative longitudinal study design. Our findings underscore the need for 
continued research on psychological distress in LVAD patients and their partners in order to 
provide effective counseling and support, prevent long-term psychological morbidity and 
improve the lives of LVAD patient-partner dyads. Although we found a decrease in distress in
LVAD patients and partners from baseline to 3 months, some LVAD patients and partners 
might experience chronic symptoms that persist over time. As it is known from other 
cardiovascular populations that anxiety, depression and PTSD can increase the risk for 
adverse clinical outcomes51 including mortality,10,52,53 it is important to examine whether 
patients scoring high on distress at baseline are really recovering and whether it is baseline 
distress, chronic distress or new onset distress that incurs the greatest risk for poor 
prognosis. 
Limitations
The limitations of this study should be acknowledged and include the relatively small sample 
size and number of female LVAD patients. Therefore, it was not possible to stratify our 
results for gender, age, use of psychotropic medication or site. As the clinical and 
psychological care of LVAD patients might slightly differ between the centers this could have 
impinged on the results. Patients and partners who refused study participation might have 
suffered from more psychological distress, therefore the results on anxiety, depression and 
PTSD in this paper could be an underestimation of the actual situation. Furthermore, this 
was a prospective study with a short-term (i.e. 6 months) follow-up, warranting replication 
of these findings over a longer period of time. The absence of information on demographic 
and clinical characteristics of the Canadian LVAD patients that did not participate might have 
a negative effect on the external validity of this study. We used self-report measures of 











symptoms of distress assessed with a self-report measure have been shown to predict 
morbidity and mortality in cardiac patients.54 
 
Implications for practice 
 As distress in partners may influence patients’ psychological adjustment, treatment 
adherence and even mortality,55 it would be important to assess and monitor distress in 
partners and to provide extra attention, education or support to partners if necessary.  
 Furthermore, more research is required on patient-partner dyads in relation to LVAD 
therapy in order to identify the specific problems and needs that might enhance the 






Table 4: Mixed modeling of anxiety, depression and PTSD scores over time (baseline - 6 
months) in LVAD patients and their partners 
 Anxiety Depression PTSD 
Model  1 
 
    
 Patient vs. partner O O O 
       Older age O O O 
      Male gender O O O 
Model 2     
 Patient vs. partner O O O 
      Older age O - O 
      Male gender O O O 
      Comorbidity O O O 
      INTERMACS  O O O 
      Duration hospitalization O O O 
Model 3     
 Patient vs. partner -- -- O 
      Older age O O O 
      Male gender O O O 
      Type D personality +++ 
 
++ +++ 
      Psychotropic  medication O O O 
O= no association, p >.10  
−− = negative association, p <.05; −−− = negative association, p<.01 
++ = positive association, p < .05; +++ = positive association. P < .01 
Model 1: role (patient vs. partner) age, gender, time 
Model 2: model 1 + clinical covariates (INTERMACS, duration hospitalization, comorbidity) 

















Figure 1: Mean scores (SE) of anxiety, depression and PTSD for patients and partner from 





























*No significant differences in patients and partners over time 
(anxiety, F=2.62, p=.11; depression, F=.55, p=.47; PTSD, F=.01, 
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Predictors of changes in health 
status between and within patients 
12 months post left ventricular 
assist device implantation






Background: Improving patient-reported outcomes (e.g. health status) has become an 
important goal in left ventricular assist device (LVAD) therapy, in addition to reducing 
mortality and morbidity. We examined predictors of changes in health status scores 
between and within patients 12 months post LVAD implantation.  
Methods: Health status (Kansas City Cardiomyopathy Questionnaire (KCCQ); Short-Form 12 
(SF-12))  were assessed at 3-4 weeks post implantation, and at 3, 6 and 12 months follow-up 
in 54 LVAD patients (74% men; mean age=54±9years). 
Results: Patients experienced significant improvements in health status between baseline 
and 3 months follow-up as assessed by the KCCQ (Clinical Summary Score: F=33.49, P<.001; 
Overall Summary Score: F=31.13, P<.001) and the SF-12 (Physical Component Score: F=31.59, 
p<.001; Mental Component Score: F=21.77, p<.001), but not between 3 months and 12 
months follow-up (p>.05 for all). Higher scores on anxiety and depression over time, older 
age, lower ejection fraction, and more comorbidity were associated with poorer health 
status scores on one or both of the KCCQ and SF-12 subscales. The majority of the between-
patient variance of the MCS scores (82.6%), but not the KCCQ-OS (41.9%), KCCQ-CS (36.2%) 
and PCS scores (23.2%), was explained by the socio-demographic, clinical and psychological 
factors. 
Conclusion: The majority of LVAD patients show a significant improvement in health status 
after LVAD implantation. However, there are large differences in individual health status 
score trajectories which are only partially explained by measures of disease severity pre-









In the last few years, left ventricular assist device (LVAD) therapy has evolved as an 
alternative therapy for end-stage heart failure patients who do not qualify for cardiac 
transplantation, or as a bridge to transplant.1 With the introduction of the second- (axial) 
and third-generation (centrifugal) continuous-flow LVADs, tremendous technical 
improvements have been achieved leading to a lower incidence of morbidity and mortality.2 
Besides reducing mortality an important goal of LVAD therapy is the improvement in patient-
reported outcomes, such as quality of life.3 Quality of life is a multidimensional concept 
which encompasses subjective health status as well as social, environmental and emotional 
domains.4 Questionnaires used for measuring subjective health status can be either disease-
specific or generic, enabling the comparison of outcomes with other heart failure patients or 
across other disease groups, respectively.5 Patient-reported outcomes can be used to assess 
the effectiveness of treatment, improve informed decision making, enhance the quality of 
care and management of patients, and to help allocate resources to patients who need it the 
most.6-8 Poor patient-reported health status has also been shown to predict mortality and 
rehospitalization in patients with coronary artery disease and heart failure independent of 
traditional biomedical risk factors.9        
 The majority of studies on health status in patients with a continuous-flow LVAD 
show significant improvements in mean health status scores from baseline up to 3, 6 and 12 
months follow-up using various instruments.2,10-16 Differentiating the groups of LVAD 
patients based on age, sex or type of LVAD did not alter these findings.11, 15, 16 However, 
Rogers et al. did find that the group of LVAD patients indicated for destination therapy had a 
higher improvement in median health status scores between baseline and 6 months 
compared to the group of LVAD patients indicated for bridge-to-transplant.17 Thus far, the 
studies on continuous-flow LVADs, which measured health status over time as a primary or 
secondary outcome, often did not report on the clinically relevant change of health status 
nor examined the potential predictors of changes in health status over time. Furthermore, 
scores on health status are reported as mean scores of the patient sample rather than 
examining differences in individual trajectories of health status scores of time. Examining the 
predictors of health status scores of individual LVAD patients is important, as it may give an 
indication for the post-implantation course and may help determine the appropriate 











 Hence, the goal of this study was to examine the predictors of the mean health status 
scores but also the individual health status scores of LVAD patients over time, using a 
disease-specific and generic instrument. 
 
METHODS 
Study population and design 
Adults with advanced heart failure implanted with the axial-flow HeartMate II LVAD 
(Thoratec) or centrifugal-flow HVAD (HeartWare) as a bridge-to-transplant were eligible for 
study participation. Patients were recruited as a consecutively implanted cohort from the 
University Medical Center, Utrecht and the Erasmus Medical Center, Rotterdam, the 
Netherlands and the Heart Center at St. Paul’s hospital in Vancouver, Canada, between 2011 
and 2013. Patients were eligible for inclusion if it was their first LVAD implant, ≥18 years of 
age, proficient in the Dutch or English language and had no history of severe psychiatric 
illness other than cognitive-affective disorders. Study endpoints included heart 
transplantation or death. 
Patients were asked to complete a set of standardized and validated questionnaires 
at baseline (i.e., 3-4 weeks after LVAD implantation when patients were still hospitalized but 
recovered sufficiently for study participation), and at 3, 6 and 12 months follow-up. The 
follow-up assessments were scheduled at the same time points as the visits to the 
outpatient clinic in order to minimize burden to patients. The questionnaires were returned 
in stamped, pre-addressed envelopes. If the questionnaire was not returned within two 
weeks, patients received a reminder telephone call or letter. The study was approved by the 
Medical Ethics Committee of the participating hospitals, and conducted in accordance with 
the Helsinki Declaration (2008).  
 
Measures 
Demographic and clinical variables 
Information on demographic variables comprised sex, age, marital status, employment and 
educational level. Information on clinical variables for patients and partners included body 
mass index (BMI), medical comorbidity and use of psychotropic medication. Information on 
these demographic and clinical variables was extracted from purpose-designed questions in 







using the Charlson Comorbidity Index (CCI), which evaluates 17 different comorbidities with 
varying assigned weights. We used an abbreviated CCI score with the following comorbid 
conditions: myocardial infarction (MI), cerebrovascular disease, chronic obstructive 
pulmonary disease, diabetes mellitus, peripheral vascular disease, liver disease, renal failure, 
and any malignancy excluding metastatic tumors.19 Other clinical variables for the patients 
included duration of hospitalization, etiology, left ventricular ejection fraction (LVEF), New 
York Heart Association (NYHA) functional class, the Interagency Registry for Mechanically 
Assisted Circulatory Support (INTERMACS) score, prescribed medications (i.e., beta-blockers, 
aldosterone receptor antagonists, anticoagulants, ACE-inhibitors, statins and diuretics) and 
previous cardiac events (i.e., myocardial infarction, coronary artery bypass graft (CABG) or 
percutaneous coronary intervention (PCI)). The INTERMACS score was developed by the 
INTERMACS Coordinator’s Council in order to improve the clinical characterization of device 
recipients. Seven profiles have been defined for the INTERMACS registry ranging from crash-




The Kansas City Cardiomyopathy Questionnaire (KCCQ) was used to assess disease-specific 
subjective health status. The KCCQ is a 23-item, self-report questionnaire that quantifies 
physical limitation, symptoms, and social and role functioning of patients with heart failure. 
Scores are transformed into a score from 0 to 100, with a higher score representing better 
health status. The validity and reliability of the KCCQ have previously been established and 
the measure is highly sensitive to clinical change in heart failure patients over a 6-12 week 
period.20-22 In the KCCQ, a Clinical and Overall Summary score can be calculated. The Clinical 
Summary score is derived from the symptom and physical limitation domain. The Overall 
Summary score is derived from the physical function, symptom (frequency and severity), 
social function and quality of life domains. For each domain, the validity, reproducibility, 
responsiveness and interpretability have been independently established. The absolute 
difference between baseline and 6-month KCCQ overall summary scores was calculated and 
dichotomized, with an improvement of ≥10 points indicating a moderately large clinically 












 Health status was also measured using the 12-item Short Form Health Survey (SF-12), 
with these 12 questions overlapping with the SF-36.23 These include questions concerning 
physical functioning, role limitations because of physical health problems or emotional 
problems, general mental health, bodily pain, general health perceptions, vitality and social 
functioning. Scoring algorithms are applied to produce the Physical Component Summary 
(PCS) and Mental Component Summary (MCS) scores. The scoring range is from 0-100 with 
100 being the best possible health status. Test-retest (2-week) correlations of 0.89 and 0.76 
were observed for the PCS and the MSC, respectively, in the general US population (n= 232). 
Reliability statistics of the MCS and PCS scales are good with Cronbach’s alpha= 0.84 and 
0.87, respectively.24  
 
Depression and anxiety 
The Patient Health Questionnaire (PHQ-9) was used to measure depressive symptoms. This 
is a 9-item questionnaire with items mirroring the diagnostic criteria for major depressive 
disorder. Patients are asked to rate how often each symptom has bothered them during the 
past 2 weeks on a scale from 0 (not at all) to 3 (nearly every day) (score range 0-27).25 
Patients who score ≥10 are considered to have moderate to severe depressive 
symptomatology. The PHQ-9 is an ideal instrument for measuring depressive symptoms 
because it is brief, responsive to change over time, and has good reliability (Cronbach’s alpha 
= 0.86) and validity in medical outpatients and patients with HF.25,26 The Generalized Anxiety 
Disorder 7-item scale (GAD-7) is a seven-item self-report measure with items rated on a 
scale from 0 (not at all) to 3 (nearly every day) (score range from 0-21).27 A score ≥10 has a 
sensitivity of 68% and specificity of 88% for detecting generalized anxiety, posttraumatic 
stress, panic, and social anxiety disorders. The GAD-7 has good psychometric properties 
(Cronbach’s alpha= 0.79-0.91) and has been used successfully in patients with cardiovascular 




We used a multilevel model procedure (covariance model: unstructured, maximum 
likelihood (ML) estimate) in SPSS version 19.0 to examine differences in KCCQ Clinical 






(PCS) and mental health status (MCS) from baseline to 3, 6 and 12 months. Due to the 
chosen statistical analysis, data from all available time points are used, thereby limiting bias 
and preserving statistical power. Predictors of KCCQ-CS, KCCQ-OS, PCS and MCS were 
entered in five consecutive models. The first model is the unconditional means model in 
which only the health status scores were entered. In Model 1 time is added to the model as 
a fixed and random variable thereby creating the unconditional growth model. By allowing 
random effects for the health status scores, there is no longer only a mean value of all 
patients in health status scores of time, but also an individual health status trajectory for 
each LVAD patient. This enables the comparison of scores within an individual patient 
between time points, but also the comparison of the scores of individual patients over time 
with the scores of other patients over time. Time was divided into two linear effects, one 
effect between baseline and 3 months follow-up and another effect between 3 and 12 
months follow-up. As the second linear effect of time showed no significant unexplained 
variance, this effect was not included as a random factor in the model. In Model 2, Model 1 
was expanded by adding the socio-demographic variables age, gender and status of 
employment prior to LVAD implantation. In Model 3, the first model was complemented by 
markers of disease severity: LVEF, INTERMACS gradation, comorbidity and etiology. In Model 
4 the psychological factors depression and anxiety were added to Model 1. Finally, in Model 
5 all models were combined creating one full model with socio-demographic, clinical and 
psychological predictors.          
 The choice of covariates was based on theoretical evidence of possible predictors in 
health status of LVAD patients.29, 30 All socio-demographic and clinical variables were 
entered into the model as fixed effects to examine whether they were associated with 
overall health status scores over time but also with individual variation in health status 
scores. Anxiety and depression were entered as time-varying variables, with different scores 
on baseline, 3, 6 and 12 months follow-up. The results of the association between health 
status scores and the predictors are indicated by symbols ranging from p<.10 (weak 

















Of the 107 patients who met the inclusion criteria from all three centers, 31 patients refused 
participation, 18 patients died or were too ill at the time of inclusion, 3 were excluded due to 
inability to write and read Dutch or English, 1 was excluded due to low intellectual 
functioning, and 1 patient underwent a heart transplantation shortly after LVAD 
implantation, leaving a sample of 54 patients for analyses. The patients not participating in 
the study did not differ on age, gender and type of LVAD compared to patients who 
participated (p>.05). The mean age of the study sample was 54.2±9.4 years and 40 (74%) 
patients were male. The underlying heart failure etiology was ischemic in 25 (46%) patients 
and the mean LVEF was 18.0±6.9. The majority of patients received a HeartMate II (n=34, 
63%) and the other patients a HeartWare device (n=20, 37%). Medication included ACE-
inhibitors/angiotensin receptor blocker (70%), beta-blockers (59%), loopdiuretics (72%) and 
statins (52%). Complete information on the demographic and clinical characteristics of the 
patients is shown in Table 1.  
 
Table 1: Clinical characteristics of LVAD patients at baseline 
 LVAD patients 
         (n=54) 
 
  Mean±SD; N (%) 
Socio-demographics  
Male 40 (74) 
Age (yrs)* 54.2±9.4 
Having a partner 49 (90) 
Secondary school and above 49 (90) 
Employed 20 (38) 
Clinical  
Type of LVAD  
      HeartMate II 34 (63) 
      HeartWare 20 (37) 

















































Etiology 25 (46) 
   Dilated 20 (37) 
   Other (hypertrophic, myocarditis) 9 (17) 
Previous CABG 7(13) 
Previous PCI 18 (33) 
Previous valve replacement 6 (11) 
Previous myocardial infarction 25 (46) 
Previous ICD/CRT-D implantation 39 (72) 
Previous CVA 7 (13) 
GFR* 54.7±34.5 
LVEF* 18.0±6.9 
IABP 7 (13) 
ECMO 6 (9) 
Comorbidity Index 
   0 
   1 
   2 
   3 
   4 









Medication use  
Amiodarone  38 (70) 




Statins 28 (52) 
Coumarin (derivates)           54 (100) 
Lisdiuretics 39 (72) 
Psychological  
Depression (PHQ-9)* 4.4±4.8 
Anxiety (GAD-7)* 6.9±4.5 
*Represented as means ± SD 
CABG= coronary artery bypass graft; PCI= percutaneous 
coronary intervention; ICD= implantable cardioverter 
defibrillator; CRT-D= cardiac resynchronization therapy; CVA= 
cerebrovascular accident; NYHA= New York Heart Assocation; 
LVEF= left ventricular ejection fraction; IABP= intra-aortic 











Change in health status during the 12-month follow-up period 
The mean KCCQ-CS and KCCQ-OS scores are shown in Figure 1a. The mean scores on the 
KCCQ Overall Summary Score were 48±19 at baseline, 70±20 at 3 months, 72±23 at 6 
months and 64±20 at 12 months. For the KCCQ Clinical Summary Score this was 47±19, 
68±18, 70±21 and 65±20, respectively. The mean scores on the KCCQ-OS and KCCQ-CS 
improved over 20 points, or 48.5% and 46.8%, respectively. Of the 54 patients, 30 (55.6%) 
had poor health status (KCCQ score <50 points) at baseline. The scores on both subscales 
showed an increase from baseline to 3 and 6 months follow-up leading to KCCQ scores 
which are in concordance with patients having NYHA class II.21 However, the scores tended 
to decrease again between 6 months and 12 months follow-up. Based on an improvement of 
≥10 points on the KCCQ-OS between baseline and 6 months follow-up, 39 patients showed a 
moderate to large clinically significant improvement (72%) while 15 patients did not (28%). 
Patients with and without a clinically significant improvement did not differ on demographic 
and clinical variables, except for responders having a higher educational level than non-
responders (responders 25% vs. 3% in non-responders, χ2=5.44, p=.02 respectively).   
Changes in the mean PCS and MCS scores during the 12-month follow-up are shown 
in Figure 1b. The mean baseline PCS score was 30.5±1.2 and the MCS score was 39.3±1.5. 
The scores on the PCS and MCS increased between baseline and 3 months, indicating an 
improvement in physical and mental health status, but stabilized after 3 months follow-up.  
 
Independent predictors of mean health status scores over time 
The mean scores on the KCCQ and SF-12 showed a significant effect of time between 
baseline and 3 months follow-up caused by a strong increase in the KCCQ Clinical and Overall 
Summary score (KCCQ-CS F=33.49, p<.001; KCCQ-OS F=31.13, p<.001), physical health status 
(PCS F=31.59, p<.001) and mental health status (MCS F=21.77, p<.001). There was no 
significant differences in mean scores over time between 3 months and 12 months follow-up 
(p>.05 for all) (Table 2). After adding the socio-demographic predictors, being employed 
prior to LVAD implantation was associated with higher scores on the KCCQ-OS (F=9.58, 

































Male gender was associated with higher scores on the MCS, however this association was 
only marginally significant (MCS F=4.04, p=.05). Age did not predict changes in health status 
over time. From the clinical predictors in Model 3 a non-ischemic etiology was associated 
with higher scores of KCCQ-OS (F=8.04, p=.008), PCS (F=6.51, p=.015) and MCS (F=8.20, 
p=.007) over time. A higher number of co-morbidities was associated with a lower MCS 











Table 2: Mixed multivariable modeling - significant covariates KCCQ response over time 
 KCCQ-OS KCCQ-CS PCS MCS 
 
Model 1 3 months vs. baseline +++ +++ +++ +++ 
 3 months vs. 6 and 12 months   O O O O 
Model 2 Older age O O O O 
 Male gender O O O + 
 Employed +++ ++ +++ O 
Model 3 Higher EF O O O O 
 INTERMACS  O O O O 
 Ischemic etiology --- O --- --- 
 Comorbidity O O O --- 
Model 4 Depression --- --- --- --- 
 Anxiety O O O -- 
Model 4 Older age O O O -- 
 Male gender O O O - 
 Employed O O O O 
 Higher EF ++ O O O 
 INTERMACS O O O O 










 Depression --- --- --- --- 
 Anxiety O O O -- 
Model 1: unconditional growth model (time)    
Model 2: Model 1 + socio-demographic factors  
Model 3: Model 1 + clinical factors 
Model 4: Model 1 + psychological factors 
Model 5: Model 1 + Model 2 + Model 3 + Model 4 
O= no association, p >.10  
− = negative association, p <.10; −− = nega�ve associa�on, p <.05;  −−− = nega�ve associa�on, p<.01 
+ = positive association, p <.10; ++ = positive association, p < .05; +++ = positive association. P < .01 
 
In Model 4 the depression and anxiety scores of the LVAD patients over time were entered 
into the model. Depression, but not anxiety, was a significant predictor of health status 
scores over time (Model 4: p<.001 for all). An increase of 1 point on depression was 
associated with a 1-3 point decrease in health status.     
 In the final model (Model 5) all predictors were entered simultaneously. Higher 
scores on depression over time were associated with a lower mean health status (KCCQ-OS F 






higher LVEF was associated with better KCCQ Overall Summary Score (F=4.60. p=.04), while 
older age, more comorbidity and higher scores on anxiety were associated with a lower 
mental health status (F=5.34, p=.026; F=12.49, p=.001 and F=5.90, p=.017, respectively.   
 
Independent predictors of between and within-person variance of health status scores 
over time 
The individual health status trajectories of each LVAD patient can be used to examine 
differences between a patient’s own scores over time, which is known as the within-person 
score variance, and differences between the scores over time of individual patients, which is 
known as the between-person score variance. The unconditional means model (without any 
predictors) of the health status scores show a significant within (KCCQ-OS: Wald z=7.40, 
p<.001; KCCQ-CS: Wald z=7.38, p<.001; PCS: Wald z=7.35, p<.001; MCS: Wald z=7.15, p<.001) 
and between-person variance (KCCQ-OS: Wald z=2.69, p=.007; KCCQ-CS=1.88, p=.05; PCS: 
Wald z=2.85, p=.004; MCS: Wald z=2.74, p=.006), indicating that the individual LVAD patients 
differ significantly from each other on the trajectory of KCCQ and SF-12 scores over time. 
Based on the unconditional means model, the estimated proportion of within- versus 
between person variance was 3:1, indicating that most of the difference in health status 
scores over time is attributable to differences within a patient over time.  
 In order to explain the within and between-person variance in health status scores, 
socio-demographic, clinical and psychological predictors were added. Similar to linear 
regression, R2 statistics can be computed to quantify how much of the outcome variations 
are explained by the predictors added to the model. After adding these predictors the 
within-person variance is reduced by 53.4% for the KCCQ-OS, 35.8% for the KCCQ-CS, 38.6% 
for the PCS and 38.9% for the MCS. The majority of this variance is explained by the scores of 
depression and anxiety over time (>50%). The between-person variance is reduced by 41.9%, 
36.2%, 23.2% and 82.6% for the KCCQ-OS, KCCQ-CS, PCS and MCS, respectively. The 
between-person variance for the MCS scores is no longer significant (p=.21), indicating that 
Model 5 explains the majority of variance in MCS scores found between the LVAD patients.
 Overall, the individual trajectories indicate that patients with a stronger incline in 
KCCQ scores between baseline and 3 months follow-up also continue to have higher scores 
after 3 months compared to patients with a less strong incline in KCCQ scores between 












The findings of this study indicate that the majority of LVAD patients experience a moderate 
to large improvement in health status between LVAD implantation and 12 months follow-up, 
which is not only statistically significant but also clinically relevant. The mean scores on the 
KCCQ-OS and KCCQ-CS over time showed a significant increase between LVAD implantation 
and 3 months follow-up, while the scores tended to stabilize or slightly decrease between 3 
months and 12 months follow-up. This effect was also seen in the scores on physical and 
mental health status, as assessed with the SF-12. The multilevel analyses showed that higher 
scores on depression over time were associated with a lower mean health status on the 
KCCQ-OS, KCCQ-CS, PCS and MCS. A higher LVEF was associated with better KCCQ-OS, while 
older age, more comorbidity and higher scores on anxiety were associated with poorer 
mental health status, respectively. Furthermore, there were significant differences in the 
health status scores over time within and between LVAD patients. The within-person 
variance in health status scores was mostly explained by variance in scores on depression 
and anxiety, and not by clinical factors. The majority of the between-person variance of the 
MCS, but not the KCCQ-OS, KCCQ-CS and PCS, was explained by the socio-demographic, 
clinical and psychological factors included in the model.     
 Despite an increasingly growing number of patients being implanted with an LVAD 
around the world, there is minimal information on patient-reported outcomes such as health 
status, especially concerning the within- and between person changes in health status scores 
and the predictors of health status. Our results indicate that scores on health status of Dutch 
and Canadian LVAD patients, as measured by the KCCQ, are consistent with those found in 
the HeartMate II trial11, 14, 17, 31, 32 and by Aaronson et al.,10 except for slightly higher KCCQ-OS 
scores at 3 and 6 months follow-up. For this comparison, it was taken into account that the 
baseline measurement for health status in these trials was performed before LVAD 
implantation, therefore our baseline measurement was compared to the 1 month follow-up 
in these studies. No differences were found on the KCCQ scores for gender and age, which is 
consistent with the findings of others.11, 16 As the INTERMACS registry used the EQ-5D to 
measure health status the outcomes of this study cannot directly be compared to theirs. 
However, the EQ-5D does show a similar health status trajectory compared to the KCCQ with 
a steep incline between baseline and 3 months which is maintained during the first year 






comparison between various patient populations. Only the study of Kugler et al. used the 
extended version of the SF-12 (i.e. SF-36) to examine the impact of a multi-model 
intervention for LVAD patients. Scores on the PCS and MCS were identical with our findings 
with PCS scores ranging from 30 to 40 points and MCS scores ranging from 45 to 50 points.2 
The LVAD patients scored considerably lower compared to the Dutch normative population 
(MCS: 51±9, PCS: 51±9; age 50-59), but did score the same as post-MI patients without LVAD 
implantation.33          
 The main goal of this study was to examine potential predictors of the mean and 
individual health status scores over time. Except for Grady et al.,30 no other studies on LVAD 
patients have examined the predictors in health status scores. Grady et al. also found that 
psychological stress was a strong predictor of health status after LVAD implantation. As is 
known from previous studies30,34,35 psychological distress is highly prevalent in LVAD patients 
post-implantation. This may be attributed to the challenges that patients face particularly 
shortly after implantation, including complications, cardiac rehabilitation and medication, 
driveline- and device-training, which could make them more vulnerable to distress. Based on 
the results of this study, it seems that not only psychological distress shortly after 
implantation is an important predictor for health status scores but also the change in 
psychological distress scores over time. As a subset of LVAD patients (≈25%) seems to suffer 
from chronic psychological stress following discharge from the hospital,36, 37 this subset of 
patients is likely to be more vulnerable for lower health status outcomes. Hence, due to the 
strong interplay between psychological distress and health status, it seems important to 
monitor psychological distress in patients in order to prevent adverse outcomes.  
 Also, comorbidity and LVEF were found to be important predictors for poor health 
status. In a study population with a relatively high prevalence of comorbidities (e.g. lipid 
dysfunction, diabetes and hypertension), it can be expected that comorbidities add 
significantly to the burden after LVAD implantation, and could therefore be important 
antecedents for lower health status scores. Interestingly, the INTERMACS score of patients 
did not affect the trajectory of health status scores after LVAD implantation, suggesting that 
the increase in health status for patients with INTERMACS category 1 and 2 is at least as 
strong as those of patients with INTERMACS category >3. Similar findings were also reported 












The variance in health scores over time within and between the LVAD patients was 
significant and could only be partly explained by the predictors in the model, suggesting that 
more factors should be explored. Other potential predictors who might explain the variance 
in health status could be other LVAD-related factors, such as adverse medication effects or 
clinical complications (i.e., ventricular tachyarrhythmia, infection) requiring hospitalization. 
However, there are also factors that can affect health status that are not LVAD-related such 
as psycho-social factors (i.e. coping, personality, marital quality, self-efficacy, locus of control, 
social isolation). Identifying these factors is important in order to delineate a profile of high-
risk patients who may benefit less from LVAD implantation. These patients could then be 
offered more intensive support or care and may benefit from adjunctive interventions.
 Limitations of this study include the relatively small sample size and the relatively few 
number of female LVAD patients. Due to the sample size, it was not possible to include 
numerous predictors of health status scores (i.e., complications, social-support) nor perform 
a latent class analysis categorizing patients into reduced, stable or improved health status 
over time. Furthermore, due to the sample size it was also not possible to stratify our results 
for type of LVAD or site of implantation. As the clinical and psychological care of LVAD 
patients might differ slightly between the centers this could have impinged on our results. As 
shown in other studies, patients who refused to participate in our study might have suffered 
from more impaired health status and psychological distress, with the possibility that the 
results could represent an overestimation of the health status experienced by patients.39 
Finally, we used self-report measures of psychological distress rather than a clinical 
diagnostic interview.   
 
CONCLUSION 
The primary target of LVAD therapy is to improve survival and well-being of patients with 
end-stage heart failure. As indicated by the findings of the current study, we found a 
significant improvement in health status after LVAD implantation. However, there were large 
differences in individual health status score trajectories which are only partially explained by 
measures of disease severity pre-LVAD, comorbidity and psychological distress. Hence, 
although LVADs may solve the problem of donor scarcity, it is important not to lose sight of 






improving their well-being and quality of life. In order to better predict the post-
implantation course, enhance the quality of care and improve the outcomes after LVAD 
therapy, future research is warranted that examines a broader range of clinical and psycho-
social predictors of changes in health status scores over time and whether these changes are 
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Health status and psychological 
distress in patients with 
noncompaction cardiomyopathy: 
The role of burden related to 







Background: Because of its genetic underpinnings and physical disease burden, non-
compaction cardiomyopathy (NCCM) is expected to be associated with a lower health status 
and increase in psychological distress. Here, we determined the health status and 
psychological distress in NCCM patients, and disentangled the role of genetic predisposition 
versus NCCM-related symptom burden by comparing NCCM patients with (1) patients with 
familial hypercholesterolemia (FH), and (2) patients with acquired dilated cardiomyopathy 
(DCM)  
Methods: NCCM patients (n=45, mean age 46.7±15.1, 38% male) were compared with 42 
DCM and 43 familial hypercholesterolemia patients using a case-control design matching for 
age and sex. Outcome measures were health status (Short Form Health Survey-12), anxiety 
(Generalized Anxiety Disorder 7-item scale) and depression (Patient Health Questionnaire 9-
item scale).  
Results:  NCCM patients showed significantly worse health status (PCS F(1,84))=9.58, p=.003; 
MCS F(1,84)=16.65, p<.001), anxiety (F(1,85)=9.63, p=.003) and depression scores 
(F(1,82)=5.4, p=.023) compared to familial hypercholesterolemia patients, also after 
adjusting age, sex,  comorbidity, educational level and time since diagnosis. However, NCCM 
patients did not differ from DCM patients ((PCS F(1,82)=2,61, p=.11; MCS F(1,82)=.55, p=.46), 
anxiety (F(1,82)=1.16, p=.28) and depression (F(1,82)=1,95, p=.17)). 
Conclusion: The cardiac symptoms of NCCM are mainly responsible for the observed poor 
health status and elevated anxiety and depression associated, instead of the genetic nature 

















Noncompaction cardiomyopathy (NCCM) is a relatively new and rare disease entity 
characterized by prominent trabecular meshwork and deep intertrabecular recesses of the 
left ventricular walls.1-4 NCCM is classified as a primary cardiomyopathy and is a potentially 
life-threatening condition because of its association with progressive left ventricular 
dysfunction, heart failure, ventricular and supra-ventricular arrhythmias, embolic events and 
sudden cardiac death, with a 5-year mortality rate up to 50%.5-7 The clinical presentation of 
NCCM is variable from asymptomatic to severe LV decompensation or life-threatening 
arrhytmias.6 Key characteristics of NCCM are the relatively young age of the patients, the 
poor clinical prognosis in symptomatic individuals, the need for detailed imaging, DNA 
diagnostics, familial screening, and genetic counseling.4 Most cases of NCCM are familial 
with an autosomal dominant inheritance pattern.8-12 NCCM can therefore be detected in 
asymptomatic individuals based on familial screening or following diagnostic tests related to 
other (non-)cardiovascular conditions. The treatment of NCCM involves pharmacological 
treatment, including heart failure medication, symptom management and prevention of 
adverse long-term events by implantable cardioverter defibrillator placement and 
anticoagulation therapy.3, 6  
Little is known about the psychological and behavioral effects of living with a 
diagnosis of NCCM. Both perceived distress related to adverse disease progression as well as 
genetic burden of cardiovascular diseases may adversely influence quality of life and general 
wellbeing. In patients with genetic risk for other disorders a wide range of psychological 
reactions have been described, including anxiety, worry about risk to children, guilt, anger, 
uncertainty, sadness, and depression.13,14 Because of its genetic underpinnings, it is likely 
that NCCM is associated with emotional and psychosocial challenges in addition to potential 
physical disease burden, which to date has not been investigated. This study examines to 
which extent psychological factors are adversely influenced by NCCM. We will differentiate 
between issues related with the genetic nature of the disorder and those related to the 
NCCM-related symptom burden. To disentangle the potential psychological impact 
associated with the genetic nature of NCCM relative to the heart failure symptoms, the 
NCCM patients were compared with (1) patients with autosomal dominant familial 
hypercholesterolemia, and (2) acquired dilated cardiomyopathy patients with a history of 












Study population and design 
Consecutive outpatients with a diagnosis of NCCM were recruited from the Erasmus Medical 
Center, Rotterdam, the Netherlands between May 2012 and August 2013. Inclusion criteria 
were a diagnosis of NCCM based on stringent echocardiographic data (and extended by 
magnetic resonance imaging as needed) as described by the criteria of Jenni et al.1, aged ≥18 
years. Exclusion criteria were >80 years of age, unable to understand and read Dutch, other 
life-threatening diseases, and cognitive impairments or psychiatric comorbidity (except for 
mood disorders).           
 The first comparison group included patients with familial hypercholesterolemia (FH). 
Because of the genetic nature of the disorder associated with increased levels of low-density 
lipoproteins, these patients are prone to develop cardiovascular diseases. Patients in this 
comparison group were not included if they had documented coronary artery disease or a 
left ventricular ejection fraction (LVEF) <40%.        
The second comparison group included patients with dilated cardiomyopathy (DCM) 
and a history of heart failure. This comparison group was used to determine the contribution 
of a positive history of cardiac disease and symptom burden as related to the NCCM group. 
These patients were identified via the Erasmus Medical Center institutional heart failure 
database with diagnosis verified by echocardiography and clinical history. Patients with 
coronary artery disease as primary cause were excluded from this control group. Both 
control groups were matched on sex and age using frequency matching.   
 Of the 105 NCCM patients registered in the Erasmus MC database 56 could be 
contacted for study participation, 11 patients refused participation or did not return the 
baseline questionnaire, leaving 45 patients eligible for analyses (79% response rate). For the 
familial hypercholesterolemia group 55 patients were approached, 12 patients refused 
participation or did not return the questionnaire leaving 43 patients for analysis in this group. 
For the cardiomyopathy group 54 patients were approached, 12 patients refused 
participation or did not return the questionnaire, resulting in a sample of 42 patients in this 
group.            
 The study protocol was approved by the medical ethics committee of the Erasmus 
Medical Center, the Netherlands. The study was conducted according to the Helsinki 






approached, for study participation, by their treating physician or heart failure nurse. 
Patients received a package containing written information about the study, an informed 
consent form, and the questionnaire booklet together with a postage-paid return envelope 
at their home address. If the questionnaire package was not returned within two weeks, 
participants received a reminder telephone call.  
 
Measures 
Health status and quality of life 
Health status was measured using the 12-item Short Form Health Survey (SF-12), which 
these 12 questions overlapping with the SF-36.15 These include questions concerning 
physical functioning, role limitations because of physical health problems or emotional 
problems, general mental health, bodily pain, general health perceptions, vitality and social 
functioning. Scoring algorithms are applied to produce the Physical Component Summary 
(PCS) and Mental Component Summary (MCS) scores. The scoring range is from 0-100 with 
100 being the best possible health status. Test-retest (2-week) correlations of 0.89 and 0.76 
were observed for the PCS and the MSC, respectively, in the general US population 
(n=232).16 Reliability statistics of the MCS and PCS scales is good with Cronbach’s alpha= 0.84 
and 0.87, respectively. 
 
Depression 
The Patient Health Questionnaire (PHQ-9), was used to measure depressive symptoms. This 
is a 9-item questionnaire with the items mirroring the diagnostic criteria for major 
depressive disorder. Patients are asked to rate how often each symptom has bothered them 
during the past 2 weeks on a scale from 0 (not at all) to 3 (nearly every day) (score range 0-
27). Patients who score a 10 or higher are considered to have moderate or greater 
depressive symptoms.17 The PHQ-9 is an ideal instrument for measuring depressive 
symptoms because it is brief, responsive to change over time, and has good reliability 
(Cronbach’s alpha = 0.86) and validity in medical outpatients and patients with HF.18 
 
Anxiety 
The Generalized Anxiety Disorder 7-item scale (GAD-7) is a self-reported seven-item anxiety 











score of 10 or higher has a sensitivity of 68% and specificity of 88% for detecting generalized 
anxiety, posttraumatic stress, panic, and social anxiety disorders.19 The GAD-7 has good 
psychometric properties (Cronbach’s alpha = 0.79-0.91) and has been used successfully in 
patients with cardiovascular disorders.20 
 
Clinical and demographic variables  
Information on these demographic and clinical variables was extracted from purpose-
designed questions in the questionnaires and from patients’ medical records. Information on 
demographic variables comprised gender, age, marital status (having a partner vs. having no 
partner), and educational level (primary school vs. secondary school and above). Information 
on clinical variables included time since diagnosis, previous cardiac events, prescribed 
medications (beta-blockers, calcium antagonists, nitrates, aspirin and other platelet-
aggregation inhibitors, anticoagulants, ACE-inhibitors, statins, loopdiuretics and psychotropic 
medication), standard laboratory values (creatinine, C-reactive protein, nt-proBNP, white 
blood cell count), alcohol and cigarette use, and BMI. The comorbidity index was calculated 
in accordance with the original Charlson Comorbidity Index (CCI) in which a weight of 2 was 
assigned to renal failure and any malignancy, and a weight of 1 to the other comorbid 
conditions (i.e. diabetes mellitus, cerebrovascular accident, peripheral arterial disease), 
depending on the relative mortality risk of each specific disease. By adding up the values 
assigned to each comorbid condition, a comorbidity score was calculated for each patient. 
Because age is a risk factor for mortality independent of the presence of comorbid 
conditions, we adjusted the score by adding one point to the score for each decade of life 
over the age of 50 at time of study entry.21 Kidney failure was measured by calculating the 
glomerular filtration rate of creatinine (GFRcreat) using the MDRD formula, and kidney 
dysfunction was defined as a GFRcreat<60mL/min per 1.73m2.22 For the NCCM and CMP 
patients also data on New York Heart Association (NYHA) functional class was collected. 
 
Statistical analyses 
Data are presented as mean ± standard deviation (SD) or N and %. To compare the 
demographic and clinical characteristics between the NCCM, FH and DCM patients, t tests, 
Mann-Whitney U tests, or χ2-tests were used depending on the measure and variable 






were compared using multivariate analyses of variance (MANOVA). If the overall MANOVA 
effects were significant subsequent analyses of covariance (ANCOVAs) were used to 
compare NCCM vs. FH and NCCM vs. DCM, adjusting for covariates that are known to be 
associated with health status and psychological factors in patients with cardiovascular 
disease. In adjusted analyses time since diagnosis, marital status, educational level and 
comorbidity, as measured using the Charlson Comorbidty Index, were entered as covariates. 
These analyses were repeated comparing only the NCCM and DCM group, thereby also 
adding NYHA classification and dosage of loopdiuretics as additional covariates. In addition 
the NCCM and DCM group was stratified based on disease severity using unadjusted 
analyses of variance (ANOVA). Furthermore, the scores for depression and anxiety were 
dichotomized based on the validated cut-off score of ≥1017, 19 and compared using χ2-tests.  





Table 1 shows that the three groups were comparable in terms of socio-demographic 
variables (p>.05) and that the matching procedures for sex and age were successful. The 
NCCM and DCM patients had significantly elevated measures on most biomedical measures 
as compared to the FH group with a higher prevalence of ICD/CRT-D implantations, 
comorbidities and use of loopdiuretics, beta-blockers and ACE-inhibitors (p<.001 for all). 
Furthermore, NCCM and DCM patients had a shorter time since diagnosis (p=.01) and a 
lower prevalence of alcohol consumption (p=.02) and statin use (p<.001). Comparisons 
between NCCM and CMP groups revealed that NCCM patients are prescribed significantly 
less loopdiuretics (p=.005) and ACE-inhibitors (p=.04). Compared to the familial 
hypercholesterolemia group, NCCM patients are more often implanted with an ICD/CRT-D 
(p<.001), have more co-morbidities (p=.002), are prescribed more ACE-inhibitors (p<.001), β-






























































































































































































































































































   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

















































































































































































































































































   



























































































































































   
   
   
   
   
   
   



























































































































































































































































































































































Health status, anxiety and depression in NCCM 
As is shown in Figure 1, unadjusted multivariate analysis showed that the three groups 
differed significantly in terms of health status, anxiety and depression scores (Wilks’ 
Lambda=0.75, F(8,230)=4.40, p<.001). Scores on physical health status (F(8,230)=11.18, 
p<.001), mental health status (F(8,230)=12.50, p<.001), anxiety (F(8,230)=5.51, p=.005) and 
depression (F(8,230)=6.4, p=.002) differed between NCCM, DCM and FH patients. When 
adjusting for age, sex, comorbidity, educational level and time since diagnosis the overall 
multivariate group effect for all outcome variables combined remained significant (Wilks’ 
Lambda=.80, F(8,220)=3.29, p=.001) (Table 2). Subsequent analyses focus on the comparison 
between NCCM vs. FH and NCCM vs. DCM patients. 
 
Comparison between patients with NCCM and familial hypercholesterolemia 
NCCM patients showed significantly worse health status scores (PCS F(1,84))=9.58, p=.003; 
MCS F(1,84)=16.65, p<.001) and higher scores on anxiety (F(1,85)=9.63, p=.003) and 
depression (F(1,82)=5.4, p=.023) compared to FH (Figure 1). Adjustment for age, sex, 
comorbidity, educational level and time since diagnosis resulted in significant differences 
between NCCM and FH for mental and physical health status (PCS F(6,78)=6.04, p=.021 MCS 
F(6,78)=12.69, p=.001) and anxiety (F(6,80)=5.28, p=.02), whereas results for depression 
became non-significant in adjusted models (F(6,76)=1.67,p=.20). Patients with a shorter time 
since diagnosis, a higher degree of comorbidity and a lower educational level had 
significantly lower physical health status scores (p’s≤.01). For anxiety and depression a 
younger age and also a higher degree of comorbidity and a lower educational level were 
significantly associated with higher scores (p’s≤.03) (Supplementary Table 1a). The 
prevalence of anxiety was significantly higher in NCCM vs. FH (16% vs. 2%; p=03). For 
depression these percentages were 16% and 2%, respectively (p=.89).  
 
Comparison between NCCM and DCM 
NCCM and DCM patients showed no significant difference in health status (PCS F(1,82)=2,61, 
p=.11; MCS F(1,82)=.55, p=.46), anxiety (F(1,82)=0.36, p=.54) or depression (F(1,82)=1,95, 
p=.17). Adjustment for age, sex, comorbidity, time since diagnosis and educational level did 
not alter these findings (Supplementary Table 1b). Additionally, NYHA functional class and 






in disease severity. NYHA classification, but not the dosage of loopdiuretics, was significantly 
associated with lower health status scores (PCS F(1,75)=12.61, p=.001; MCS F(1,75)=6.43, 
p=.01) and higher depression (F(1,72)=4.86 p=.03) scores. The prevalence of depression was 
lower in NCCM vs. DCM (18% vs. 32%) but this difference was not significant (p=.13). No 
differences in anxiety were observed (16% vs. 18%, respectively (p=.73).  
 
The role of symptoms in NCCM, DCM and FH  
Because symptom status as measured by NYHA classification was significantly associated 
with health status, anxiety and depression in the NCCM and DCM group, both groups were 
stratified by NYHA classification (NYHA I vs. NYHA II/III) thereby creating four groups. Results 
show a significant group effect (Wilks’ Lambda=.67, F(12,188)=2.61, p=.003) and an effect for 
symptom status on physical health status (F=8.19, p<.001, Cohen’s d=.21) (Figure 2).  
To compare the NCCM with patients with FH (who are asymptomatic), the NCCM 
patients with NYHA with class I (N=25) were compared to the FH patients. No significant 
group effect between the NCCM NYHA class I patients and the patients with FH were found 
(Wilks’ Lambda=.86, F(4,58)=2.45, p=.06) except for a lower mental health status (F=7.41, 
p=.008) and higher levels of anxiety (F=5.33, p=.02) NCCM patients compared to familial 
hypercholesterolemia patients (Figure 3). 
 
DISCUSSION 
NCCM is a relatively new disease entity, contrary to DCM and familial hypercholesterolemia, 
of which the definition, pathogenesis, treatment and prognosis are still under debate.23 In 
the Netherlands the expertise on NCCM is limited with the Erasmus Medical Center being 
the only center performing research on the clinical as well as the psychological aspects of 
having a diagnosis of NCCM.  As expected, noncompaction cardiomyopathy and dilated 
cardiomyopathy patients had significantly elevated measures on most biomedical items 
related to cardiac disease as compared to the familial hypercholesterolemia group. Patients 
with NCCM also had a significantly lower health status and elevated levels of anxiety and 
depression compared to patients with familial hypercholesterolemia. However, no 
significant group effect was found between asymptomatic patients with NCCM and patients 











observed poor health status and elevated anxiety and depression associated with NCCM. 
Consistent with this observation is that the NCCM group did not differ from the DCM group 
on any of the psychological outcome measures and that the main driving factor appeared to 
be the presence of symptoms (as indicated by NYHA classification) or total daily dose of 
loopdiuretics. Specifically, stratification of the NCCM and DCM group by NYHA classification 
showed that patients having NYHA class II/III had lower health status and higher anxiety and 
depression scores compared to NYHA class I patients, irrespective of having NCCM or DCM.
  
Figure 1: Means (SE) of health status, anxiety and depression scores NCCM, dilated 






































PCS= physical component scale; MCS= mental component scale; NCCM= non-





















































































































































































































































































































































































Other studies that have examined the psychological impact of genetic cardiovascular 
conditions show mixed results, with some studies finding high anxiety and/or depression 
levels in patients with hypertrophic cardiomyopathy or patients at risk for arrhythmias and 
sudden cardiac death,24-26 while other studies found almost no adverse effects on health 
status or relatively low prevalence’s of anxiety and depression compared to the general 
population.27-30 Steptoe et al. compared the health status and psychological distress of 
familial versus non-familial DCM and found that the presence of familial DCM was related to 
better physical functioning and fewer role limitations related to emotional problems 
compared to patients without a familial DCM.31 A reason for this finding could be a 
difference in disease severity between the familial and non-familial DCM group, as non-
familial cases might have experienced more symptoms while familial DCM patients were 
often asymptotic and diagnosed through genetic family screening. In the current study, 
there are no such differences in disease severity between the NCCM and DCM patients, 
thereby possibly explaining the discrepancy in results between the studies.  
 Overall, the non-significant differences between patients having NCCM and DCM 
suggest that the presence and severity of symptoms, activity restrictions and possible 
adverse medication side effects are mainly responsible for the negative effects on health 
status, anxiety and depression. The health status scores of the familial hypercholesterolemia 
patients was significantly higher compared to the NCCM and DCM patients, and equal to 
those of the Dutch normative population.32 Four other studies on familial 
hypercholesterolemia patients also found no differences between the health status of 
familial hypercholesterolemia patients and healthy control populations,33-37 while one study 
even found a higher health status scores for familial hypercholesterolemia patients 
compared to a control population.38 The prevalence of anxiety in the group of familial 
hypercholesterolemia was higher compared with the study of Hollman et al. who found a 
prevalence rate for anxiety of 5%.38 However, another study found that 44% of the patients 
expressed anxiety, mainly originating from the fear of developing cardiovascular disease.39  
The use of two comparison groups and the well-characterized sample of NCCM 
patients are strengths of this study. Several limitations need to be considered including the 
relatively small sample size. Furthermore, this was a single center cross-sectional study 
which limited the ability to determine the directionality of any relationship between health 






of anxiety and depression we used a self-report measure, and caution is required regarding 
the outcomes of the analyses in relation to a clinical diagnosis of depression. The study did 
not use performance-based indices of functional status such as treadmill exercise or the six 
minute walking test.  
 
CONCLUSION 
NCCM is a new, potentially life-threatening condition with genetic underpinnings. The 
prevalence of NCCM will probably increase in the coming years as a result of improved 
modalities available for cardiac imaging and a higher awareness amongst cardiologists about 
the nature and presentation of this condition. In the current study we found that NCCM 
patients have a poorer health status and reported more psychological distress compared to 
patients having familial hypercholesterolemia while their reported wellbeing was equal to 
that of DCM patients. These findings indicate that the genetic nature of a NCCM diagnosis 
does not seem to result in an additional burden with respect to quality of life. Additional 
studies are warranted to replicate these findings, to examine the role of psychological 
distress in the course of disease progression and prognosis in NCCM patients, and to explore 
differences in health status and psychological distress between NCCM and other 























Figure 2: Health status, anxiety and depression of NCCM and dilated cardiomyopathy 













PCS= physical component scale; MCS= mental component scale; NCCM= non-compaction 
cardiomyopathy;  DCM= dilated cardiomyopathy; FH=familial hypercholesterolemia; NYHA= New 






Figure 3: Health status, anxiety and depression of NCCM and familial hypercholesterolemia 










PCS= physical component scale; MCS= mental component scale; NCCM= non-compaction 
cardiomyopathy; FH=familial hypercholesterolemia; NYHA= New York Heart Association functional 
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Anti-depressant use and risk 
for mortality in 120,443 heart 
failure patients with or without a 







Background: Depression increases the risk for mortality in heart failure (HF) patients. 
However, effectively treating depression by anti-depressant therapy does not seem to be a 
guarantee for improving survival. The objectives of the current study were to identify the 
correlates of anti-depressant use subsequent to hospital discharge, and examine the relation 
between anti-depressant use, clinical depression and mortality. 
 Methods and Results: The study sample included 120,443 HF patients from the Danish 
Patient Registry. In total, 16.6% (19,348) received anti-depressants subsequent to discharge, 
of which 86.7% (16,780) had no diagnosis of clinical depression and 13.3% (2,568) had a 
diagnosis of clinical depression. Patients using anti-depressants, with or without clinical 
depression, had a significantly higher risk for all-cause mortality (HR=1.22; 95%CI, 1.22-1.27; 
HR=1.25; 95%CI, 1.17-1.27, respectively) as compared to patients not using anti-depressants 
in adjusted analysis. Female gender, older age, increasing HF severity and number of co-
morbidities were also strong predictors for all-cause mortality (p<.001). After adjustment for 
multiple confounders all anti-depressant groups were independently associated with a 
higher all-cause mortality risk compared to patients using no anti-depressants (SSRIs: 
HR=1.24; 95%CI, 1.21-1.27; TCAs: HR=1.23; 95%CI, 1.07-1.29; other anti-depressants: 
HR=1.29; 95%CI, 1.24-1.35; combination of anti-depressants: HR=1.20; 95%CI, 1.13-1.27).  
Conclusion: More attention is needed towards anti-depressant prescriptions in HF patients, 
especially in those without a clinical depression. Future research should focus on differences 
in patient characteristics between anti-depressant subgroups, and identify the unique 
pharmacological properties of individual anti-depressants, as this may be crucial in 
















Depression is prevalent in 15%-40% of patients with heart failure (HF) and increases the risk 
for mortality and rehospitalization.1, 2 Given the assumption that treating depression in HF 
would improve prognosis, there has been a considerable rise in anti-depressant use in these 
patients over the past years.1,3,4 Paradoxically, effectively treating depression by anti-
depressant therapy does not seem to be a guarantee for successfully reducing the risk for 
adverse events in cardiovascular patients,5, 6 with some studies even suggesting an increased 
risk for HF mortality.3, 7 The association between anti-depressant use and cardiovascular 
events appears to depend on the class of anti-depressant medication8 and may vary across 
different cardiovascular populations, definitions of anti-depressant use and statistical 
analyses used.1Not all studies adjusted statistically for depressive symptoms, nor examined 
the combined effect of anti-depressant use and depressive symptoms,9-12 let alone include a 
diagnosis of clinical depression. 
The two main classes of anti-depressant medication are the selective serotonin 
reuptake inhibitors (SSRIs) and the tricyclic anti-depressants (TCAs).1 TCAs are known to have 
pharmacological properties that can precipitate life-threatening arrhythmias, increase heart 
rate and orthostatic hypotension and prolong QT-interval in patients with ischemic heart 
disease.13 Despite these side effects only a few studies found that TCAs significantly 
increased the risk for cardiovascular disease,8 ischemic heart disease10 and myocardial 
infarction 9 in population-based samples, or mortality in patients with pre-existing HF.3  
Findings on SSRIs suggest that their use in cardiac patients is relatively safe and 
induces only minimal cardiovascular effects, making them preferable over TCAs.13 Two 
studies confirmed the safety of SSRIs by showing reduced incidence of myocardial infarction 
or mortality in HF patients using SSRIs.14, 15 However, other studies found no significant 
difference in risk in relation to SSRI use.4, 5, 8-12                  
            Hence, there is an urgent need to re-examine the prescription pattern of anti-
depressants post HF diagnosis and the mortality risk associated with anti-depressant use in 
large cohorts of HF patients in order to optimize the treatment and care of these patients. 
The objectives of the current study were to (1) examine the prevalence of anti-depressant 
use in HF patients 5-years post diagnosis, (2) identify the correlates of anti-depressant use 
subsequent to hospital discharge, and (3) examine the relation between anti-depressant use 











anti-depressant, and clinical diagnosis of depression were derived from the Danish registries. 
These registries provide a unique opportunity to track anti-depressant use over time and to 
examine whether the association between different anti-depressant use and mortality is 
similar in HF patients with and without a clinical diagnosis of depression, while controlling 
for potential confounders.  
 
METHODS 
Data sources and study population 
The Danish National Health Service provides tax-supported health care which allows access 
to general practitioners and hospitals, and partially reimburses prescribed drugs. Using the 
civil registry number, which is unique to every Danish citizen, it is possible to perform a 
complete linkage of all administrative population-based registries at the individual level. The 
Danish registries include data on socio-demographic characteristics, socio-economic status, 
hospitalizations, vital status, and prescribed medications. Vital status was obtained from the 
Danish Civil Registration System. Diagnostic information from hospital admissions are coded 
using the International Classification of Diseases, Tenth Revision (ICD-10), and drugs were 
grouped according to Anatomical Therapeutic Chemical (ATC) codes. Because of partial 
reimbursement of drug expenses by the healthcare system, pharmacies in Denmark are 
required to register all dispensed prescriptions, ensuring complete data on date of 
dispensing and dosage.   
 
Study population 
For this study, we obtained information from all individuals who survived their first 
hospitalization admission for HF between 1997 and 2010 (ICD-codes: I11.0, I50, I42, and J81). 
First time admission was defined as no previous admission for HF since 1978. The registry 
did not allow us to distinguish between HF with preserved or reduced ejection fraction. A 
diagnosis of clinical depression included unipolar (i.e., major depressive episode, dysthymia) 
depression (ICD-codes: DF30-DF39). The prevalence of clinical depression was extracted 
from the registry at 90 days after discharge and at 1- and 5-year follow-up.  
To ensure equal time for all patients to claim prescriptions for new medications after 
hospitalization, we only included patients alive 90 days after discharge. This approach has 






prescriptions.3 The observational time started 90 days after discharge (from now on referred 
to as ‘study baseline’) and followed patients at risk for all-cause mortality until maximally 
December 31st 2010.  
 
Medical treatment: Cardiac and anti-depressant medication  
We used the following ATC codes to identify the use of anti-depressants (N06A), beta-
blockers (C07), statins (C10A), loopdiuretics (C03C), spironolactone (C03D), aspirin (B01AC06) 
and angiotensin-converting enzyme (ACE) inhibitors (C09). The prevalence of anti-
depressant use and cardiac medication use was extracted from the registry at 90 days after 
discharge, and for the anti-depressants as well at 1- and 5-years follow-up. 
 
Statistical analysis 
All continuous variables were tested for normal distribution. Continuous and categorical 
variables were described by the presence or absence of clinical depression and/or the use of 
anti-depressant medication. Statistical comparisons were made between groups using the 
Pearson Chi-square test for categorical variables and the Student’s t-test or the Mann-
Whitney U test for continuous variables. In addition, a multivariate logistic regression was 
performed to assess associations of anti-depressant use with mortality, adjusting for age, 
gender, socio-economic status, days of hospitalization, comorbidity (Charlson Comorbidity 
Index version 9.5.12), HF severity, other cardiac medications (i.e., beta-blockers, statins, 
ACE-inhibitors), and clinical diagnosis of depression. To determine the severity of HF, the 
average daily dosage of loop diuretics in the first 90 days after discharge was calculated 
(group I: 0-39mg; group II: 40-80 mg; group III: 81-160 mg; group IV: >160 mg.3 Socio-
economic status was calculated using the family income 5 years before the first diagnosis of 
HF, divided by the number of family members. All incomes were then divided into quintiles 
to generate equal size income groups. 
All-cause mortality was compared between HF patients with Kaplan-Meir plots and 
through the estimated hazard ratio from a multivariable Cox proportional hazard regression 
analysis based on the use of anti-depressants thereby creating 3 groups; (1) patients using 
no anti-depressants and having no clinical diagnosis of depression, (2) patients using anti-
depressants having no clinical diagnosis of depression, and (3) patients using anti-











but not on anti-depressants were removed from the analysis (n=809). For this analysis the 
use of anti-depressants was defined as at least 1 prescription at 90 days after discharge from 
the hospital. Multivariate models were fitted with the use of socio-demographic (age, 
gender, marital status), socio-economic and clinical variables (days of hospitalization, 
comorbidity, HF severity, cardiac medication). Another Cox proportional hazard regression 
analysis was performed examining the impact of the use of different anti-depressant groups 
(i.e., TCAs, SSRI, other (tetracyclic, NaSSA, SNRI) as compared to no anti-depressant use, and 
on the impact of different types of anti-depressants on all-cause mortality. All analyses were 
performed using the Stata statistical package version 11.2 (Stata Corp, College Station, Tex). 
 
Ethics 
The Danish Data Protection Agency approved the study (No.2003-54-1269). In Denmark, 





A total of 120,443 patients survived their first hospitalization for HF during the study period. 
Baseline characteristics of patients in the total sample and stratified according to anti-
depressant use at baseline (90 days after discharge) are shown in Table 1. In total, 16.6% 
(19,348) received anti-depressants at baseline, while 83.3% (101,095) patients received no 
anti-depressants. Of the patients using anti-depressants, 86.7% (16,780) of the patients had 
no diagnosis of clinical depression but were on anti-depressant treatment, and 13.3% (2,568) 
of patients were diagnosed with clinical depression and were on anti-depressant treatment 
subsequent to discharge.  
 
Prevalence and correlates of anti-depressant use 
The prevalence of anti-depressant use at 90 days after discharge was 16.6%. At 1-year, 
98,590 patients were still alive of which 21% (20,802) patients received anti-depressant 
treatment while only 2% (1,972) of these patients also had a diagnosis of clinical depression. 
At 5-years, 37,813 patients were still alive of which 28.9% (12,083) received anti-depressant 






the multivariate logistic regression analysis, female gender, older age, higher socio-economic 
status, more comorbidities, increased use of statin, spironolactone and aspirin, a lower use 
of beta-blockers and ACE-inhibitors, increase in hospitalization days, greater HF severity and 
a diagnosis of clinical depression were independently associated with anti-depressant use 
subsequent to discharge (Table 2).  
 
Incidence of mortality during the follow-up period 
The median follow-up duration was 2.9 years (interquartile range 1.1-5.6 years).  During this 
period, 61.1% (61,800) of patients died in the group not using anti-antidepressants, 70.3% 
(11,801) died in the group using anti-depressants, and 71.3% (21,830) patients died in the 
group with clinical depression and using anti-depressants. The 1-, 3- and 5- year crude 
mortality rates were 19.0%, 49.3% and 69.8%. 
 
Clinical depression, anti-depressant use and all-cause mortality 
Univariate Cox proportional hazard regression analysis showed that patients using anti-
depressants without clinical depression (HR: 1.45; 95%CI, 1.43-1.48, p<.001) and patients 
using anti-depressants with clinical depression (HR: 1.68; 95%CI, 1.60-1.76, p<.001) had a 
greater risk of all-cause mortality in comparison to HF patients not  using anti-depressants 
and no clinical depression (Figure 1). In multivariate Cox proportional hazard analyses, 
patients using anti-depressants, with or without clinical depression, had a significantly higher 
risk for all-cause mortality (ps<.001) after adjustment for socio-demographic and clinical 
variables (Table 3). Also female gender, older age, greater HF severity and more 
comorbidities were significantly associated with a higher all-cause mortality risk (all ps<.001).
  
Anti-depressant groups and all-cause mortality 
In order to examine whether group of anti-depressant (i.e., TCA, SSRI, other (tetracyclic, 
NaSSA, SNRI) was associated with a differential risk for all-cause mortality, a univariate Cox 
proportional regression hazard analysis was performed for patients using anti-depressants, 
stratified by anti-depressant group, using no anti-depressant use as the reference category 
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Table 2: Associates of anti-depressant use at baseline (90 days after discharge)  
 OR 95% CI p-value 
Sex (males) .59 .57 -  .61 <.001 
Age 1.01 1.00 - 1.02 <.001 
Socio-economic status 1.03 1.01 - 1.04 <.001 
Ischemic etiology 1.00 .97- 1.04 .86 
HF severity 1.10 1.09 - 1.12 <.001 
Beta-blockers .83 .80 - .86 <.001 
ACE-inhibitors .87 .84 - .90 <.001 
Spironolactone 1.07 1.03 - 1.11 <.001  
Statins 1.05 1.00 - 1.09 .028 
Aspirin 1.15 1.09 - 1.19 <.001 
Hospitalization days .99 .99 - 1.00 <.001 
Comorbidity* 1.18 1.16 – 1.19 <.001  
Clinical depression 4.03 3.87 - 4.20 <.001 
*The comorbidity (index) was entered as a nominal variable (see Table 1) 
*n=120,453 due to missing data on predictor variables 
 
Use of SSRIs (HR: 1.53; 1.49-1.56, p<.001), TCAs (HR: 1.18; 1.12-1.24, p<.001), other anti-
depressants (HR: 1.50; 1.44-1.56, p<.001) and a combination of anti-depressants (HR: 1.57; 
1.49-1.67, p<.001) was associated with an increased all-cause mortality risk compared to no 
anti-depressant use (Figure 2). In adjusted analysis, there remained a significant increased 
all-cause mortality risk for all anti-depressant groups (SSRIs, TCAs, other anti-depressants, 
combination of anti-depressants; p<.01) (Table 4). 
 
A similar analysis was performed within the group of anti-depressant users only (n=19,348), 
with SSRI used as reference category. In univariate analysis, use of TCA (HR: 0.86; 0.82-0.89, 
p<.001), other anti-depressants (HR: 0.86; 0.84-0.89, p<.001) and a combination of anti-
depressants (HR: 0.81; 0.79-0.84, p<.001) were associated with a lower all-cause mortality 
risk compared to SSRI use. In adjusted analysis, the use of TCAs remained associated with a 
lower all-cause mortality risk compared to SSRI use (p<.001), but not the use of other anti-







Anti-depressant type and all-cause mortality 
Analyses of individual anti-depressants showed that prescriptions of the SSRIs fluoxetine (HR: 
1.13; 1.03-1.24, p=.01), sertraline (HR: 1.17; 1.11-1.24, p<.001), citalopram (HR: 1.20; 1.17-
1.23, p<.001) and escitalopram (HR: 1.28; 1.19-1.37, p<.001) at baseline were associated 
with an increased all-cause mortality risk (Table 5). Similar results were found for the TCAs 
nortriptyline (HR: 1.16; 1.04-1.28, p=.005) and amitriptyline (HR: 1.14; 1.06-1.21, p<.001), 
the SNRIs venlafaxine (HR: 1.16; 1.07-1.25, p<.001) and duloxetine (HR: 1.39; 1.05-1.85, 
p=.02) and the NaSSA mirtazapine (HR: 1.21; 1.16-1.27, p<.001). 
 
DISCUSSION 
To our knowledge, this is the first large-scale study using national registry data to examine 
the prevalence of anti-depressant use during 5-years follow-up and the relationship between 
anti-depressant use and all-cause mortality in HF patients taking into account a clinical 
diagnosis of depression and stratifying analyses by anti-depressant group and type. We 
found a relatively high prevalence of anti-depressant use at baseline, which increased during 
the 5 years of follow-up, as was also found in a previous study.5 In multivariate regression 
analyses the prescription of anti-depressants was especially associated with a diagnosis of 
clinical depression (OR=4.03), but also with older age, female sex, a higher severity of HF, 
more comorbidity, a longer duration of hospitalization after discharge and less use of cardiac 
medication. A combination of anti-depressant use and clinical depression subsequent to 
hospitalization for HF had no additive effect on the risk for all-cause mortality (HR: 1.25; 
1.17-1.27), after adjustment for socio-demographic and clinical variables, compared to anti-
depressant use without a diagnosis of clinical depression (HR: 1.22; 1.22-1.27). This could 
indicate that anti-depressant use is a proxy for unregistered (sub)clinical depression or that 
anti-depressant use per se could  be responsible for the increase in all-cause mortality risk. In 
addition, the group of anti-depressant users without clinical depression might have been 
prescribed anti-depressants for other types of illnesses such as fibromyalgia or anxiety (SSRI), 
or diabetic neuropathy (TCA).  
           
No previous studies have examined the combined effect of clinical depression and anti-
depressant use, and studies which have investigated the separate risk of anti-depressant use 











the majority of studies found a significant increased mortality risk for both anti-depressant 
use4,7,9,10,16,17 and clinical depression,4,5,17 separately. Some studies could not distinguish the 
specific effect on mortality of the anti-depressants under investigation in comparison to the 
effect on mortality caused by the disease (i.e. depression) itself as they did not correct for 
depression.1, 9, 10 Other studies examined the prevalence of depression by means of self-
reported questionnaires, such as the Beck Depression Inventory (BDI) and the Geriatric 
Depression Scale.4,5,17 The prevalence rates of depression in these studies were much higher 
as compared to the prevalence of clinical depression that we found in the current study (20-
30% versus 3%, respectively), suggesting a discrepancy in the identification of depression in 
HF patients. Freedland et al. found that only 55% of the patients scoring in the depressed 
range on the BDI had clinically significant depression according to the Diagnostic Interview 
Schedule, and 16% of patients classified as non-depressed on the BDI were depressed 
according to the Diagnostic Interview Schedule despite the strong association between the 
BDI and the classifications of the Diagnostic and Statistical Manual of Mental Disorders.18 
Beside the differences in the assessment of depression, there were also differences in the 
time of assessment, as they asked patients to complete depression measures during 
hospitalization. Furthermore, it could be that depression which is diagnosed in primary care 
is not always registered as clinical depression in the patient registry, Overall, this makes it 
difficult to directly compare the findings.  
  
Subgroup analyses of anti-depressants showed that use of SSRIs, TCAs, SNRIs, other anti-
depressants or a combination of anti-depressants at baseline significantly increased the risk 
for all-cause mortality in this cohort of HF patients, even after correction for clinical 
depression. Although confounding by indication, in which the higher mortality risk is induced 
by the depression itself, cannot be ruled out the use of anti-depressants per se could also 
induce higher mortality risk through pharmacological, physiological or behavioral 
mechanism. TCAs, SSRI, SNRIs and other anti-depressants may have some pharmacological 
characteristics that are raising the mortality risk.13 Anti-depressants have found to 
precipitate life-threatening arrhythmias, prolong the QT-interval and cause toxicity by drug-
drug interactions.13 There have also been found adverse physiological effects of anti-
depressant us, for example on heart rate variability, sympathetic control, hypertension and 






confounding due to unmeasured or unknown factors, such as poor self-care. The use of SSRIs 
has been associated with increased risk of non-adherence to evidence-based 
pharmacotherapy in HF, which could explain the adverse clinical outcomes in patients on 
SSRIs. Equally, it is plausible that a subset of patients suffers from treatment-resistant 
depression, in which the anti-depressant is not capable of reducing the depressive 
symptoms sufficiently to decrease the mortality risk.23      
 
These results, however, are surprising when compared to the findings of other studies that 
found no significant effect of SSRI use in adjusted analyses on mortality,4,5,8-12 or even a 
significant decrease in the risk of mortality.14,15 Furthermore, as two large randomized 
clinical trials that enrolled patients with coronary artery disease (i.e., Sertraline Against 
Depression and Heart Disease in Chronic Heart Failure SADHART and the Canadian Cardiac 
Randomized Evaluation of Antidepressant and Psychotherapy Efficacy trial) found no safety 
issues with SSRI use an explanation for this finding is lacking.6 These differences in findings 
might be attributed to methodological differences between studies including the length of 
follow-up.    
 
Studies on TCAs also show mixed findings, with one study on post MI patients finding a 
lower but non-significant risk for mortality15 while other studies found no significant increase 
in the risk for mortality, first time MI or ischemic heart disease.5,8, 10, 11 For the group of other 
anti-depressants, only the study by Monster et al. found a protective effect in relation to the 
risk of MI,12 with most other studies finding no significant difference in risk of use of other 
anti-depressants in relation to MI,11, 15 ischemic heart disease10 or mortality.8 When we 
evaluated the mortality risk stratified by type of anti-depressant, the use of TCAs was 
associated with a 10% reduction in mortality risk in HF patients compared to the use of SSRIs 
(HR: 0.90; 0.85-0.95, p<.001), but not compared to the use of other anti-depressants or a 
combination of anti-depressants. The results we found might be explained by a selection 
bias as HF patients using TCAs are significantly younger, more often female, had a lower SES 
and more comorbidity although they were not significantly different with respect to disease 
severity (i.e. based on loopdiuretic use). However, it could be that there are unmeasured 








Table 3: Association between clinical depression, anti-depressant use (at 90 days) and all-
cause mortality (multivariate Cox proportional hazard analysis)*  
Variables All-cause mortality
HR 95% CI p-value
Group
 Anti-depressants, no depression 
  Anti-depressants, depression
1.25 
1.21 
1.22 – 1.27 
1.17 – 1.27 
<.001 
<.001 
Sex 1.27 1.25 – 1.29 <.001










.99 – 1.04 
1.01 – 1.06 
.96 – 1.01 













1.09 – 1.14 
1.30 – 1.36 




Beta-blockers .82 .81 - .84 <.001
ACE-inhibitors .90 .80 - .91 <.001
Spironolactone 1.12 1.10 – 1.14 <.001
Statins .78 .76 - .79 <.001
Aspirin 1.00 .99 – 1.02 .39












1.34 – 1.38 
1.54 – 1.61 
1.64 – 1.73 
1.92 – 2.03 






* Reference group is no anti-depressants, no depression group.
†n=120,453 due to missing data on predictor variables 






Previous findings on the effect of individual anti-depressants on the risk of mortality in HF 
patients were based on the use of anti-depressants at any time during follow-up, and could 
therefore create discrepancies in relation to the outcomes of our study. Overall, the 
individual anti-depressants were found to have similar risk estimates for mortality in our 
cohort. We found that the use of fluoxetine, sertraline, citalopram and escitalopram 
subsequent to discharge leads to a higher risk of all-cause mortality in HF patients. Diez-
Quevedo et al. found similar results for fluoxetine, but found no significant difference in risk 
for sertraline and escitalopram and even a tendency towards a lower mortality risk for 
citalopram.5 Also the TCAs nortriptyline and amitriptyline, the SNRIs venlafaxine and 
duloxetine and the NaSSA mirtazapine showed a significant higher risk for mortality in our 
cohort. Except for nortriptyline, these individual anti-depressants were also examined in 
previous studies in which no significant difference in risk on mortality was found.5, 10  
 
Limitations 
The results of the current study should be interpreted with the following limitations in mind. 
The main limitation is inherited in the observational nature of the study and lack of 
information on clinical variables, e.g. left ventricular ejection fraction, New York Heart 
Association (NYHA) functional classification, smoking, alcohol consumption, body mass index 
and use of psychotherapy. Furthermore, there was a large discrepancy between the number 
of patients receiving anti-depressants in comparison to the number of patients having a 
clinical depression. It could be that depression was diagnosed in primary care and therefore 
not registered in the patient registry, therefore prescription of anti-depressants could be a 
proxy for (sub)clinical depression. We do not know anything about those who have 
undiagnosed depression and not receive treatment. Exposure to anti-depressants was 
measured only once (i.e., at 90 days post HF diagnosis), with the risk that study results could 
have been biased towards the null because a patient’s exposure to medication may change 
over time. This approach was chosen as we did not obtain information on the duration of 
anti-depressant treatment use nor on the dosage. Furthermore, recorded prescriptions of 














Table 4: Association between type of anti-depressant (at 90 days) and all-cause mortality 
(multivariate Cox proportional regression hazard analysis)*  
Variables All-cause mortality 
 HR 95% CI p-value 
Any SSRI 1.24 1.21 – 1.27 <.001 
Any TCA 1.23 1.07 – 1.19 <.001 
Any other anti-depressant  (SNRI, NaSSA, tetracylic) 1.29 1.24 – 1.35 <.001 
Combination of anti-depressants 1.20 1.13 – 1.27 <.001 
*Reference group is no anti-depressant use; n=120,453 due to missing data for predictor variables 
*Analysis controlled for other variables: age, sex, socio-economic status, etiology, HF severity, 
comorbidity, statin, beta blocker, ACE inhibitor, spironolactone, aspirin, hospitalization (days), 
diagnosis of clinical depression) 
 
CONCLUSION 
In the current study, we found a high prevalence of anti-depressant use in HF patients, with 
and without a diagnosis of clinical depression, subsequent to hospital discharge. Use of anti-
depressants increased over time after a diagnosis of HF and use of anti-depressants after 
hospital discharge was significantly associated with a higher all-cause mortality risk, even 
when adjusting for socio-demographic and clinical variables and diagnosis of depression. 
These results argue for more attention towards anti-depressant prescriptions in HF patients, 
especially in those without a clinical depression. Future research should also focus on 
differences in patient characteristics between the anti-depressant subgroups, and identify 
the unique pharmacological properties of individual anti-depressants, as this may be crucial 














Table 5: Anti-depressant use differentiated by type in relation to all-cause mortality 
(n=120,443)*  
Variables Number of patients (%) All-cause mortality 
 
Anti-depressant use at 90 days  HR 95% CI p-value 
SSRIs     
   Fluoxetine 622 (0.5%) 1.13 1.03 – 1.24 .01 
   Paroxetine 570 (0.5%) 1.08 .98 – 1.20 .12 
   Sertraline 1,633 (1.4%) 1.17 1.11 – 1.24 <.001 
   Citalopram 9,372 (7.7%) 1.20 1.17 – 1.23 <.001 
   Escitalopram 1,551 (1.3%) 1.28 1.19 – 1.37 <.001 
TCAs     
   Nortriptyline 556 (0.5%) 1.16 1.04 – 1.28 .005 
   Amitriptyline 1,366 (1.1%) 1.14 1.06 – 1.21 <.001 
   Imipramine 289 (0.3%) 1.04 .90 - 1.21 .06 
   Dosulepine 53 (0.05%) .95 .68 – 1.32 .74 
Tetracyclics     
   Mianserine 26 (0.02%) .98 .63 - 1.54 .93 
SNRIs     
   Venlafaxine 1034 (0.9%) 1.16 1.07 - 1.25 <.001 
   Duloxetine 155 (0.1%) 1.39 1.05 - 1.85 .02 
NaSSAs     
   Mirtazapine 2789 (2.3%) 1.21 1.16 - .1.27 <.001 
*Reference group is no anti-depressant use 
*Multivariate Cox proportional regression analysis adjusting for age, sex, socio-economic status, 
etiology, HF severity, comorbidity, statins, beta blockers, ACE-inhibitors, spironolactone, aspirin, 


















Figure 1: Association between clinical depression and anti-depressant use (at 90 days) and 
all-cause mortality (Kaplan Meier survival curve) 







(1) p < .001 





















Figure 2: Association between anti-depressant groups (at 90 days) and all-cause mortality 
(Kaplan Meier survival curve)* 
 







(1) p < .001 
(2) p < .001 
(3) p < .001 































Figure 3: Association between anti-depressant groups (at 90 days) and all-cause mortality 
(Kaplan Meier survival curve)* 












(1) p < .001 
(2) p < .001 
















Other (SNRI, NaSSA, tetracyclic) (2)
SSRI
(1) p <.001
(2) p <. 01
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and mortality in implantable 
cardioverter defibrillator 
patients: Is there a link?






Implantable cardioverter defibrillator (ICD) therapy is the first line treatment for the 
prevention of sudden cardiac death (SCD). Despite demonstrated survival benefits of the ICD, 
predicting which patients will die suddenly from a ventricular tachyarrhythmia remains a 
major challenge. So far psychological factors have not been considered as potential risk 
markers that might enhance the prediction of SCD. We reviewed the evidence for a link 
between psychological vulnerability, ventricular tachyarrhythmias, and mortality, and the 
pathways that might explain such a link. This review demonstrates that there is cumulative 
evidence supporting a link between psychological vulnerability and risk of ventricular 
tachyarrhythmias and mortality in ICD patients independent of disease severity and other 
biomedical risk factors. It may be premature to include psychological factors in risk 
algorithms, but information on the psychological profile of the patient may help optimize the 







The implantable cardioverter defibrillator 
Implantable cardioverter defibrillator (ICD) therapy constitutes state-of-the-art and first 
line treatment for the prevention of sudden cardiac death (SCD).1, 2 Key indications for ICD 
implantation are secondary prevention in patients who have survived a previous cardiac 
arrest without transient or reversible cause or spontaneous symptomatic sustained 
ventricular arrhythmia and primary prevention in patients considered at high risk due to a 
left ventricular ejection fraction (LVEF) ≤35% with ischemic or non ischemic 
cardiomyopathy in the absence of a history of cardiac arrest or sustained ventricular 
arrhythmia.3 Risk reductions associated with ICD therapy compared to anti-arrhythmic 
drugs range from 37% for all-cause mortality to 57% for SCD, with ICDs being equally 
efficacious as primary and secondary prevention.4     
 Arrhythmias affect the electrical system of the heart, producing abnormal heart 
rhythms that cause the heart to pump less effectively. The ICD continuously monitors the 
heart rhythm, and will provide the appropriate therapy (i.e., either anti tachycardia pacing 
(ATP), cardioversion or a shock – up to 800 volts) to restore a normal rhythm if a life-
threatening ventricular arrhythmia is detected. Generally, patients receive no warning prior 
to receiving a shock, and the shock itself may be uncomfortable and disturbing to the 
patient, with patients describing it as being similar to getting kicked in the chest by a 
horse.5  
 The number of patients with heart disease living with a cardiovascular implantable 
electronic device (CIED), such as the ICD, the bi-ventricular pacemaker providing cardiac 
resynchronization therapy (CRT), or the bi-ventricular pacemaker with an ICD (CRT-D), has 
increased substantially.6, 7 At this time, nearly one million patients in North America and 
more than 800,000 in Europe have a CIED.8 Since FDA approval and the first human implant 
in 1980, the complexity of the ICDs has increased considerably with novel features 
introduced, such as dual-chamber pacing and sensing, sophisticated algorithms to reduce 
the incidence of shocks, 50-fold increase in device memory, while also reducing the size of 
the ICD substantially (by a factor of 8).9,10 Hence, we are dealing with an increasing 
population of patients with an ICD with devices that are becoming increasingly complex, 
although more simple devices are now also being introduced, such as the entirely 











implanted without leads in or on the heart, thereby preserving the vasculature of the 
heart.11  
 
Risk stratification – an unresolved challenge 
Despite the demonstrated benefits of ICD therapy, predicting which patients will die 
suddenly from a ventricular arrhythmia remains a major challenge in clinical cardiology 
practice. Left ventricular dysfunction has been used for risk stratification but appears to lack 
sufficient sensitivity and specificity to be a good predictor of risk for SCD.12 Other potential 
candidates have been pursued, such as markers of autonomic nervous system functioning 
(e.g. heart rate variability and baroreflex sensitivity) and microvolt T-wave alternans, but as 
single markers they seem to fall short of resolving the issue of optimal risk stratification.12 
Studies examining the contribution of multiple risk markers, such as the Alternans Before 
Cardioverter Defibrillator (ABCD) and the Risk Estimation Following Infarction Noninvasive 
Evaluation – ICD efficacy (REFINE-ICD) trials, show more promising results in terms of being 
closer to obtaining better prediction models.13, 14 The challenge of generating algorithms 
that are sufficiently sensitive and specific to predict which patients are at risk of SCD is likely 
attributable to the complex pathology underlying SCD and the contribution of several 
different processes and factors interacting, including markers of arrhythmic and non-
arrhythmic death.12 
 
Risk stratification – is there a role for psychological factors? 
The pursuit of factors that may help enhance risk stratification has mainly focused on clinical 
factors and physiological markers, negating the potential role of psychological factors. At this 
point in time, it may be too premature to suggest the inclusion of psychological factors in 
risk algorithms. Nevertheless, there is evidence to suggest that traumatic and psychologically 
taxing life events, as shown in studies examining the impact of the terrorist attack on the 
World Trade Center on 9/11, may increase the risk of shocks in ICD patients with a relative 
risk of more than two-fold.15, 16 Although such events are rare, psychological distress and 
morbidity is not uncommon in ICD patients, with prevalence rates of about 20% to 25% for 
anxiety and depression, as reported in a recent meta-analysis.17 Post traumatic stress 
disorder (PTSD) is also seen in ICD patients, although the prevalence is somewhat lower 






patients who are anxious already at the time of ICD implant, with as many as 50% of patients 
remaining anxious 12 months post implant.20  
Whether distress in ICD patients should be attributed to the device itself, associated 
therapies, such as appropriate and inappropriate shocks,21 hardware malfunctioning,22 
underlying disease (e.g. symptomatic heart failure),23, 24 indication for ICD implantation,25 or 
the patient’s pre implant psychological functioning26 and personality disposition27 is the 
subject of some debate. Irrespectively, if one out of four ICD patients suffers from significant 
levels of distress, we need to know whether this has consequences above and beyond its 
impact on quality of life 28 in this vulnerable subset of patients.  
Hence, the aim of this review is (1) to examine the evidence for a link between 
psychological vulnerability, ventricular tachyarrhythmias, and mortality in ICD patients, and 
(2) to discuss the mechanisms that may be responsible for this link and implications for 
future research and clinical practice.   
 
Evidence for a link between psychological vulnerability and poor clinical outcome 
To date, 15 individual studies examined the association between psychological vulnerability 
and distress and ventricular tachyarrhythmias and mortality in ICD patients. Of all studies, 
seven focused on ventricular tachyarrhythmias as the outcome, while six studies focused on 
mortality, and two on both. Table 1 provides an overview of these studies, with the main 
results summarized in the following section.  
 
Ventricular tachyarrhythmias 
In 1999, Dunbar and colleagues were the first to examine the emotional status of the patient 
as a potential determinant of arrhythmias in ICD patients. A higher level of total mood 
disturbance, as assessed with the Profile of Mood States (POMS), was associated with a 
greater likelihood of experiencing an arrhythmia that required ATP, cardioversion, or 
shock.29 For each 10-point increase on the POMS, the chance of experiencing an arrhythmia 
increased by 10-20%, after controlling for factors that are traditionally associated with 
arrhythmia risk. More specifically, higher anxiety, fatigue, or confusion levels and a lower 
vigor level at one and three months post implant were associated with a higher risk of 
arrhythmia at three and six months, respectively. Neither anger nor depression was a 











occurrence of arrhythmic events at one or three month follow-up. In 2005, Whang and 
colleagues showed that moderate to severe depression (Center for Epidemiologic Studies 
Depression (CES-D) scale ≥ 27) was associated with statistically significant increased risk of 
appropriate ICD shocks, after controlling for multiple potential confounders.30 However, 
three other studies in ICD recipients did not support an association between patient-
reported health status,31 patient-reported32 or physician-diagnosed33 depression or anxiety 
and ventricular tachyarrhythmias. In two of these studies, the association between 
psychological distress and the occurrence of ICD shocks did approach statistical significance 
in univariable analysis (p=0.09).32, 33 
Three studies examined the link between psychological distress and ventricular 
arrhythmias in ICD patients that had already received one or more shocks. By structured 
interviews, Fries and colleagues asked patients who had received an appropriate shock to 
indicate the presence and intensity of negative emotions (i.e., tension/nervousness, 
depression or anger) during one hour prior to a recurrent shock.34 Based on the responses, 
the calculated relative risk of arrhythmia recurrence associated with mental stress was 9.5 
(95% CI: 6.3-14.5). In another study, 42 ICD patients were asked to complete a diary page 
when they experienced a shock to retrospectively evaluate their mood state in the 15 
minutes preceding the shock.35 Results showed that moderate levels of anger were more 
likely during the period preceding shock than during a matched control period one week 
later. Other mood states (i.e., anxiety, worry, sadness, happiness, challenge, feeling in 
control, or interest) did not differ prior to shock compared to the control period. In 2004, 
Burg and colleagues showed that the patients in this sample who reported at least moderate 
anger in the 15 minutes preceding shocks scored significantly higher on trait anger than 
those who did not (p<.0001).36 Trait anger was independently associated with anger-
triggered arrhythmias (p<0.0001). Also, patients who reported at least moderate anxiety 
before shock scored significantly higher on trait anxiety (p<0.008). Van den Broek and 
colleagues showed that the clustering of anxiety at the time of implant and having a 
distressed (Type D) personality predicted arrhythmia, while no main effect was found for 
anxiety or depression.37 Patients with a Type D personality experience a broad range of 
negative emotions and tend to inhibit self-expression in social interaction.38 The two latter 
studies suggest that stable psychological factors increase the risk of emotion-triggered 






In aggregate, there is some evidence that psychological distress may increase the risk 
for ventricular arrhythmias in ICD patients but negative studies are also available. These 
mixed findings might be attributed to differences in study design, the measure(s) used to 
assess psychological distress, sample size and variability in the follow-up period. In addition, 
stable psychological factors (e.g. personality) may modulate the influence of emotional 
distress on arrhythmias.36, 37  
 
Mortality 
In the past five years, studies have emerged that examined the impact of psychological 
vulnerability and distress on mortality in ICD patients. A sub-study of the prospective 
Antiarrhythmics Versus Implantable Defibrillators (AVID) trial showed that a disease-specific 
quality of life measurement (Quality of Life Index – Cardiac Version (QLI-CV)) was a 
significant predictor of all-cause mortality, even after controlling for conventional clinical risk 
factors including left ventricular function and symptomatic heart failure 39, 40. However, the 
mental health component score of the generic 36-item Short Form health survey (SF-36) was 
not associated with mortality. By contrast, the Multicenter Automatic Defibrillator 
Implantation Trial (MADIT-II) showed a significant association between mental health status 
as assessed with the SF-12 and mortality.31 In adjusted analyses, patients who reported 
psychological distress had a 39% higher risk of mortality.  
Ladwig and colleagues showed that patients reporting symptoms of PTSD after ICD 
implantation had a three-fold higher mortality risk, even after adjusting for ICD-specific 
factors and for affective morbidity.41 In another study, the risk of poor prognosis was 
enhanced by two-fold in patients with a Type D personality or patients with a high pre-
implantation level of  ICD concerns (i.e., patient concerns about the ICD giving a shock and 
irrespective of whether patients have actually received a shock).42 The risk of poor prognosis 
increased to almost four-fold in patients with clustering of both psychological risk markers 
compared with patients with only one or none of these markers.42 
In a recent cohort study with a long-term follow-up, the presence of depressive symptoms 
was shown to significantly increase risk for all-cause mortality in ICD patients.43 However, 
depression lost its predictive value when adjusting statistically for potential confounders.43 
The association between depression and mortality was investigated further by van den 











(i.e., somatic symptoms and cognitive symptoms).44 Results indicated that somatic, but not 
cognitive, symptoms of depression predicted mortality, independent of demographic and 
clinical factors. Patient-reported negative but not positive mood was also independently 
related to all-cause as well as cardiac-related mortality.44 In a recent study in patients with 
an CRT-D, Shalaby and colleagues found that patients with a diagnosed mood disorder were 
at significantly higher risk of heart failure hospitalization or combined  heart failure 
hospitalization and mortality, but not mortality alone.33 
  Thus, the majority of available studies support an association between psychological 
distress and mortality in ICD patients, indicating that a subset of patients is at risk of 
mortality despite state-of-the-art treatment due to their psychological profile. Whether 
psychological factors exert an independent effect on clinical outcome in ICD patients or 
whether their relationship with clinical outcome can be explained by other factors that are 
causally related to this outcome is as yet unclear.  
 
Mechanisms linking distress to poor health outcomes 
There are several plausible mechanisms that may explain the association between 
psychological distress and ventricular tachyarrhythmias and mortality in ICD patients. 
However, most of this evidence is implicit and is derived from studies that were conducted 
in individuals without somatic disease or in patients with general cardiovascular disease. 
These pathophysiological and behavioral mechanisms will be outlined in further detail below. 
 
Autonomic nervous system dysfunction 
An imbalance between the sympathetic and parasympathetic nervous systems is assumed to 
be one of the primary physiological mechanisms through which distress may influence 
overall health and predict clinical outcomes in patients with cardiovascular disease.45 
Patients with depression and anxiety tend to have impaired vagally mediated baroflex 
control of the heart and an increase in sympathetic tone, characterized by an increased level 
of norepinephrine,46 a decrease in heart rate variability,47,48 and abnormal heart rate-
turbulence.49 These parameters which reflect imbalance in autonomic tone have been 
implicated in the onset of cardiac events, including ventricular fibrillation, ventricular 







Heterogeneities in ventricular repolarization: QT-dispersion and T-wave alternans  
Heterogeneities in ventricular repolarization, including QT-dispersion and T-wave alternans, 
have also been implicated in cardiovascular prognosis and SCD.45 The QT-interval is the 
electrocardiographic representation of ventricular repolarization time, and variability in the 
QT-interval has been consistently linked with depression and emotional stress in patients 
with a myocardial infarction or acute coronary syndrome.52,53 These findings could be 
explained by the use of selective serotonin reuptake inhibitors (SSRIs) and tricyclic 
antidepressants which are known to exert a proarrhythmic effect attributed to cardiac and 
vascular sodium, potassium and calcium channel blockage and disruption of channel protein 
trafficking,54 thereby causing a prolongation of the QT-interval. However, findings on this 
topic are scarce, and in only one of the studies the relation between QT-interval and 
depression remained significant even after excluding patients on anti-depressants, but only 
among women.52 
T-wave alternans is a marker of ventricular repolarization instability that may be 
mechanistically related to arrhythmias.55 One study found that T-wave alternans induced by 
anger in a laboratory setting predicted future ventricular arrhythmias in patients with an ICD, 
suggesting that distress (e.g. anger) may lead to repolarization instability.56 
 
Inflammation 
Depression might lead to an increased activity of the hypothalamic-pituitary-adrenal axis, 
which results in corticotrophin hypersecretion, increased release of glucocorticoids, and 
elevated corticotrophin releasing hormone (CRH) activation.57 Cortisol, which is the primary 
glucocorticoid in humans, and CRH have been found to stimulate pro-inflammatory cytokine 
release which exerts a deleterious effect on the heart due to its implication in plaque 
ruptures58 and by suppressing cardiac contractility58 while impeding cardiac remodeling.57, 59 
In addition, excess cortisol can contribute to abdominal obesity, insulin resistance, 
hypertension, oxidative stress, altered plasma lipoprotein metabolism and vascular tone 
change, which can all contribute to cardiovascular disease progression.45 
 
Two studies found elevated levels of anxiety and PTSD to be independently associated with 
abnormal levels of acute-phase proteins and several pro-inflammatory cytokines (e.g. 











personality was associated with higher levels of pro-inflammatory cytokines and lower levels 
of anti-inflammatory cytokines in patients with heart failure.61  
 
Up till now, a paucity of studies have investigated the relationship between inflammatory 
(bio)markers and ventricular tachyarrhythmias in ICD patients. One study found no 
correlation between plasma levels of IL-6, TNF- α, high-sensitive C-reactive protein (hs-CRP) 
and brain natriuretic peptide (BNP) and ventricular arrhythmic events among stable heart 
failure patients having ICD’s, while in another study hs-CRP was correlated with ventricular 
tachyarrhythmias in 121 ICD recipients over a 1-year period.62, 63  
 
Platelet activation 
 A few studies found a link between depression and change in platelet activation, and 
between phobic anxiety and abnormalities in the platelet serotonin transporters and 
intracellular calcium levels leading to changes in the fibrinolytic system.64 Platelets play a key 
role in the development of atherosclerosis, thrombosis and acute coronary syndromes,65 
thereby possibly increasing the risk for cardiac mortality in ICD patients. This effect might be 
attenuated by the use of SSRIs, since these have been demonstrated to reduce platelet 
activation by inhibiting their serotonin uptake capacity which is necessary for platelet 
aggregation. SSRIs may therefore also protect against the risk for new cardiovascular 
events.66 However, it is not completely clear whether the normalization of platelet function 




On the behavioral side, the primary candidate mechanisms that could explain poor health 
outcomes in distressed ICD patients include poor medication adherence, insufficient exercise, 
unhealthy lifestyle habits and the cancelling of scheduled medical appointments.68,69 
Evidence suggests that patients with depression tend to more often forget or skip their 
medication also after adjustment for potential confounding variables, including age, 
ethnicity, education, social support, and measures of cardiac disease severity,69 thereby 
increasing the risk of arrhythmia’s and mortality. Similarly, depression has found to be a 






disease,70 which may influence patient motivation to engage in exercise.70 The lack of 
exercise may also result from anticipatory-anxiety, with ICD patients having a restricted 
lifestyle because of the fear of a shock.71 Also PTSD has been associated with a higher rate of 
physical inactivity in terms of overall exercise and self-rated level of exercise in 
cardiovascular patients.72 Due to inactivity, distressed patients may experience weight gain 
and be more prone to develop obesity. Weight gain and obesity can also be side effects of 
psychotropic drugs prescribed for affective disorders.73 Depressed patients who have been 
hospitalized for cardiovascular disease are also more likely to smoke.74 with smoking likely 
serving as an ‘emotional painkiller’. Smoking is known to cause a restriction of the arteries, 
modify oxygen-dependent enzymes, increase blood pressure, diminish the amount of 
oxygen in the body, and reduce blood flow to the extremities.75 Chemicals present in 
cigarettes lead to atherosclerosis and damage arteries and blood vessels, which eventually 
lead to cardiovascular disease, arrhythmogenic events or death.75 
Furthermore, impaired cognitive focus, reduced energy, and motivation associated 
with depression and anxiety might affect patients’ willingness to engage in self-care, to 
attend scheduled hospital appointments and to complete cardiac rehabilitation.76,77 Also 
Type D personality has been associated with inadequate consultation behaviour among 
heart failure patients (i.e., consulting a physician when experiencing cardiac symptoms), 




There is considerable evidence that patients implanted with an ICD may be at increased risk 
for ventricular tachyarrhythmias and mortality due to their pre implant psychological 
vulnerability or post implant distress level, as shown in this review. The majority of this 
evidence comes from large-scale and well designed prospective studies, emphasizing that 
the evidence is unlikely to be spurious. Moreover, the risk associated with psychological 
vulnerability and distress is clinically relevant with up to a three-fold increased risk, and 
seems to be independent of traditional risk factors, such as left ventricular dysfunction and 
extent of heart failure as indicated by New York Heart Association (NYHA) functional class.31, 
37, 41 Thus, despite state-of-the-art treatment with ICD therapy for the prevention of SCD, a 











optimally from their device. This should be placed in the context of the cost of the ICD, 
which is considerable with an average price of US$ 25,000 for the device itself.79 Although 
cost-effectiveness analyses of ICD treatment as compared to anti arrhythmic drugs show 
that device therapy is cost-effective,80,81 these studies did not take into account the 
psychological risk profile of patients.  
 
Further research in this area is warranted in order to establish whether psychological factors 
carry independent risk, act indirectly via physiological or behavioral pathways, or whether 
they can be explained by other factors. We should also explore whether psychological 
factors interact with demographic and clinical risk factors to enhance risk for poor clinical 
outcome, and whether psychological factors have a place in algorithms used for risk 
stratification. With this knowledge, we will be better able to manage and care for the subset 
of ICD patients who have an increased vulnerability for adverse clinical outcomes due to 
their psychological profile. Until such evidence is available, we need to acknowledge that the 
psychological profile of ICD patients matters in the clinical management and care, and that a 
vicious cycle may ensue if we do not target distress in our patients irrespective of the cause 
(i.e., ICD shock, underlying heart disease, pre implantation psychological profile, etc.) of that 
distress (Figure 1).82 Such investment seems worthwhile given the cost of the ICD but also 
for the sake of the well being of our patients, as it would otherwise be tantamount to ignore 
the considerable body of evidence from cardiovascular and behavioral medicine that shows 
that the body, mind and heart interact to influence health outcomes in cardiac patients.83   
 
Conclusion 
Cumulative evidence from large-scale prospective studies indicates that distress and 
psychological vulnerability may increase the risk of ventricular tachyarrhythmias and 
mortality in ICD patients independent of traditional clinical risk factors and despite state-of-
the-art treatment with this life-saving device. Further research is warranted to disentangle 
whether psychological factors constitute risk factors in their own right, whether they exert 
indirect effects via physiological and behavioral pathways, or whether their link with 
prognosis can be explained by other factors. Although it may be too premature to suggest 






profile of the patient may help optimize the management and care of this subset of 
vulnerable ICD patients in clinical practice. 
 















During the course of the next five years, if we continue to invest in the patient perspective in 
patients with an ICD combined with evaluating potential mechanistic pathways, we will be 
able to document the role of the patient’s psychological profile and level of post implant 
distress on clinical outcome and identify the subset of patients at risk for SCD. We will be 
more knowledgeable about the factors that determine the risk for SCD, whether it be due to 
the complex pathology underlying SCD, the psychological profile of the patient, or the 
interaction between several different processes and factors of a physiological, behavioral, 
and psychological nature. There is currently considerable interest in the patient perspective 
by policy makers, physicians and other health care professionals. This is also reflected in the   
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recommendations as set out by the American Institute of Medicine for the health care 
system of the 21st century, which should be a system that provides consistent and high-
quality care that is patient-centered.84 In these recommendations, it is stipulated that future 
medical treatment should fulfill the key aspects of being safe, effective, timely, equitable, 
efficient and patient-centered. The European Heart Rhythm Association (EHRA) - under the 
auspices of the European Society of Cardiology - also emphasizes the importance of the 
patient perspective in their mission statement: “The EHRA mission statement is to improve 
the quality of life of the European population by reducing the impact of cardiac arrhythmias 
and reduce sudden cardiac death.”  Similarly, the device industry is investing in the patient 
perspective by including quality of life as an endpoint when designing trials and registries to 
evaluate the safety and efficacy of new hardware and algorithms (e.g. to reduce appropriate 
and inappropriate shocks).  
 
This holds important promise for the future well being of ICD patients and is hopefully a 
trend that will continue. Based on these trends, it will be interesting to see how the 
management and clinical care of ICD patients will evolve during the next five years also due 
to changes in clinical care, with more ICD patients being followed via remote monitoring. 
One of the important questions will be whether the subset of ICD patients with a vulnerable 
pre implant psychological profile or post implant distress will be detected and treated in 
order to preserve their well being and enhance their survival. Screening and monitoring of 
ICD patients for mental health issues is not yet part of standard clinical practice, but will 
hopefully be entered on equal footing with offering patients cardiac rehabilitation in the 
future. Current evidence from behavioral and psychological intervention trials in ICD patients 
indicate that we do have something to offer to the subset of vulnerable ICD patients in terms 
of reducing their distress levels and improving their well being. Even though some of these 
trials are plagued by methodological short comings, they show that multifactorial 
interventions are likely to be the most successful, including for example cognitive behavioral 
therapy, psycho-education about the ICD, and cardiac rehabilitation as some of the mainstay 
components,85 which can if warranted be combined with pharmacological treatment. Other 
trials with the aim to improve to improve mental health outcomes in ICD patients are 
currently underway that use comprehensive and state-of-the-art techniques in behavioral 









 Implantable cardioverter defibrillator (ICD) therapy is the first line treatment for the 
primary and secondary prevention of sudden cardiac death with superior survival 
benefits as compared to anti-arrhythmic drugs.  
 Predicting which patients will die suddenly from a ventricular tachyarrhythmia still 
remains a major challenge in clinical cardiology practice.  
 The pursuit of factors that may help enhance risk stratification has solely focused on 
clinical factors and physiological factors. This despite cumulative evidence supporting a 
link between psychological vulnerability and the risk of VTs and mortality in ICD patients.  
 Little is known about the pathways through which psychological factors may exert an 
influence on clinical outcome in ICD patients with both plausible physiological and 
behavioral pathways existing. 
 Further research is warranted to establish whether psychological factors comprise risk 
factors or risk markers that may be attributed to other factors such as an imbalance 
between the sympathetic and parasympathetic nervous systems. 
 It may be premature to include psychological factors in risk algorithms, but information 
on the psychological profile of the patient may help optimize the management and care 
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     PART THREE 
 
Health status and psychological distress - the link with inflammation 














































Association between psychological 
measures and brain natriuretic 
peptide in chronic heart failure 
patients






Objective: Brain natriuretic peptide (BNP) is a promising marker for heart failure diagnosis 
and prognosis. Although psychological factors also influence HF (HF) prognosis, this might be 
attributed to confounding by BNP. Our aim was to examine the association between 
multiple psychological markers using a prospective study design with repeated N-terminal 
pro-B-type natriuretic peptide (NT-proBNP) measurements.  
Design: The sample comprised 94 outpatients with systolic heart failure (80% men; mean 
age=62.29.3). The psychological markers (i.e., anxiety, depression and Type D personality), 
assessed with the Hospital Anxiety and Depression Scale (HADS), the Beck Depression 
Inventory (BDI), and the Type D Scale (DS14) were assessed only at baseline. Plasma NT-
proBNP levels were measured at baseline and 9 months. 
Results: The prevalence of anxiety, depression and Type D personality at baseline was 23.4% 
(HADS-A), 17.0% (HADS-D), 46.6% (BDI) and 21.3%, respectively. At baseline, none of the 
psychological risk markers were associated with NT-proBNP levels (all p >.05). In the subset 
of patients with scores on psychological risk markers both at baseline and 9 months, there 
was no association between anxiety (p=0.44), depression (HADS-D: p= 0.90; BDI: p=0.85), 
and Type D (p=0.63) with NT-proBNP levels using ANOVA for repeated measures.  
Conclusions: Our findings indicate that measures frequently used in HF to assess 
psychological risk markers are unconfounded by NT-proBNP. Further studies are warranted 
that replicate these findings and examine whether psychological risk markers are 
independent predictors of prognosis in HF or an artifact that may be attributed to other 

















Heart failure (HF), which is typically identified by features such as dyspnea, fatigue, signs of 
fluid retention and cardiac remodeling, is associated with considerable physical 
impairments, poor quality of life and increased psychological distress.1, 2 
Despite the availability of a wide array of laboratory and radiological tests, a 
diagnosis of HF may initially go unnoticed. In recent years, brain natriuretic peptide (BNP) 
and its N-terminal pro-hormone (NT-proBNP), have been introduced as an additional 
method to facilitate a diagnosis of HF. BNP, which is known as B-type natriuretic peptide,  
belongs to the natriuretic peptide family, which contribute to cardiovascular homeostasis by 
promoting natriuresis and diuresis, acting as vasodilators, and exerting antimitogenic effects 
on cardiovascular tissues. Increased BNP levels have been shown to be strong risk indicators 
for a poor prognosis, but also to be of value in guiding therapy to treat HF.3-5  
Besides being a valuable prognostic marker for HF, evidence suggests BNP may also 
influence psychological distress (e.g. anxiety and depression) by affecting the corticosterone 
response in the hypothalamus-pituitary-adrenal gland (HPA) axis.6 However, since 
psychological distress is also known as an independent risk factor for HF prognosis on its 
own, psychological distress might be confounded by BNP and thus be a risk marker rather 
than a risk factor, with the relation between distress and poor prognosis being explained by 
increased BNP levels.7, 8  
A paucity of studies have examined the association between episodic and chronic 
psychological distress and BNP levels, with most studies being cross-sectional and examining 
single psychological risk markers. Of the 10 available studies,6-14 seven were conducted in HF 
patients.7, 10-13, 15 Two studies focusing on anxiety found that in patients with mild HF 
changes in BNP concentration were positively associated with both anxiety and state 
anger.13, 15 Findings on depression6-11, 14 were mixed.  The single study that focused on the 
distressed (Type D) personality found no association with BNP levels.12 Thus, the evidence 
regarding psychological factors and BNP and NT-proBNP is inconsistent. Knowledge of the 
extent to which psychological measures frequently used in HF research are associated to 
indicators of disease severity is important, as the prevalence of psychological symptoms may 
be inflated and reflect somatic disease rather than true psychological morbidity if 











Hence, we examined the link between NT-proBNP and the continuous and 
dichotomized scores of a broad range of psychological risk markers (i.e., depressive 
symptoms, anxiety and Type D personality) using a prospective study design with 
measurements of NT-proBNP at baseline and at 9 months. 
 
METHODS 
Study population and design 
Consecutive patients (n=94) with a diagnosis of systolic HF comprised the patient sample for 
the current study. Patients were recruited from four different centers, that is, Aarhus 
University Hospital (Skejby), Aarhus University Hospital (Aalborg), Aarhus University Hospital 
(Amtssygehuset), and Odense University Hospital. Patients were asked to complete a set of 
standardized and validated questionnaires at baseline, assessing the psychological risk 
markers, while NT-proBNP levels were assessed both at baseline and at 9 months. Inclusion 
criteria were: diagnosis of systolic heart failure, left ventricular ejection fraction (LVEF) ≤40%, 
and stable on HF medication within the last 1 month prior to inclusion. Patients ≥75 years of 
age, unable to understand and read Danish, with clinical signs of acute infection, other life-
threatening diseases, cognitive impairments or psychiatric comorbidity (except for affective 
disorders), or a myocardial infarction within the last two months were excluded. The study 
was approved by the Medical Ethics Committee of all participating hospitals and was 




Demographic and clinical variables 
Information on demographic and clinical variables was obtained from the patients’ medical 
records or from purpose-designed questions in the questionnaire. Demographic variables 
comprised gender, age, marital status, education, working status, smoking status and body 
mass index (BMI). Clinical variables included left ventricular ejection fraction (LVEF), time 
since HF diagnosis, etiology of HF, previous cardiac events, previous hospitalizations for HF, 
angina pectoris, New York Heart Association (NYHA) functional class, presence of valvular 
heart disease, presence of coronary artery disease (CAD), hypertension, 






(betablockers, calcium antagonists, nitrates, aspirin and other platelet-aggregation inhibitors, 
anticoagulants, angiotensin-converting-enzyme (ACE)-inhibitors, statins, diuretics, 
angiotensin-receptor blockers) and psychotropic medication. LVEF was measured using the 
Simpson biplane method, wall motion scoring, and eyeballing depending on the patient, the 
echocardiographer and the available acoustic conditions. 
 
Anxiety and depressive symptoms 
The Hospital Anxiety and Depression Scale (HADS) was developed by Zigmond and Snaith in 
1983 to identify probable anxiety disorders and depression among patients in non-
psychiatric hospital clinics. HADS comprises of two 7-item subscales, that is, Anxiety (HADS-A) 
and Depression (HADS-D).16 Items are answered on a four-point Likert Scale from 0-3 (score 
range 0-21). HADS is a valid and reliable measure, with good internal consistency as 
demonstrated by Cronbach’s α (HADS-A = .80; HADS-D = .81).16 A score of 8 to 10 is 
suggestive of the presence of the respective state, while a score of 11 or higher indicates 
probable presence of the mood disorder.17 In the current study, a cut-off of ≥8 was used for 
both subscales to indicate the presence of anxiety and depressive symptoms.16 To prevent 
‘noise’ from somatic disorders on the scores, all symptoms of anxiety or depression relating 
also to somatic disease, such as dizziness, headaches, insomnia, energy and fatigue, are 
excluded from the HADS, which makes it an opportune measure to use in patients with HF.18 
The HADS only takes 2 to 5 minutes to complete. It has been shown to be acceptable by the 
population for which it was designed.16-18 The HADS was administered at baseline. 
The Beck Depression Inventory (BDI) is a 21-item self-report questionnaire.19 It is 
composed of items relating to symptoms of depression such as hopelessness and irritability, 
cognitions such as guilt or feelings of being punished, as well as physical symptoms such as 
fatigue, weight loss, and lack of interest in sex.20 Each item on the BDI is answered on a scale 
from 0 to 3. A score of 0–9 indicates that a person is not depressed, 10–18 mild to moderate 
depression, 19–29 moderate to severe depression, while 30–63 indicates severe depression. 
A higher score indicates more severe depressive symptoms. For this study, we used a cut-off 
of ≥10.21 The BDI can be separated into two subcomponents, that is a cognitive/affective (e.g. 
mood) and a somatic component (e.g. fatigue). As evidence suggests that the BDI may be 











measure of anxiety, but also to examine the extent of confounding of depression with NT-
proBNP with two different depression measures.21 The BDI was administered at baseline. 
 
Type D personality 
The Type D Scale (DS14) was used to assess the distressed (Type D) personality and its two 
constituent 7-item subscales, negative affectivity and social inhibition. Negative affectivity 
refers to the tendency to experience negative emotions, like anger, dysphoria, irritability, 
hostile feelings, depressed affect, and anxiety. Social inhibition refers to discomfort in social 
interactions, reticence and lack of social poise.22 Items are rated on a 5-point Likert scale 
ranging from 0 (false) to 4 (true), with subscale scores ranging from 0-28. A cut-off of ≥10 on 
both subscales is used to classify patients as Type D.22 The construct of Type D personality is 




The N-terminal (NT) proBNP, the biologically inactive preprohormone of BNP, which has a 
longer half-life than BNP and is found in plasma was evaluated at baseline and 9 months.  
Blood was obtained by venipuncture under standardized conditions (after 15 min. rest – no 
tourniquet used) and collected in tubes containing ethylenediamine-tetraacetic acid. The 
blood samples were centrifugated at 2000x for 20 min. at 4°C. The plasma was then 
extracted and stored at -80°C prior to testing. NT-proBNP was measured using an 
electrochemiluminescence immunoassay (Cobas, Elecsys 2010 Systems, Roche Diagnostics 
Gmbh, Mannheim, Germany) according to the manufacturer’s instructions. The coefficient 
of variation for the NT-proBNP assay was 2-5% and the analytical measurement range for 
NT-proBNP was 5-35,000 pg/mL.  
 
Statistical analysis 
Descriptive statistics were obtained to describe the demographic and clinical characteristics 
of the study sample. Student’s t-test for independent samples and Pearson’s correlation for 
parametric tests were used for examining the associations between baseline psychological 
risk markers and NT-proBNP at baseline and 9 months follow-up. Analysis of variance 






dichotomized psychological risk markers assessed at baseline and NT-proBNP at baseline and 
9-months follow-up. NT-proBNP levels were positively skewed and logarithmic 
transformations were applied prior to parametric analyses. All data were analyzed using 
SPSS 17.0 for Windows (SPSS Inc., Chicago, Illinois). All tests were two-tailed, and a p-value 




Of 190 eligible patients, 3 were omitted due to personnel error, and 65 declined 
participation resulting in a final response rate of 65.8% (n=122). Twenty-eight patients had 
either no psychological measuremen6ts or no NT-proBNP measurement and were excluded 
from analysis leaving 94 systolic HF patients. All study participants were outpatients at the 
time of recruitment. Of these patients, all (100%) had complete HADS and DS14 scores, and 
76 had complete BDI scores (80.9%). The prevalence of anxiety at baseline, as measured 
with HADS-A, was 23.4% (22/94). The prevalence of depressive symptoms at baseline was 
17.0% (16/94) with the HADS-D and 46.6% (41/88) when assessed with the BDI. Of all 
patients, 21.3% (20/94) had a Type D personality. Demographic, clinical and psychological 
baseline characteristics of the patients are shown in Table 1.  
 
NT-proBNP  
Prior to analyses, NT-proBNP was tested for outliers and its distribution; due to its skewed 
distribution, the data were transformed prior to statistical analysis using natural log. These 
data are presented as a median with inter-quartile range (IQR) for the untransformed data 
and as mean (SD) for the log transformed data. NT-proBNP measurement was missing 
randomly in some patients for logistic and practical reasons. In the total patient sample 
(n=122) patients with available NT-proBNP levels (baseline: n=94, 9 months: n=76) did not 
differ systematically from patients who did not have a NT-proBNP measurement (baseline: 
n=28, 9 months: n=46) on clinical, demographic, and psychological characteristics, except for 
patients without an NT-proBNP measurement being less likely to have valvular heart disease 
(79.2% vs. 93.8% p=0.025) and angina pectoris (66.7% vs. 84.7% p=0.043) than patients with 











927.0 pg/mL (IQR= 386-2268 pg/mL) at baseline, while at 9 months this level declined 
significantly to 614.0 pg/mL (IQR=231-1229 pg/mL) (p<0.001).  
 





























HADS-A= Hospital Anxiety and Depression Scale; BDI= Becks  
Depression Inventory; BMI= Body Mass Index; NYHA= New York  
Heart Association class; LVEF= left ventricular ejection fraction 
        Total (n=94) 
Mean ± SD; n (%) 
Demographics 
Male 75 (80) 
Age (yrs) 62 ± 9 
Partner                                                                                   68 (72) 
Secondary school and above 24 (25) 
BMI 27.5 ± 5.4 
Psychological 
HADS-A 5.0 ±4.5 
HADS-D 4.5 ± 4.0 
BDI* 10.7 ± 9.5 
Type D personality 20 (21) 
Clinical 
Etiology 
    Ischemic heart disease  39 (42) 
    Cardiomyopathy 30 (32) 
    Other (bacterial, congenital e.g.) 15 (15) 
NYHA functional class 
    I/II 64 (68) 
    III 30 (32) 
Angina pectoris 15 (16) 
Hypercholesterolemia 36 (38) 
Diabetes 20 (22) 
Anemia 5 (4) 
Kidney failure 15 (15) 
LVEF 26.1 ± 6.8 
Current smoker 23 (24) 
Hospitalizations over 9 months 20 (22) 
Medication use 
Beta blockers 91 (98) 
Angiotensin-converting enzyme inhibitors 80 (86) 
Angiotensin-receptor blockers (ARB) 12 (13) 
Statins 48 (52) 
Diuretics 76 (81) 






Relationship between anxiety, depression and Type D personality and NT-proBNP levels 
(unadjusted analysis) 
Table 2 presents the associations between the psychological risk markers (i.e., symptoms of 
anxiety, depression, and Type D personality), assessed at baseline, and NT-proBNP levels 
measured at baseline and at 9 months follow-up. Patients with Type D personality had 
higher NT-proBNP levels than patients without Type D at baseline and follow-up, but these 
differences were not statistically significant. There was almost no difference in NT-proBNP 
level between patients with and without anxiety and depression at baseline. The results did 
not change when calculating Pearson’s rho with the continuous scores of the HADS-A (r=-
.109, p=0.296), HADS-D (r=0.027, p=0.796), BDI (r=0.101, p=0.385) and DS14 (r=0.130, 
p=0.210 (SI) and r=0.013, p=0.903 (NA)) in relation to NT-proBNP at baseline and the HADS-A 
(r=-.065, p=0.581), HADS-D (r=-.064, p=0.586), BDI (r=0.109, p=0.445) and DS14 (r=0.085, 
p=0.474 (SI) and r=0.002, ρ=0.987 (NA)), in relation to NT-proBNP at follow-up. Neither of 
the subcomponents of the BDI at baseline (BDIb n=86, df=1) and follow-up (BDIf n=47, df=1) 
were significantly related to the NT-proBNP using the total continuous scores of the affective 
(BDIb r=0.057, p=0.631; BDIf r=0.063, p=0.670, respectively) and somatic items (BDIb r=0.153, 
p=0.187; BDIf r=0.156, p=0.275, respectively) (data not shown). Note that baseline NT-
proBNP levels were negatively correlated with anxiety scores, and follow-up NT-proBNP 
levels were negatively correlated with anxiety and depression scores, as measured by the 
HADS-A and HADS-D. 
In a secondary analysis, ANOVA with repeated measures was performed with the 
psychological risk markers (i.e., dichotomous scores (presence/absence) of anxiety, 
depressive symptoms, and Type D personality) entered as the between-subjects factors in 
four separate analyses with log NT-proBNP at baseline and 9 months as the outcome (Figure 
1). Of the total patients in the analysis (n=94), 61 (64.9%) had available data on the HADS or 
DS14 in combination with NT-proBNP measurements at baseline and follow-up, while 47 
(50%) had available data on the BDI in combination with NT-proBNP at baseline and follow-
up. The DS14 ((n=61, df=1) F=0.236; p=0.63), HADS-A ((n=61, df=1) F=0.603; p=0.44), HADS-D 
((n=61, df=1) F=0.016; p=0.90), and BDI ((n=47, df=1) F=0.035; p=0.85) showed no significant 
interaction with NT-proBNP levels over time. Moreover, the affective ((n=47, df=1) F=0.095; 











significantly related to the NT-proBNP levels, nor were the NA ((n=61, df=1) F=0.749; p=0.28) 
and SI (n=61, df=1) F=0.058; p=0.18) subscales of the DS-14.          
 
Table 2: Association between baseline psychological risk markers (i.e., symptoms of 
anxiety and depression and Type D personality) and NT-proBNP levels (pg/ml) and log NT-
proBNP at baseline and 9 months follow-up*  
* T-tests were performed with natural log NT-proBNP values, p-value *<0.01 **<0.05
BASELINE NT-proBNP log NT-proBNP p-value 
 Median (IQR) Mean (SD)  
HADS-A  (n=94) 
Anxiety ≥8 718 ± (258-1791) 2.83 ± 0.61  
0.25 No anxiety <8 1049 ± (483-2272) 2.98 ± 0.50 
HADS-D (n=94) 
Depression ≥8 931 ± (338-3232) 2.94 ± 0.65  
0.27 No depression <8 973 ± (390-2015) 2.95 ± 0.50 
BDI (n=76) 
Depression ≥10 849 ± (290-3027) 2.92 ± 0.60  
0.22 No depression <10 958 ± (431-1745) 2.92 ± 0.49 
DS14 (n=94) 
Type D ≥10 1204 ± (541-4940) 3.14 ± 0.60  
0.24 Non-Type D <10 886 ± (379-1642) 2.90 ± 0.50 
FOLLOW-UP (9 MONTHS) 
HADS-A (n=74) 
Anxiety ≥8 480 ± (194-1199) 2.69 ± 0.57   
0.68 No anxiety <8 679 ± (232-1249) 2.73 ± 0.58 
HADS-D (n=74) 
Depression ≥8 567 ± (221-997) 2.71 ± 0.59  
0.76 No depression <8 613 ± (217-1264) 2.76 ± 0.52 
BDI (n=51) 
Depression ≥10 650 ± (216-1379) 2.77 ± 0.68  
0.85 No depression <10 567.0 ± (263-1248) 2.74 ± 0.43 
DS14 (n=74)    
Type D ≥10 487 ± (171-1304) 2.74 ± 0.65  






Given the absence of a significant main effect between psychological risk markers and NT-
proBNP in unadjusted analysis, it makes little sense to perform analysis of covariance 
(ANCOVA) with repeated measures to study the potential confounding of clinical and 




In the current study, we investigated whether common psychological risk markers in HF are 
confounded by disease severity, as measured by NT-proBNP. Although NT-proBNP is not a 
standalone marker of HF prognosis and mortality, caused mainly by the large intra-individual 
changes in concentrations which questions its specificity for HF, it has earned an important 
status of contributing to prognosis in HF patients in combination with other clinical 
measures. This is in part due to many HF patients having preserved LVEF but also due to the 
assessment of functional class being strongly influenced by symptoms of depression and 
having a poor inter-rater reliability.24 Our results demonstrated that none of the 
psychological measures examined (i.e. HADS-A, HADS-D, BDI and DS14) were confounded by 
levels of NT-proBNP.  
Previous studies examining the relationship between psychological risk markers and 
markers of HF used either BNP,7, 10-13, 15 or NT-proBNP.8, 9 Although these markers are not 
directly comparable in terms of their levels, it is possible to compare the overall results of 
the studies. Six out of the nine studies dedicated to this topic found a significant association 
between BNP or NT-proBNP and anxiety or depression. The two studies examining more 
than one psychological risk marker found a significant relation with anxiety or depression, 
but not both.9, 13 In relation to depression, the studies of Gottlieb et al. and Van den Broek et 
al., which contained the largest sample sizes of respectively 2,322 and 4,332 (HF and non-HF) 
individuals, showed that BNP levels did not predict BDI scores in multivariate analyses,10, 14 
suggesting that depression and (NT-pro)BNP are independent and additive predictors that 
may adversely affect HF progression via independent pathophysiological pathways. The 
study of Pelle et al. found no relation between BNP and Type D personality nor between the 
Type D subdomains negative affectivity and social inhibition and BNP levels.12 Half of these 
studies used a cross-sectional study design,8-10, 12 having only a (NT-pro)BNP measurement at 











and NT-proBNP is so high that it is beneficial to increase the number of assays over time to 
reach a better estimate of a patients’ homeostatic setpoint.25 Hence, the prospective design 
of our study, with assessments of NT-proBNP both at baseline and at 9-month follow-up, and 
the examination of a broader range of psychological risk markers, including both episodic 
(i.e., anxiety and depression) and chronic (i.e., Type D personality) markers is a strength in 
comparison to some of the current literature on the relationship between psychological 
markers and potential confounding by HF disease severity.     
 The study of Parissis et al. reported a remarkably high prevalence of patients with 
depressive symptoms in their study sample (62%) using the BDI and Zung SDS.7 In our study 
sample, the BDI also showed a considerably higher prevalence of depression (46.6%) than 
found by the HADS-D (17.0%). However, we found neither a significant relation between NT-
proBNP and depressive symptoms when measured with the BDI, nor between NT-proBNP 
and depressive symptoms when measured with the HADS-D. In the other studies that found 
a significant relation between NT-proBNP and depression, analyses were performed with 
severely depressed patients.8, 9, 11 Other limitations of the previous studies were the use of a 
self-report questionnaire for depression for which there was no designated cut-off for the 
severity of depression, and the inclusion of patients with less severe cardiac impairments 
(LVEF≥ 30%).11, 15 
In contrast to some previous studies, we did not find a significant association 
between NT-proBNP levels and psychological risk markers. This indicates that the 
psychological measures used in the current study may not be confounded by disease 
severity, as measured by NT-proBNP, increasing the likelihood that they reflect true 
psychological morbidity rather than underlying disease severity in patients with HF. 
Simultaneously, this finding also points to the complexity of the relationship between 
psychological risk markers and HF severity, especially with respect to depression which 
shows the most contradicting results. It is possible that the relationship between BNP and 
emotional distress (e.g. depression) is dependent on the subgroup of HF patients, or on the 
severity of distress and symptoms. Previous studies in other HF populations show prevalence 
rates of depression of 21.5% (range: 19.3% - 33.6%),26 for anxiety up to 40%,2 and for Type D 
between 19 - 44% with a lower percentage in Northern and Western European country 
clusters (24%),27 for Type D between 19-44% with a lower percentage in Northern and 






However, it seems prevalence rates of have been shown to vary greatly among HF subgroups, 
this might explain in part our null finding between psychological risk markers and NT-proBNP 
levels. The fact that the results found in our sample of systolic HF patients could have been 
dissimilar with respect to the relationship between BNP and psychological measures. An 
unresolved issue also pertains to the question of the ‘chicken and the egg’. Although most 
studies indicate that the relation between emotional distress and disease severity might be 
bidirectional, HF is more often assumed to be the cause of emotional distress than the other 
way around.10 
 
Figure 1: Association between psychological risk markers and NT-proBNP at baseline and 











Another important consideration is pointed out by Gottlieb et al., who suggest that 
emotional distress is more strongly related to subjective heart failure indices, such as NYHA 
functional class, than to objective indices, such as LVEF and BNP.10 The findings by Scherer et 
al. concur with this notion, as there was a significant correlation between NYHA functional 
class and anxiety and depression, as measured by the HADS in primary care HF patients.10, 28 
Since BNP is not based on a patient’s (or a clinician’s) perception of disease severity, this 
could explain why BNP did not predict emotional distress in our study sample, as in the 
sample of Gottlieb et al. Furthermore, this might indicate that depression influences the 
perception of severity of disease to a greater extent than severe HF causing depression.10 
Taken together, it is possible that HF symptoms improve by addressing psychological 
problems, and that the combination of the presence of emotional distress together with BNP 
levels may have an additive prognostic influence in HF patients, as already mentioned by 
Parissis et al.7   
The potential limitations of our study merit consideration. Since this study only 
analyzed the relationship between NT-proBNP and psychological measures, we cannot make 
any statements on whether any association between repeated NT-proBNP measures and 
psychological measures could directly contribute to the observed relationship between 
psychological measures and poor outcomes for HF. Unfortunately, we also did not have 
information on exercise, diet, medical adherence, heart rate variability and socio-economic 
status, which might have influenced our results. By excluding HF patients older than 75 years, 
the mean age of our sample was relatively low compared to a general HF outpatient 
population which could affect the generelizability of the results. Furthermore, this exclusion 
criteria has reduced the sample size the percentage of women within this sample. However, 
since the risk of cognitive deficits and the burden of filling in a package of questionnaires at 
several time points is expected to be more substantial with increasing age, the validity of 
patients’ answers to the questionnaires is less likely to have been compromised.  
 Furthermore, for only 75% of the patient sample NT-proBNP measurements were 
available at baseline and 9 months. For the assessment of anxiety and depression we used a 
self-report measure rather than a clinical diagnostic interview. Hence, we have no 
information as to whether NT-proBNP is related to a clinical diagnosis of anxiety and 
depression. Nevertheless, even minimal symptoms, as assessed with self-report measures of 






In conclusion, we found no relationship between any of the psychological risk 
markers assessed (i.e., anxiety, depressive symptoms (both with the HADS-D and the BDI), 
and Type D personality) and NT-proBNP levels using a prospective study design with the 
assessment of NT-proBNP levels both at baseline and 9-months follow-up in our sample of 
systolic HF outpatients. However, we have to keep in mind that until we have gained more 
insight into the determinants that govern het high intra-individual levels of BNP and NT-
proBNP we have to be careful in drawing conclusions in relation to these outcomes with 
psychological measure.25  
Although more large-scale studies are warranted to investigate and replicate BNP and 
its relation to anxiety, depression and Type D, these preliminary results are promising in that 
they show that measures frequently used in HF to assess psychological risk markers seem to 
be unconfounded by NT-proBNP. This suggests that screening for and treating depression in 
HF might have additional prognostic benefits to current standard care and management. 
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Depressive symptoms in outpatients 
with heart failure: Importance of 
inflammatory biomarkers, disease 
severity and personality





Objective: Depressive symptoms are highly prevalent in heart failure (HF) patients, however 
the underlying etiology of depression in HF patients remains yet unclear. Hence, the goal is 
to examine the relative importance of inflammation, disease severity and personality as 
predictors of depression in HF patients. 
Design: Depressive symptoms (Hospital Anxiety and Depression Scale, depression subscale) 
were assessed at baseline and 1 year follow-up in 268 HF patients (75.6% men; mean age 
=66.7±8.7). Markers of inflammation (TNFα, sTNFr1, sTNFr2, IL-6 and IL-10), disease severity 
(e.g. NYHA classification) and personality (Type D personality, loneliness) were assessed at 
baseline.                                                                                        
  Results: At baseline, NYHA class, body mass index, educational level, Type D personality 
and loneliness were significantly associated with depression. Higher NYHA class (B=2.25; 
SE=.83), higher educational level (B=1.41; SE=.48), Type D personality (B=2.56; SE=.60) and 
loneliness (B= .19; SE=.05) were also independently associated with higher depression levels 
at one year follow-up (all p-values <0.005). Inflammation, BNP and LVEF were not related to 
depression over time.  
Conclusions: Personality factors, but not inflammation, were independent concomitants of 
depressive symptoms in patients with HF. Gaining more insight into the etiology of 
depression in HF patients is important in order to identify potential targets for novel 






Depression has a high prevalence in heart failure (HF) populations (15%-40%) and is 
associated with a higher rate of mortality, rehospitalization, and general health care use 
among HF patients.1-3 The underlying etiology of depression in HF patients remains yet 
unclear. It has been argued that physiological mechanisms and physical deterioration as a 
result of HF progression are the main causes of depression in HF patients.4-6 An important 
physiological mechanism in HF is inflammation, which can, when being exacerbated in 
duration and intensity, lead to a state of depression.7 This form of depression is generally 
assumed to be an inflammation-related syndrome,7 which is characterized by somatic 
depressive symptoms8 and sickness behavior.9 In this model, bidirectional associations 
between depression and inflammation may contribute to the progression of HF.10  
 In case of reversed causality, depression is only a marker of greater disease severity 
because disease severity would cause both poor prognosis and depression. In this case 
depression would not be more than an epiphenomenon of the disease manifestation. 
However, the evidence on the relation between disease severity indices and depression is 
mixed.11-14  
 In addition to inflammation and disease severity, psychological vulnerability (i.e. 
personality, social relationships) can play a potential role in the development of 
depression.15-18 Examples of the latter are Type D personality and loneliness which may 
influence the ability to deal with life events and to cope with one’s mental and physical 
health challenges which is crucial to mitigate these events causing depression.19 Type D 
(distressed) personality refers to individuals with elevated levels of both negative affectivity 
(tendency to experience negative emotions) and social inhibition (tendency to inhibit self-
expression in social interactions),20 and has been indicated in previous studies as a possible 
causative factors for depression in HF.21  
Based on current knowledge we suggest the presence of three explanatory models 
for depression in HF, namely inflammation, disease severity and personality. Establishing the 
main cause of depression in HF patients is vital to identify potential targets for novel 
interventions in order to improve clinical outcome and quality of life. Hence, our goals were 
to examine the relative importance of these models as underlying etiological factors of 











METHODS AND MATERIALS 
Study population and design 
Consecutive outpatients with a diagnosis of HF were recruited from the St. Elisabeth 
Hospital, Tilburg, the Netherlands between June 2006 and February 2009. Inclusion criteria 
were: LVEF ≤40%, stable on oral HF medication within one month prior to inclusion, New 
York Heart Association (NYHA) functional class I-III, and no hospital admissions in the month 
prior to inclusion. Exclusion criteria were >80 years of age, inability to understand and read 
Dutch, clinical signs of acute infection, active episodes of gout or arthritis, use of anti-
inflammatory medication, other life-threatening diseases, myocardial infarction 2 months 
prior to inclusion, and cognitive impairments or psychiatric co morbidity (except for mood 
disorders). n=404 patients were eligible for study participation of which n=120 patients 
refused. Of the n=284 recruited patients, n=24 patients were non-responders and n=2 
patients died at baseline leaving 268 patients eligible for analyses. Patients were asked to 
complete a set of questionnaires at baseline and 12 months follow-up assessing socio-
demographic variables and personality risk markers. This questionnaire was returned in a 
stamped and pre-addressed envelope. If the questionnaire was not returned within two 
weeks, patients received a reminder letter. At baseline 7.8% (21/268) and at 12 months 
11.2% (29/257) of the patients received at least one reminder letter for the return of the 
questionnaire. All questionnaires were checked for completeness. Blood samples were 
drawn at baseline to determine cytokine levels and clinical laboratory values (i.e. creatinine). 
The study was approved by the Medical Ethics Committee of the St. Elisabeth hospital in 
Tilburg and conducted in accordance with the most recent version of the Helsinki 




Demographic and clinical variables 
Demographic variables included gender, age, marital status (having a partner vs. having no 
partner), education (primary school vs. secondary school and above), and working status 
(employed/pensioner vs. unemployed). Clinical variables included etiology of HF (ischemic vs. 
non-ischemic), previous cardiac events (i.e., previous myocardial infarction [MI], coronary 





medications (beta-blockers, calcium antagonists, nitrates, aspirin and other platelet-
aggregation inhibitors, anticoagulants, ACE-inhibitors & ARB’s, statins, diuretics and 
psychotropic medication), current smoking status and Body Mass Index (BMI). 
 
Depressive symptoms  
All patients filled out the Dutch version of the Hospital Anxiety and Depression Scale, 
depression subscale (HADS-D) to assess depressive symptoms.22-24 The HADS-D comprises 7-
items, which are answered on a four-point Likert Scale from 0-3 (range [0-21]). The HADS-D 
is a valid and reliable measure, with good internal consistency (Cronbach’s α HADS-D 
= .81).22, 23 In the current study, a cut-off of ≥8 was used to indicate the presence of clinically 
relevant levels of depressive symptoms, based on the optimal cut off found in large-scale 
studies examining the psychometric properties of the HADS.25 The HADS has shown to be an 
adequate measure of depressive symptoms in cardiac patients.26  
 
Inflammation 
Levels of tumor necrosis factor (TNF)-α, soluble TNF receptors 1 and 2 (sTNFr1 & sTNFr2), 
interleukin (IL)-6 and IL-10 were obtained using standard hospital protocol. Venous blood 
samples were drawn and centrifuged at baseline. Blood was allowed to clot at room 
temperature for at least 20 minutes and centrifuged. Aliquoted serum samples were stored 
at -80°C in anticipation of further processing. Concentrations of IL-6 (sensitivity: 2 pg/ml), IL-
10 (sensitivity: 1 pg/ml), and TNFα (sensitivity: 1.7 pg/ml), were measured using a solid-
phase, enzyme labeled, chemiluminescent immunometric assay (Immulite 1000, Siemens 
Healthcare Diagnostics Breda, The Netherlands). Soluble tumor necrosis factor receptors 
(sTNFR1 and sTNFR2; sensitivity for both: 15.6 pg/ml) were measured using quantitative 
enzyme-linked immunosorbent assay (Hycult Biotechnology, Uden, The Netherlands). All 
tests were measured in accordance with the manufacturer’s recommendations. The 
sensitivity of all tests was calculated as the mean of six zero-values plus three SDs 
extrapolated on the standard curve. The intra-assay variation was less than 10%, and the 














Disease severity variables included etiology left ventricular ejection fraction (LVEF), brain 
natriuretic peptide (BNP) and New York Heart Association functional class (NYHA). A 
comorbidity score was computed using the Charlson Comorbidity Index (CCI), which 
evaluates 17 different comorbidities with varying assigned weights. We used an abbreviated 
CCI score with the following comorbid conditions: myocardial infarction (MI), 
cerebrovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, 
peripheral vascular disease, liver disease, renal failure, and any malignancy excluding 
metastatic tumors.27 Renal failure was measured by calculating the glomerular filtration rate 
of creatinine (GFRcreat) using the MDRD formula, and kidney dysfunction was defined as a 
GFRcreat <60mL/min per 1.73m2.28,29 The comorbidity index was calculated in accordance with 
the original CCI in which a weight of 2 was assigned to renal failure and any malignancy, and 
a weight of 1 to the other comorbid conditions, depending on the relative mortality risk of 
each specific disease. By adding up the values assigned to each comorbid condition, a 
comorbidity score was calculated for each patient. Because age is a risk factor for mortality 
independent of the presence of comorbid conditions, we adjusted the score by adding one 
point to the score for each decade of life over the age of 50 at time of study entry.27 The CCI 
was calculated at baseline.  
 
Personality 
For the personality model of depression we included the distressed (Type D) personality. The 
Type D Scale (DS14) was used to assess Type D personality and its two constituent 7-item 
subscales, negative affectivity and social inhibition.30 Negative affectivity refers to the 
tendency to experience negative emotions (like dysphoria, irritability, hostile feelings and 
anxiety), and social inhibition to the tendency to inhibit self-expression in social interaction. 
Items are rated on a 5-point Likert scale ranging from 0 (false) to 4 (true), with subscale 
scores ranging from 0-28. A cut-off of ≥10 on both subscales is used to classify patients as 
Type D.30 The construct of Type D personality is stable over time.31 The DS14 was 
administered at baseline. The NA and SI subscales of the DS14 have good psychometric 
properties with Cronbach's α=.88/.86 and 3-month test–retest reliability r=.72/.82. 
The social inhibition component of Type D personality might serve as an obstacle in 





sense of loneliness.32 Loneliness represents a distressful affective state in which one holds 
the undesired perception of having few social relationships and being isolated from others.32 
Several studies have found evidence for a relationship between loneliness and depressive 
symptoms,33 but also between Type D and loneliness.34 Based on these associations we 
added the 10-item University of California, Los Angeles (UCLA) Loneliness Scale, which 
assesses feelings of loneliness or social isolation,35 to the personality model as an potentially 
important covariate.  Responses of the UCLA scale may range from 1 (never) to 4 (often). The 
scores ranged from 10 to 40, with higher scores indicating higher experienced levels of 
loneliness. This instrument has an internal consistency of 0.94.36,37 
 
Statistical analyses 
To compare the demographic and clinical characteristics between patients with and without 
cytokine measurements, t tests, Mann-Whitney U tests, or χ2-tests were used depending on 
the measurement and variable distribution. Cytokines were positively skewed and 
logarithmic transformations were applied prior to parametric analyses. Due to missing 
variables on depression, inflammation, disease severity, personality and socio-demographic 
variables (≈25%) we performed a multiple imputation by using Predictive Mean Matching, 
(Markov Chain Monte Carlo, 20 imputations). Predictive Mean Matching is similar to the 
regression method except that for each missing value, it imputes a value randomly from a 
set of observed values whose predicted values are closest to the predicted value for the 
missing value from the simulated regression model. The predictive mean matching method 
ensures that imputed values are plausible and might be more appropriate than the 
regression method if the normality assumption is violated.38    
 Linear regression was used to examine inflammation markers, disease severity 
indices, and personality factors as associates of the depressive symptoms at baseline and 12 
months follow-up. Markers of inflammation, disease severity and personality were entered 
in the hierarchical regression analyses using the enter method (Model 1). Subsequently, 
socio-demographic variables (age, sex, educational level, marital status, BMI) were added to 
the analyses thereby creating Model 2. In secondary analyses medication (statins, aspirin) 
was entered into the regression model to check for confounding (Model 3). To determine if 
inflammation markers, disease severity indices, or personality factors are predictive of 










linear and logistic regression models (Model 4). The rationale for this lies in the assumption 
that the best predictor of subsequent depression is a prior depressive episode.39 Therefore, 
one can argue that variables predicting depression at follow-up could substantially be 
changed or attenuated when controlling for baseline depression. The pooled estimates for 
the multiple imputation data were reported. The explained variance of the inflammation, 
disease severity and personality model, and socio-demographic variables were estimated 
using block entry of the variable groups and were calculated based on a method for 
combining R square values from imputed data sets.40 Next, logistic regression models were 
constructed to enhance clinical interpretation. Continuous and dichotomous depression 
scores were used as the dependent variables. All predictor variables were tested for 
colinearity. Data were analyzed using SPSS 17.0 for Windows (SPSS Inc., Chicago, Illinois). All 




The mean age of the 268 patients was 66.7±8.7 year, 203 patients (75.6%) were men. Of all 
patients, 21.7% (58/268) were classified as having a Type D personality. Further information 
on the demographic, clinical and psychological baseline characteristics of the patients are 
shown in Table 1. Included (n=268) and non-included (n=26) patients did not differ on any 
socio-demographic, clinical or personality variables.      
 The prevalence of clinically significant depressive symptoms (HADS-D≥8) was 28% 
(80/268) at baseline and 29% (75/257) at 12 month follow-up. The mean HADS-D score was 
4.9 (±4.0) at baseline, and 5.0 (±3.8) at follow-up. About half of the patients (141/257=66%) 
was neither depressed at baseline nor follow-up, 7% (17/257) of the patients were only 
depressed at baseline, 8% (19/257) of the patients were only depressed at 12 months 
follow-up and 21% (51/257) of the patients were depressed at baseline and 12 months 
follow-up. The proportion of patients with depression at baseline (n=80) were significantly 
higher educated (51% vs. 28%, p<.001), had more often NYHA functional class III (18% vs. 7%, 
p=.008), a (biventricular) pacemaker (22% vs. 11%, p<.001), kidney failure (45% vs. 27%, 
p=.007), a Type D personality (46% vs. 13%, p<.001) and were prescribed less diuretics 
compared to non-depressed patients (n=188). Depressed and non-depressed patient did not 
differ significantly on any other socio-demographic or clinical characteristics. 
196
Table 1: Baseline and follow-up patient characteristics
   Total (n=268)
n (%); mean ± SD
Socio-demographic characteristics
Sex (% male) 202 (76%)




















LVEF (mean ± SD) 33.1±7.0
Ischemic etiology 175 (65%)
Previous MI 160 (60%)
Previous PCI 63 (24%)
Previous CABG 76 (29%)
Previous CVA 20 (8%)
Previous TIA 19 (7%)
BNP (pmol/L) 69.1±117.9
Intervention/Medication







ACE inhibitors or ARB’s 162 (67%)
Psychotropic medication 46 (17%)
Comorbidity
COPD 50 (19%)

















BMI= body mass index; LVEF= left ventricular ejection fraction; 
MI= myocardial infarction; PCI= Percutaneous coronary 
intervention; CABG= coronary artery bypass surgery; CVA= 
cerebrovascular accident; TIA= transient ischemic attack; 
ICD=implantable cardioverter defibrillator; ARB= angiotensin 
receptor blocker; COPD= chronic obstructive pulmonary disease  
Psychological   
HADS-D baseline (mean ± SD) 4.9±4.0 
HADS-D 12 months (mean ± SD) 5.0±3.8 
UCLA loneliness baseline (mean ± SD) 19.0±5.2 







Cytokines (TNFα, sTNFr1, sTNFr2, IL-6 and IL-10) 
In the total baseline sample, the median cytokine levels were: sTNFr1 6.37ng/mL 
(IQR=3.09ng/mL), sTNFr2 1.00ng/mL (IQR=0.97), TNFα 11.80pg/mL (IQR=5.59pg/mL), IL-6 
4.13pg/mL (IQR= 3.83ng/mL) and IL10 1.83ng/mL (IQR=2.94ng/mL). 
 
Independent correlates of depressive symptoms at baseline 
In the cross-sectional adjusted model the inflammation model explained 6.0% of the total 
variance in baseline depression scores (Table 2).The disease severity model and personality 
model added another 6% and 42.4%, respectively, thereby explaining 54.5% of the total 
model variance. NYHA classification (B1=2.43 (SE=.75), p=.001; B2=2.38 (SE=.74), p=.001), 
Type D personality (B1=2.60 (SE=.55), p<0.001; B2=2.43 (SE=.55), p=<0.001) and loneliness 
(B1=.29 (SE=.04), p<0.001; B2=.28, p=<0.001) were independent correlates of depression 
before (B1) and after (B2) correction for socio-demographic variables. In addition, NYHA 
classification (B3=2.44 (SE=.74), p=.001), Type D personality (B3=2.42 (SE=.55), p=<.001), 
loneliness (B3=.28 (SE=.04), p=<.001), educational level (B3=1.22 (SE=.45, p=.007) and body 
mass index (B3=.09 (SE=.04), p=.02) remained significant after adjustment for the medication 
aspirin and statins (B3), which added 1.0% of the total variance explained. 
 
Predictors of depressive symptoms at 12 months 
Linear regression analyses were also performed with continued HADS-D scores at 12 months 
follow-up (Table 3).  The inflammation model, disease severity model and personality model 
explained respectively 4.5%, 6.2% and 29.6% of the model variance. NYHA classification 





(B1=.21 (SE=.05), p<.001) were significant predictors of depressive symptoms at 12 months 
follow-up, and remained so after correction for socio-demographic characteristics (B2=2.33 
(SE=.83), p=.005; B2=2.58 (SE=.60), p=<.001 and B2=.18 (SE=.05), p<.001, respectively). 
Higher educational level (B2=1.45 (SE=.48), p=0.02) also appeared to be a significant 
predictor of depression at follow-up. Correction for aspirin and statin use added 1.2% to the 
total variance explained by the models and did not alter any significant results. After 
correction for baseline depression (B4), which added another 16.5% to the total model, only 
Type D personality (B4=1.00 (SE=.52), p=.05) and statin use (B4=.072 (SE=.49), p=.04) were 
significant predictors of depression at 12 months follow-up. 
 
Clinically relevant levels of depression 
Neither the inflammation model nor the disease severity model, except for NYHA 
classification (OR=4.54, p=.02), was significantly associated with clinically relevant 
depression at 12 months in the unadjusted model. Conversely, Type D personality (OR=3.65, 
p=.002) and loneliness (OR=1.11, p=.008) were significant predictors of clinical levels of 
depression at 12 months. After correcting for socio-demographic factors, NYHA classification 
(OR=4.85, p=.02) was a significant predictor of depressive symptoms in addition to Type D 
personality (OR=4.07, p=.02), and loneliness (OR=1.09, p=.03). These findings remained 
relatively unchanged by adding aspirin (OR=1.41, p=.12) and statins (OR=.49, p=.34) to the 
model, as NYHA classification (OR=5.18, p=0.02), Type D (OR=4.24 p=.002) and loneliness 
(OR=1.09 p=0.03) remained significant predictors of depressive symptoms at 12 months. 
However, in this model also the comorbidity index became a significant predictor of 
depression at follow-up (OR=1.50, p=.02). The correction for baseline depression attenuated 
the significant predictive value of NYHA classification, Type D personality and loneliness 
while comorbidity index and age became significant predictors for the change in depression 
scores over time (OR=1.68, p=.02 and OR=2.51, p=.03, respectively) (Figure 1). 
 
DISCUSSION 
Inflammation, disease severity, and personality markers have all been implicated as 
potential explanatory pathways for depression in cardiac patients.17,41 In this study 
personality factors (i.e. Type D personality and loneliness) predicted depressive symptoms 










demographic variables (i.e. age, sex, educational level, marital status, BMI). The 
inflammation model, composed of five cytokines levels, did not reach a statistically 
significant level in the linear regression analyses. In the cross-sectional analysis NYHA 
classification, educational level and body mass index were the most important clinical and 
socio-demographic variables for predicting depression at baseline. Most of these variables 
lost their value as predictors of depressive symptoms in the prospective analysis, except for 
BMI, while Type D personality and loneliness remained statistically significant. 
The role of inflammation as a predictor of depressive symptoms is based on the 
evidence that cytokines are involved in the stimulation of the hypothalamic corticotrophin-
releasing hormone release that activates the neuroendocrine cascade of the hypothalamic-
pituitary-adrenal (HPA) axis and provokes a wide range of immune functions.10 Evidence on 
the role of cytokines as predictors of depression is mixed and limited to a relatively small 
number of studies,5,6, 42-48 of which some used relatively small sample sizes and cross-
sectional study designs.5, 6, 42 In addition, none of these studies included personality factors.  
In our sample the individual cytokines of TNFα, sTNFr1, sTNFr2, IL-6 and IL-10 were 
not significantly associated with depression at baseline or 1 year follow-up in the total 
sample. However, since depression is a heterogeneous disorder, and groups of depressed HF 
patients are likely to differ in psychopathology and inflammation,9 this does not imply that in 
a small subset of patients a status of systemic inflammation could be the underlying cause of 
their depressive symptoms. The possible existence of different depression-subsets should 
therefore be explored in future studies with larger groups of patients suffering from a 
heightened systemic inflammatory state. Our findings seem consistent with the negative 
findings of Stewart et al.,48 Duivis et al.,46 and Steptoe et al.49 using IL-6, TNFα, and other 
inflammatory markers. Discrepancies in findings on depression and inflammation may also 
be explained by the difference in study set-up (cytokine induction studies vs. (un)controlled 
prospective studies), the study samples or the depression assessment tools.8, 50 About 30-
50% of the patients with major depression do not show HPA axis hyperactivity,51 making it 
hard to discriminate the subset of these patients that are experiencing ‘sickness behavior’ as 
a result of inflammation.9 The association between inflammatory processes and depressive 
symptoms might be specific either to clinically depressed groups, to HF patients with NYHA 
class III-IV, or to older age samples (>70 years).45 In fact, age is also characterized by 




























Most markers of disease severity (BNP, LVEF, etiology) were not associated with depressive 
symptoms. Only medical NYHA classification and co morbidity were independent predictors 
in the linear and logistic regression model of increased depressive symptoms. In a study 










 comorbidity index 
Loneliness*  










   ORs [95% CI] 
OR=0.33 [0.1 - 18.12] 
OR=1.79 [0.52 - 24.80] 
OR=0.56 [0.1 - 23.83] 
OR=0.73 [0.11 - 5.02] 
OR=1.81 [0.44 - 7.42] 
OR=1.95 [0.36 - 10.53] 
OR=0.99 [0.92 - 1.06] 
OR=0.99 [0.98 - 1.01] 
OR=0.77 [0.24 - 2.45] 
OR=1.68 [1.09 - 2.60]* 
OR=0.94 [0.84 - 1.05] 
OR=2.17 [0.70 - 6.74] 
OR=0.92 [0.85 - 0.99]* 
OR=2.51 [0.69 - 9.06] 
OR=1.44 [0.53 - 3.92] 
OR=0.61 [0.19 - 1.91] 
OR=1.02 [0.94 - 1.11] 
OR=1.21 [0.46 - 3.21] 
OR=0.52 [0.17 - 1.61] 
OR=1.80 [1.47 - 2.20]** 
0.1 10 
1 Prospective analysis of dichotomous depression scores  












hypertension), it can be expected that co morbidities add significantly to the burden of HF, 
and could therefore be important antecedents for developing depression. There was a 
difference in the strength of the association between depression and subjective (NYHA 
classification) versus objective (LVEF, BNP) disease severity measures, which coincides with 
the results found by Gottlieb et al.13 
The findings of the present study support the validity of the personality model in 
patients with HF. Type D personality and loneliness were found to be major significant 
predictors of depressive symptoms, adjusting for medication and demographic and clinical 
covariates. Personality factors can predispose people to depression through having 
dysfunctional beliefs, distorted social roles, social losses, and a low rate of effective coping 
and positive reinforcement.52 The importance of Type D and loneliness as independent 
predictors of depression was also observed in a few other studies.15, 18, 52-55 One recent study 
even found that Type D personality not only independently predicted depression status over 
time, but also predicted the different depression trajectories. Furthermore, Type D 
personality and other psychological vulnerabilities were found to be especially important for 
persistent depression.15 Based on the fact that Type D personality is constructed out of a 
negative affect scale which has a potential overlap with depression, these current findings 
could be, in part, expected.56 However, Type D and depression clearly differ in the presence 
of social inhibition and in their conceptualization as either a disorder or a personality trait.57  
This is supported by evidence from factor analytic research which shows that items from the 
Type D personality scale are different from depressive symptoms.58 Furthermore, intra-
individual variability in depressive symptoms over time did not affect Type D status,31 while 
Type D personality is able to predict major cardiac events above and beyond concurrent 
symptoms of depression.57 In relation to loneliness, more insight is needed into the 
prevalence and cause of loneliness among HF patients with depression. Loneliness can 
develop not only as a result of inadequate social support after a negative life event, but can 
also be caused by alienation or a distorted view on social support of the depressed 
patients.59 A focus on conserving and rebuilding adequate social relationships could 
therefore be of great value for the well-being and survival of these patients.  
This study has a number of limitations. The three theoretical models we use in our 
analyses do not exist in isolation, but interact with one another via pathways that are not 





directionality of any relationship between inflammation, disease severity and personality. 
The number of personality variables used in our analyses was limited, therefore future 
studies ought to expand this model by also including psychological vulnerability variables 
such as low-reinforcement, low-self esteem and neuroticism.  Furthermore, since about 60% 
of the patients were males with NYHA class I the results of this study cannot necessarily be 
extrapolated to women with HF in general or to patients with clinical heart failure, 
respectively. For the assessment of depression we used a self-report measure, and caution is 
required regarding the outcomes of the analyses in relation to a clinical diagnosis of 
depression. Another aspect of attention in regard to the HADS is its lack of somatic items of 
depression, thereby potentially making it more difficult to find a relationship with 
inflammation induced ‘sickness behavior’. However, sickness behavior is also known to 
manifest itself mentally and previous studies have shown that also cognitive/affective 
depressive symptoms can be prospectively associated with sTNFr1 and sTNFr2, independent 
from clinical and demographic covariates.60 Therefore, this should not have been a major 
problem in this study.  A number of potential predictors of depression were not assessed in 
this study, including C-reactive protein, autonomic nervous system dysfunction, and platelet 
dysfunction.61 Most of these variables have not been intensively studied as plausible 
alternative mediating pathways for depressive symptoms in HF thus far. Lifestyle and health 
behaviors, such as smoking, alcohol use, diet and exercise, have also been associated with 
depression and are a possible mediator in the depression-to-inflammation relationship.8, 46,50 
In this study only BMI was taken into account in the analyses to prevent overfitting of the 
regression model. Current findings indicate that BMI is significantly associated with 
depressive symptoms. However, since no formal tests of mediation were performed, the 
role of BMI as mediator remains unconfirmed.  
 
CONCLUSION 
Determining the predictors of depression in HF patients is important to identify potential 
targets for novel interventions. This study shows that clinical parameters [i.e. NYHA 
functional class, co morbidity] and personality factors [i.e. Type D personality and loneliness] 
have to be considered as concomitants of depressive symptoms in patients with HF. Further 
studies are warranted to replicate these findings, to further explore the relative importance 










factors, physiological risk markers), secondary effects and the complexity of psychological, 
and physiological and pharmacological pathways to be able to disentangle and resolve the 
‘system’ of cause-effect relationships.  Since we used only two measures for personality we 
propose future studies to explore a broader range of cognitive, behavioral, and interpersonal 
personal vulnerabilities, but also social and behavioral risk factors. Based on current findings 
it may be too premature to suggest the inclusion of personality factors in risk algorithms for 
depression in HF patients, however it seems information on the personality of the patient 
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Positive affect dimensions and 
their association with inflammatory 
biomarkers in patients with chronic 
heart failure





Background: In cardiac patients positive affect has found to be associated with improved 
clinical outcomes, with reduced inflammation being one of the potential mechanisms 
responsible. 
Methods: Positive affect was assessed using The Global Mood Scale (GMS), Positive and 
Negative Affect Schedule (PANAS), and Hospital Anxiety and Depression Scale (HADS) in 
patient with chronic heart failure (N=210; 67±9 years, 79% men). Markers of inflammation 
(TNFα, sTNFr1, sTNFr2, IL-6 and CRP) were measured and averaged at three consecutive 
time points.  
Results: The positive affect dimensions of the GMS and PANAS were significantly associated 
with a lower averaged levels of sTNFr2, TNFα and IL-6 (p<0.1), even after adjustment for 
clinical and lifestyle confounders. Positive affect of the HADS was significantly associated 
with lower averaged levels of hsCRP (p<0.1), but was no longer significant after correction 
for lifestyle confounders and depressive symptoms.   














There is emerging evidence that emotions play a key role in linking psychological stress to 
physical health.1,2 Apart from the detrimental effects of negative affect, such as anger, 
depression, and anxiety, there is a growing interest in the role of positive affect as a 
potentially protective factor in the progress of chronic disease.3    
 Positive affect is defined as feelings that reflect a state of high energy, full 
concentration and a level of pleasurable engagement with the environment, such as joy, 
happiness and contentment.1 Positive affect can confer benefit to individuals beyond the 
feeling of well-being, given that it has been associated with an overall prolonged healthy life 
expectancy,4 5 reduced blood pressure,5-7 a higher heart rate variability8 and a reduced risk 
for stroke, coronary heart disease9 and hypertension.3,5      
 The mechanisms responsible for the link between positive affect and improved 
health ought to be found in behavioral and biological pathways such as a healthy lifestyle 
and inflammation.2 Assuming the mechanisms between negative and positive affect are 
similar and acting in a opposite manners, positive affect is expected to render an anti-
inflammatory effect as negative affect has been associated with higher pro-inflammatory 
levels.10-12           
 Indeed, previous studies have found positive affect to be associated with functional 
changes of the immune system,13-16 and specifically also with lower levels of the stress 
hormones epinephrine, norepinephrine and cortisol.17 These hormones are important 
regulators of immune functioning, and subsequently of the level of inflammatory biomarkers 
(i.e. Interleukin-6 (L-6), Tumor necrosis factor alpha (TNFα), C-reactive protein (CRP)) in the 
body.17 IL-6 and CRP are crucial in the regulation of thrombopoiesis, the acute phase 
response, and the formation of fibrosis in cardiac tissue.18 Several studies have also 
observed an association between positive affect and levels of Interleukin-6 (IL-6) and C-
reactive protein (CRP).2,19-22 Some studies found an inverse association between positive 
affect and levels of IL-6 in healthy adults,19, 20 women21 or men,22 adjusting for age, ethnicity, 
socioeconomic status, body mass index (BMI), smoking and depressed mood.      
Furthermore, positive affect was associated with reduced levels of the inflammatory 
marker CRP in healthy women from the Whitehall II study, but not in men.21 There are also 
several studies linking mood to tumor necrosis factor alpha (TNFα) and its receptors, which 









and release TNF-α in response to cardiac stress, such as left ventricular pressure, or volume 
overload. TNF-α release then leads to an increase in soluble receptors sTNFr1 and sTNFr2 
which act as immunomodulatory elements.23 However, most studies on TNFα and its 
receptors have used negative affect states such as depression,24 and did not further 
investigate positive affect.  
 Despite several studies reporting an association between positive affect and lower 
levels of inflammation, the association is not always found for all cytokines,20 and sometimes 
even entirely absent.25 An explanation for this could be the use of different instruments for 
positive affect in a variety of populations, making it difficult to compare the results. 
Moreover, since there seems to be little agreement on what is actually meant by positive 
affect,1 one can also not just assume that what these instruments measure is identical. On 
top of that, many studies examining the relation between positive affect and prognosis or 
survival are limited by a lack of control for potential confounders such as negative affect. 
 Therefore the aim of this study was first of all, to examine the differences in three 
positive affect constructs which are commonly used in cardiovascular populations, i.e. the 
Global Mood Scale (GMS), the Positive and Negative Affect Schedule (PANAS) and the 
positive affect dimension of the Hospital Anxiety and Depression Scale,1 in a single patient 
population, and second, to examine whether these positive affect constructs differ in their 
association with five inflammatory biomarkers (e.g. TNFα, sTNF1, sTNFr2, IL-6, CRP) using a 
prospective mixed model, additionally correcting for depressive symptoms. 
 
METHODS AND MATERIALS 
Study population and design 
Consecutive outpatients with a diagnosis of heart failure (HF) were recruited from the St. 
Elisabeth Hospital, Tilburg, the Netherlands between June 2006 and February 2009. Inclusion 
criteria were: LVEF ≤40%, stable on oral HF medication within one month prior to inclusion, 
New York Heart Association (NYHA) functional class I-III, no hospital admissions in the month 
prior to inclusion. Exclusion criteria were >80 years of age, unable to understand and read 
Dutch, clinical signs of acute infection, active episodes of gout or arthritis, use of anti-
inflammatory medication, other life-threatening diseases, myocardial infarction 2 months 
prior to inclusion, and cognitive impairments or psychiatric comorbidity (except for mood 




participation, died or did not return the baseline questionnaire, leaving 244 patients eligible 
for analyses. In total 34 patients had no cytokine measurements and were excluded from the 
final analyses leaving 210 (78%) HF patients. Patients were asked to complete a set of 
questionnaires at inclusion assessing socio-demographic and psychological variables. This 
questionnaire was returned in a stamped and pre-addressed envelope. If the questionnaire 
was not returned within two weeks, patients received a reminder telephone call or letter. All 
questionnaires were checked for completeness. Blood samples for cytokines measurement 
and clinical laboratory values were drawn at baseline, 12 months and 18 months follow-up. 
The blood draws were taken across the day during regular scheduled visits at the outpatient 
clinic. Patients were instructed not to exercise, smoke or drink coffee immediately prior to 
the blood draws. The study was approved by the Medical Ethics Committee of the St. 
Elisabeth hospital in Tilburg and conducted in accordance with the most recent version of 
the Helsinki Declaration (2008). All patients provided written informed consent before 
entering the study. 
 
Measures 
Demographic, lifestyle and clinical variables 
Demographic variables comprised gender, age, marital status (having a partner vs. having no 
partner), and educational level (primary school vs. secondary school and above). Clinical 
variables included time since HF diagnosis, etiology of HF (ischemic vs. non-ischemic), 
previous cardiac events (i.e., previous myocardial infarction (MI), coronary artery bypass 
graft (CABG) or percutaneous coronary intervention (PCI)) and prescribed medications (beta-
blockers, calcium antagonists, nitrates, aspirin and other platelet-aggregation inhibitors, 
anticoagulants, ACE-inhibitors & ARB’s, statins, diuretics and psychotropic medication).  
Lifestyle variables included current smoking status, exercise and BMI. Disease severity 
variables included etiology left ventricular ejection fraction (LVEF), brain natriuretic peptide 
(BNP) and New York Heart Association functional class (NYHA), and medical co morbidity (i.e., 
included presence of COPD, peripheral arterial disease, hypertension, lipid dysfunction, 
gastrointestinal disease, diabetes, liver disease, and kidney failure). Kidney function was 
measured by calculating the glomerular filtration rate of creatinine using the MDRD formula, 
and kidney dysfunction was defined as a GFRcreat<60mL/min per 1.73m.26,27 Lifestyle 










Positive affect was measured using three different measures which are widely used in the 
field of cardiovascular behavioral medicine; i.e., the positive affect items of the Global Mood 
Scale (GMS), the positive items of the Positive and Negative Affect Schedule (PANAS) and the 
positive affect dimension of the Hospital Anxiety and Depression Scale. The Global Mood 
Scale (GMS) comprises 10 negative (“fatigued” and “listless”) and 10 positive (“lively” and 
“hard working”) mood terms that especially tap vitality concepts that are commonly 
reported by cardiac patients.28 The respondent is asked to rate on a 5-point Likert scale 
(ranging from 0, not at all to 4, extremely) the extent to which he/she has experienced each 
mood state lately; scores on both the NA and PA scales range from 0 to 40. Both the NA and 
PA scales of the GMS are internally consistent; i.e., Cronbach's α = .94 and α = .91 28, α = .87–
.94 and α = .90 and α = .90,29 respectively. The GMS has also been shown to be responsive to 
treatment-related changes in negative and positive affect among cardiac patients.29,30  
 
The PANAS is a 20-item self-report measure of positive and negative affect developed by 
Watson, Clark, and Tellegen (1988b).31 NA and PA reflect dispositional dimensions, with 
high-NA epitomized by subjective distress and unpleasurable engagement, and low NA by 
the absence of these feelings. By contrast, PA represents the extent to which an individual 
experiences pleasurable engagement with the environment. Compared to the GMS, this 
scale is relatively more cognitive-motivational oriented with items such as “strong” and 
“inspired”.32 Each item is rated on a 5-point scale ranging from 1 = very slightly or not at all 
to 5 = extremely to indicate the extent to which the respondent has felt this way in general. 
Watson et al. 31 reported Cronbach’s alpha coefficients for a general period, alpha was .88 
for Positive Affect and .87 for Negative Affect. Test-retest correlations for an 8-week period 
ranged from .47 to .68 for Positive Affect, .39 to .71 for Negative Affect (for the general time 
period, Positive Affect stability = .68, Negative Affect stability = .71). 
 
Previous research in myocardial infarction patients showed the HADS comprised a subscale 
to assess (the absence) of positive affect (e.g. anhedonia) in cardiac patients.33  Explanatory 
factor analyses was used to extract the items of the positive affect dimension, i.e., being 
cheerful, looking forward with enjoyment to things, being still able to enjoy things and 




compared with the GMS and PANAS. Corrected item-total correlations ranging between 
0.69/0.72 and Cronbach’s α=0.86 indicated a high internal consistency of this four-item 
dimension.33 Each item of the HADS has a 4-point response scale ranging from 0= just as 
much/most of the time to 3= not at all to indicate how the respondent has felt in the last 
week. Since normally higher item scores of the HADS represent a lower positive affect, we 
reversed the scoring of the HADS positive affect scale to make the interpretability the same 
as for the GMS and the PANAS positive affect scales, thus higher scores representing a 
higher positive affect.  
 
Depressive symptoms 
Depressive symptoms were assessed to be able to control for this widely used concept in 
relation to inflammation. The 10-item Center for Epidemiological Studies Depression Scale 
(CES-D),34, 35 a measure that has frequently been used to measure depressive symptoms in 
CHF, was assessed at a baseline. The 10 items are answered on a four-point Likert scale 
ranging from 0 (rarely or none of the time) to 3 (most or all of the time). A cut-off score of 11 
is indicative of “significant” or “mild” depressive symptomatology. Reliability statistics with 
the 10-item CES-D were found to be comparable to those reported for the original CES-D. 




Levels of tumor necrosis factor (TNF)-α, soluble TNF receptors 1 and 2 (sTNFr1 & sTNFr2), 
interleukin (IL)-6 and high sensitive C-reactive protein (hsCRP) were obtained using standard 
hospital protocol. Venous blood samples were drawn and centrifuged at baseline. Blood was 
allowed to clot at room temperature for at least 20 minutes and centrifuged. Aliquoted 
serum samples were stored at -80°C in anticipation of further processing. Concentrations of 
IL-6 (sensitivity: 2 pg/ml) and TNFα (sensitivity: 1.7 pg/ml), were measured using a solid-
phase, enzyme labeled, chemiluminescent immunometric assay (Immulite 1000, Siemens 
Healthcare Diagnostics Breda, The Netherlands). Soluble tumor necrosis factor receptors 
(sTNFR1 and sTNFR2; sensitivity for both: 15.6 pg/ml) were measured using quantitative 
enzyme-linked immunosorbent assay (Hycult Biotechnology, Uden, The Netherlands). hsCRP 









Diagnostics, Almere, The Netherlands). All tests were measured in accordance with the 
manufacturer’s recommendations. The sensitivity of all tests was calculated as the mean of 
six zero-values plus three SDs extrapolated on the standard curve. The intra-assay variation 
was less than 10%, and the inter-assay variation less than 11%.   
 
Statistical analyses 
To compare the demographic and clinical characteristics between patients with and without 
cytokine measurements, t tests, Mann-Whitney U tests, or χ2-tests were used depending on 
the measure and variable distribution. The descriptives of the cytokines over time are given 
for the non-transformed levels of sTNFr1, sTNFr2, TNF-α, IL-6 and hsCRP, median and 
interquartile range. Prior to analyses, the cytokine data was tested for outliers and its 
distribution; due to its skewed distribution, the data were transformed using log10. We used 
exploratory factor analyses (i.e. principal components analysis with oblimin rotation) to 
examine differences in positive affect dimensions that were assessed in the current study. 
The scree plot was used as a criterion for the number of underlying components to extract. 
To examine the relation between the positive affect constructs, and the relation between 
the constructs and the cytokines over time, a Pearson’s correlation coefficient was 
calculated.  
For the multivariate analyses we used the linear mixed model procedure (covariance 
model: unstructured, maximum likelihood (ML) estimate) in SPSS version 17.0. The 
dependent cytokine variables were measured at baseline, 12 months and 18 months, and all 
available data was used, thereby limiting bias and preserving statistical power. The mixed 
multivariate analyses were composed of four models. The first model (Model 1) is the base 
model in which positive affect was entered together with age, gender and time. In the 
second model (Model 2), the first model was complemented by BNP, diabetes, kidney failure, 
statin and aspirin use. In the third model (Model 3), BMI, exercise, smoking and educational 
level were added to the first model, and in the fourth model (Model 4) depressive symptoms 
were added to Model 1 by using the continuous CES-D scores. The choice of covariates was 
based on theoretical evidence of possible confounders of inflammation.6, 21, 37-43 Positive 
affect (baseline) and other covariates were entered into the model as fixed effects to 
examine whether they are significantly associated with the (variance of) the averaged 




comparisons due to the high probability of finding small effect sizes, the moderate to high 




The mean age of the 210 patients was 66.7±8.7 year, 166 patients (79%) were men. 
Complete information on the demographic, clinical and psychological baseline characteristics 
of the patients is shown in Table 1.  
 
Table 1: Socio-demographics of patients at baseline  
 
 Total (N= 210) 
Mean ± SD; n (%) 
Demographics 
Male 166 (79%) 
Age (yrs) 66.7±8.7 
Partner 161 (77%) 
Education 
    Primary school 71 (34%) 
    Secondary school and above 139 (66%) 
Clinical 
Etiology 
    Ischemic heart disease  138 (66%) 
    Other (congenital, bacterial, valvular disease e.g.) 72 (34%) 
NYHA functional class 
    I 116 (55%) 
    II 76 (36%) 
    III 18 (9%) 
LVEF 33.70±6.73 
BNP (pmol/L) 70.3±118.6 
Chronic obstructive pulmonary disease 44 (21%) 
Hypercholesterolemia 142 (68%) 
Diabetes 61 (29%) 
Kidney failure 65 (32%) 
Current smoker 45 (23%) 
BMI 28.1±5.3 
Medication use 
 Beta blockers 139 (66%) 
 Nitrates 106 (51%) 









 Angiotensin-receptor blockers 70 (33%) 
 Statins 146 (70%) 
 Diuretics 131 (62%) 
 Psychotropic medication 36 (17%) 
 Aspirin 75 (36%) 











CES-D = Center for Epidemiological Studies Depression Scale; GMS= Global  
Mood Scale; HADS= Hospital Anxiety and Depression Scale; PANAS=Positive  
And Negative Affect Schedule 
 
Cytokines levels 
Cytokine levels were measured at baseline, 12 months and 18 months follow-up. Cytokine 
levels were missing at random in some patients for logistic and practical reasons. From the 
total number of patients in the study (n=244), patients excluded from the analyses due to 
missing cytokine values (baseline: n=34) did not differ systematically from patients who did 
have positive affect baseline scores (baseline: n=210) on clinical, demographic, and 
psychological characteristics, except that patients excluded from the analyses were more 
likely to be on betablockers (88% vs. 66%, χ2=6.65, p=.010). See Table 2 for the median and 
interquartile range (IQR) of the non-transformed cytokine levels at baseline, 12 months and 
18 months.  
 
Positive affect dimensions 
The positive affect constructs of the GMS, PANAS and HADS had a Cronbach’s α coefficient 
of .87, .91 and .78, respectively. Exploratory factor analysis revealed that the three positive 
affect constructs loaded on 3 separate components, thereby indicating that the GMS, PANAS 
and HADS measure different dimension (Table 3). The correlation between component 1 
(mainly GMS) and 2 (mainly HADS) was .12, between 1 and 3 (mainly PANAS) was .56 and 
between 2 and 3 was .04. GMS item 17 (Cheerful) loaded together with the positive affect 




Correlation coefficients between the GMS, PANAS and HADS scales were r=.726 (p<0.001) 
between GMS and PANAS, r=.52 (p<0.001) between the GMS and HADS, and r=.46 (p<0.001) 
between PANAS and HADS. The factor analyses, correlation and reliability coefficient were 
calculated on the full sample size at baseline of n=244 HF patients. 
 







sTNFr1 [ng/ml] 6.2 (3.1) 7.2 (3.9) 7.5 (4.5) 
sTNFr2 [ng/ml] 0.99 (0.91) 0.81 (0.99) 0.96 (0.94) 
TNFα [pg/ml] 11.9 (5.2) 11.9 (4.7) 11.9( 4.1) 
IL-6 [pg/ml] 3.9 (3.3) 3.6 (3.2) 3.4 (2.4) 
hsCRP [mg/L] 2.9 (4.8) 2.5 (4.3) 2.1 (3.5) 
hsCRP = high sensitive C-reactive protein; IL6 = interleukin 6; TNFα = tumor  
necrosis factor α; sTNFr1/2 = soluble tumor necrosis factor receptor 1 or 2 
Cytokine levels are non-transformed, N = 210 max 
Median and IQR = interquartile range are shown 
 
Positive affect and cytokine levels 
Correlation analysis was performed for baseline positive affect and cytokine levels over time, 
in which IL-6, sTNFr2 and TNF-α showed consistent negative associations with positive affect 
while hsCRP and sTNFr1 showed almost no associations (data not shown). TNFα had a 
significant correlation with the GMS positive affect at baseline (r=-.157, p=.036) and with the 
GMS and PANAS at 18 months (r=-.333, p=.004 and r=-.327, p=.004, respectively). For IL-6 
the correlation was significant with the GMS and PANAS at baseline (r=-.200, p=.008; r=-.162, 
p=.028, respectively) and with the GMS and HADS at 18 months (r=-.232, p=.047; r=-.261, 
p=.024). sTNFr2 correlated negatively with positive affect at most occasions (significant 
correlations ranging from r=-.17 (p=.017) at baseline for the HADS to r=-.26 (p=0.002) for the 
GMS).  
Using mixed multivariate modeling the three positive affect constructs were analyzed 
as predictors of the averaged level of inflammatory markers over time (Table 4). The GMS 









(F(1,186)=9.19, p=.003), and IL-6 (F(1,195)=7.72, p=.006), but not with sTNFr1 (F(1,142)=1.26, 
p=.26), or hsCRP (F(1,202)=.90, p=.34) adjusted for age, gender and time (model 1). Further 
adjustment for clinical confounders (model 2), lifestyle confounders (model 3) and 
depressive symptoms (model 4) did not attenuate these findings (sTNFr2 range 
(Fmodel2(1,175)=7.51, p=.007 to Fmodel4(1,185)=4.76, p = .03), TNFα range (Fmodel3(1,186)=7.55, p=.007 
to Fmodel2(1,175)=5.14, p=.025)), and IL-6 range (Fmodel2(1,185)=4.57, p=.003 to Fmodel4(1,192)=7.03, 
p=.009). The PANAS positive affect scores was significantly associated with lower levels of 
sTNFr2 (F(1,173)=8.11, p=.005) and TNFα (F(1,166)=4.95, p=.028) after adjustment for age, 
gender and time, and also after additional correction for clinical and lifestyle confounders 
(p<.05 for all). Only the association between the PANAS positive affect and sTNFr2 remained 
marginal significant (F(1,175)=3.78, p=.053) after an additional correction for depressive 
symptoms. The PANAS was not significantly associated with sTNFr1 or hsCRP before or after 
adjustment for clinical and lifestyle confounders and depressive symptoms (p>.1 for all), and 
only marginally significant in relation to IL-6 (p<.1 for all models). 
The positive affect score of the HADS was not significantly associated with sTNR1, 
TNFα or IL-6 in any of the models (p>.1 for all). HADS positive affect was significantly 
associated with sTNFr2 and hsCRP after correction for age, gender and time (sTNFr2: 
F(1,196)=5.45, p=.021; hsCRP: F(1,210)=5.72, p=.018) and clinical confounders (sTNFr2: 
F(1,185)=4.63, p=.033; hsCRP, F(1,200)=3.61, p=.059). Only the association with sTNFr2 remained 
marginally significant after correcting for lifestyle confounders (F(1,198)=3.48, p=.068), but this 
association was attenuated after correction for depressive symptoms (F(1,189)=.57, p=.45).  
The covariates introduced in the first model of the mixed modeling included age, gender and 
time. Older age increased the level of sTNFr1, sTNFr2 and IL-6 in the analyses of the GMS, 
PANAS and HADS (all ps<.01), while male gender appeared to lower the cytokine levels of 
sTNFr1 (GMS) and sTNFr2 (PANAS and HADS). Comparing baseline cytokine levels with those 
at 12 and 18 months follow-up, there seems to be a consistent increase in averaged sTNFr1 
and TNFα over time (GMS, PANAS and HADS), almost no difference in sTNFr2 and hsCRP 







Table 3: Factor analysis of positive affect measures at baseline      
Pattern Matrix 
Items Component 
 1 2 3 
GMS 09  -  Lively .94 .24 .07 
GMS 05  -  Bright .94 .02 .29 
GMS 07  -  Hard working .94 .02 .07 
GMS 17   - Cheerful .94 .37 .07 
GMS 20   - Self-confident .94 .02 .27 
GMS 16   - Sociable .94 .02 .07 
GMS 04   -  Dynamic .69 .01 .14 
GMS 02   -  Active .66 .05 .12 
GMS 13   -  Enterprising .55 .01 .01 
GMS 14   -  Relaxed .44 .37 .07 
HADS 04   - Positive attitude .01 .81 .02 
HADS 12   - Looking forward .02 .79 .02 
HADS 02   - Enjoying things .16 .77 .07 
HADS 06    - Feeling cheerful .11 .75 .06 
PANAS 14  -  Inspired .15 .04 .86 
PANAS 05 -  Strong .04 .05 .86 
PANAS 09  -  Enthusiastic .04 .20 .85 
PANAS 12  -  Alert .04 .11 .76 
PANAS 16  -  Determined .21 .02 .69 
PANAS 10  -  Proud .28 .05 .62 
PANAS 17  -  Attentive .23 .01 .58 
PANAS 03  -  Excited .24 .24 .57 
PANAS 01  -  Interested .20 .01 .55 
PANAS 19  - Active .00 .02 .30 
GMS=Global Mood Scale; HADS= Hospital Anxiety and 
Depression Scale; PANAS= Positive And Negative Affect 
Schedule 
Pattern matrix N=244 












Table 4: Mixed multivariate model of positive affect according to HADS, GMS and PANAS 
 
 sTNFr1 sTNFr2 TNFα IL-6 hsCRP 
GMS positive affect      
Model 1 O _ _ _ _ _ _ _ _ _ O 
Model 2: clinical confounders       O _ _ _ _ _ _ _ O 
Model 3: lifestyle confounders  O _ _ _ _ _ _ _ O 
Model 4: depression O _ _ _ _ _ _ _ _ O 
PANAS positive affect      
Model 1 
 
O _ _ _ _ _ _ _ O 
Model 2: clinical confounders O _ _ _ _ _ _ O 
Model 3: lifestyle confounders O _ _ _ _ _ O 
Model 4: depression O _ O O O 
HADS positive affect      
Model 1 
 
O _ _ O O _ _ 
Model 2: clinical confounders       O _ _ O O _ 
Model 3: lifestyle confounders O _ O O O 
Model 4: depression O O O O O 
hsCRP = high sensitive C-reactive protein; IL6 = interleukin 6; TNFα = tumor necrosis factor α; 
sTNFr1/2 = soluble tumor necrosis factor receptor 1 or 2 
O = nonsignificant p>.1;  − = negative association p<.1;  −− = negative association p<.05;  
 −−− = negative association p<.01; + = positive association p<.1;  ++ = positive association p< .05;   
+++ = positive association p < .01 
Model 1: Positive affect + age + gender + time (baseline vs. 12 or 18 months follow-up) 
Model 2: Model 1 + BNP, kidney failure + diabetes + aspirin use + statin use 
Model 3: Model 1 + BMI + activity level + smoking + education level 






In relation to the clinical confounders, kidney failure significantly increased averaged levels 
of sTNFr1, sTNFr2, TNFα and IL-6 over time (GMS, PANAS and HADS). Higher levels of BNP 
also lead to a significant increase in averaged levels of IL-6 (GMS, PANAS and HADS) and 
TNFα (PANAS). The use of statins caused a strong decrease in hsCRP levels (p<.01) (GMS, 
PANAS and HADS). Model three which corrected for lifestyle confounders showed that a low 
amount of exercise significantly increased the averaged levels of sTNFr1 and hsCRP over 
time (GMS, PANAS and HADS). A higher BMI had only a significant effect on hsCRP (GMS, 
PANAS and HADS). The correction for depressive symptoms in model 4, indicated that higher 
depressive symptoms significantly increase the levels of sTNR2 (HADS) and hsCRP (GMS, 
PANAS and HADS) (p<.01) 
 
DISCUSSION 
Based on the factor analysis, in which the factors fell almost completely in line with the 
specific scales, it appears that the difference between the positive affect measures and the 
inflammatory markers could well be explained by the presence of method-variance, in which 
the variance is attributable to the measurement method rather than to the constructs the 
measures represent. However, looking at these results in combination with those from 
previous literature, there seem to be consistent differences in the relation between different 
positive affect measures and inflammation,19,20,25 thereby suggesting the explanation is more 
likely to be sought elsewhere. At the same time, as this is the first study examining three 
different positive affect measures in the same patient sample, it is difficult to give clear-cut 
alternative explanations for these differences in findings. 
Previous studies on the negative affect (NA) of the GMS and PANAS found that the 
GMS-NA was more focused on emotional exhaustion while the PANAS-NA was focused more 
on anxious apprehension, thereby suggesting that the GMS taps a unique form of negative 
mood states that is not incorporated into the PANAS.44 Therefore, this could be the case for 
positive affect as well in which the GMS seems to focus more on emotional vitality, whereas 
the PANAS seems to be focused more on emotional motivation, which could suggests that 
the GMS and PANAS positive affect measures cannot necessarily be used interchangeable.44 
Another potential explanation, analogue to studies relating positive affect and 
cardiovascular function, could be a difference in the type and intensity of the emotional 









activated (e.g. enthusiastic, joyful) and non-activated (e.g. calm, content) positive affect,1, 2,17 
in which activated emotions are more likely to influence health. However, although this 
being an interesting aspect to consider in research on positive affect, there seem to be no 
clear cut differences between the GMS, PANAS and HADS in assessing primarily activated 
emotions. The fact that the HADS was not designed a priori to measure positive affect, and 
perhaps has a stronger cognitive component (e.g. optimism, attitude) seems therefore more 
likely. Yet another explanation could be the difference in timeframe asked for by each scale’s 
set of instructions. One could speculate that by measuring positive affect in general (e.g. 
PANAS) in comparison to last week (e.g. HADS) could have led to differential associations 
caused by performing state vs. trait assessments of positive affect. Rather than their content 
and timeframe also the clustering of questions and response alternates could be responsible 
for the difference between the measures, however the probability of this seems low since all 
three measures use a 4-or 5 point Likert response scale and have mixed the negative and 
positive affect items.  
Results from the mixed modeling confirm the findings of the factor analysis by 
showing that although the models of sTNFr1, sTNFr2, TNFα and IL-6 appear fairly similar in 
their associations with the covariates (e.g. age, time, BMI, BNP, kidney failure and statin use), 
the association with positive affect differs depending on the construct used. For sTNFr1, 
sTNFr2, TNFα and IL-6 and hsCRP the results for the positive affect scales of the GMS and 
PANAS are almost similar (except for the model including depression). However, the HADS 
positive affect scale found no significant association with TNFα or IL-6 at all, while it was the 
single construct that found an association with hsCRP in the first and second model. 
Adjustment for depression changed the association between the PANAS and TNFα 
and IL-6, and also between the HADS and sTNFr1 and hsCRP. The CES-D scores for depressive 
symptoms were only significant with respect to hsCRP (PANAS and HADS) and sTNFr2 (HADS). 
This could indicate that positive affect moderates the cardiovascular response to negative 
affect2 or even that positive emotions may be a better predictor of inflammatory function 
and clinical outcomes than negative emotions.45-47 Positive affect may therefore represent 
unique components of psychobiological resilience,48 and interventions to maintain positive 
affect during stressful situations could be critical in obtaining lower numbers of cardiac 




or effective, since it is also possible that stable genetic components influence both affect and 
inflammation.50  
The findings of this study are in concordance with the scarce amount of existing 
previous literature, which is scattered among multiple different study populations varying 
from health adults to rheumatoid arthritis and coronary heart disease. Previous studies, of 
which only few corrected for depressive symptoms in their multivariate analysis, mostly 
originate from Cohen, Steptoe and colleagues.5, 13-15 In relation to our current findings the 
Whitehall II study is the most eminent. In this study positive affect was assessed by asking 
participants how happy, excited, or content they felt immediately after saliva collections 
using four response options (not at all - extremely). They found that positive affect was 
associated with reduced levels of IL-6 and CRP, in healthy women.5 In this case it seems that 
the differences in populations and positive affect measure did not alter the results on the 
association with inflammation. Other studies found that plasma and soluble IL-6 receptors 
are associated with psychological well-being in aging women and that positive affective style 
covaries with stimulated IL-6 production in a middle-aged community sample.19, 20 These 
studies used the MASQ (Mood and Anxiety Symptom Questionnaire) and the PANAS to 
measure positive affect, respectively. Similar to our findings Prather et al. did not find any 
association between TNF-α and the PANAS positive affect scale. As to our knowledge there 
are no other previous study on the relation with positive affect and the TNF-family, except 
for mood induction studies with TNFα.51  
 A recent paper from Andreasson et al. found no evidence on a relation between 
positive affect, as measured by four items of the CES-D, and IL-6. This is interesting since the 
positive affect items of the HADS and CES-D are both focused on anhedonia, and appear 
fairly similar (HADS: “I feel cheerful”, CES-D: ”I felt happy”).  
Based on the mixed modeling results the most important covariates of increased 
cytokine levels appeared to be time, age, gender, BNP, kidney failure, statin use, BMI and 
exercise.  Kidney dysfunction, a lower amount of physical exercise, older age, female gender, 
a higher BMI and increased BNP levels were associated with higher averaged cytokine levels 
of soluble TNFr1 and TNFr2, TNFα, IL-6 and hsCRP (depending on positive affect measure). 
Statin use was associated with lower averaged levels of hsCRP as found in previous 









A number of limitations must be acknowledged. First, except for including gender as 
a covariate in our multivariate analyses we did not specifically look whether the association 
between positive affect and cytokine levels was different among men and women, which 
could have affected our results based on the gender differences observed in the Whitehall II 
study. Therefore future large scale studies are necessary allowing statistical analyses with 
stratification into different age and gender groups. Furthermore, we did not correct for 
multiple comparison testing in this study since it was explorative in nature. As a result our 
Type I error is increased and the external validity decreased, which possibly overestimates 
some of the effects. In this study the association of positive affect with immune functioning 
at baseline was even maintained at 18 months follow-up, but since this study only included 
information on positive affect at baseline the effect of changes in positive affect over time 
on the cytokine levels is unknown. Therefore the question formulated by Dockray and 
Steptoe whether positive affect should be sustained to lead to an overall reduction in the 
activation of immune systems still remains unanswered. Furthermore, although we cannot 
rule out the possibility of reversed causality, comorbidity and disease severity measures 
have been controlled for, making their influence as the primary cause of the association 
unlikely. The percentage of women in this study was relatively low, which could affect the 
generalizability of the results to women with HF in general. About 20% of the patients were 
lost due to missing values in cytokines. A number of potential predictors of changes in 
cytokine levels over time were not assessed in this study due to a possible over fit of the 
mixed model, including socio-economic status, exercise, smoking and various other available 
comorbidities, medication and clinical variables. However, in our view, the most relevant 
variables have been selected to be included in the models.  
 
CONCLUSION 
Although research on the psycho-neuro-immunological mechanism in which positive affect 
can influence health might still be in its infancy, positive affect is increasingly recognized for 
its beneficial effect on physical health in general, but also for specifically improving 
prognosis and lowering mortality rates in cardiac patients through its involvement in 
neuroendocrine, autonomic, immune and inflammatory pathways. Based on the current 
findings we can conclude that there is a substantial difference between the GMS, PANAS and 




outcomes in studies measuring different types of positive affect. Results indicate positive 
affect is an important independent concomitant of inflammation in this sample of patients 
with chronic heart failure. However, targeting positive affect as a potential way to improve 
clinical outcomes in HF patients seems premature, as it is important to first attain a common 
view on the meaning of positive affect, to replicate these findings using other social and 
cognitive factors that might correlate with positive affect (e.g. self-esteem, optimism and 
self-reported health status) and to take a closer look at the exact mechanism involved 
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Association between brain 
natriuretic peptide, markers of 
inflammation and the objective and 
subjective response to cardiac 
resynchronization therapy 




Introduction: Studies suggest that cardiac resynchronization therapy (CRT) can induce a 
decrease in brain natriuretic peptide (BNP) and systemic inflammation, which may be 
associated with CRT-response. However, the evidence is inconclusive. We examined levels of 
BNP and inflammatory markers from pre-CRT implantation to 14 months follow-up in CRT-
responders and nonresponders, defined by two response criteria. 
Methods: We studied 105 heart failure patients implanted with a CRT-defibrillator (68% men; 
age=65.4±10.1 years). The objective CRT-response was defined as a reduction of ≥15% in left 
ventricular end systolic volume; subjective CRT-response was defined as an improvement of 
≥10 points in patient-reported health status assessed with the Kansas City Cardiomyopathy 
questionnaire. Plasma BNP and markers of inflammation (CRP, IL-6, TNFα, sTNFr1 and 
sTNFr2) were measured at three time points.  
Results: Pre-implantation concentrations of TNFα were significantly lower for subjective 
responders compared to nonresponders (p=.05), but there was no difference in BNP and the 
other inflammatory markers at baseline. Objective CRT-response was significantly associated 
with lower BNP levels over time (F=27.31, p<.001), and subjective CRT-response with lower 
TNFα levels (F=5.67, p=.019). 
Conclusion: Objective and subjective response to CRT was associated with lower levels of 
BNP and TNFa, respectively, but not with other markers of inflammation. This indicates that 
response to CRT is not automatically related to a stronger overall decrease in inflammation. 
Large-scale studies are warranted that further examine the relation between the clinical 
effects of CRT on inflammatory markers, as the latter have been associated with poor 





Cardiac resynchronization therapy (CRT) is an established treatment for patients with severe 
heart failure (HF) and ventricular conduction disturbances.1-2 The biventricular pacing 
induced by CRT can help restore left ventricular (LV) systolic function by correcting the 
electro-mechanical dyssynchrony, which improves exercise capacity and reduces 
rehospitalization and mortality.3-6 CRT has also been associated with favorable changes in 
circulating levels of neurohormones and inflammatory cytokines in HF patients.2, 7-12  The 
two most commonly examined neurohormones in relation to heart failure are B-type 
natriuretic peptide (BNP) and N-terminal pro B-type natriuretic peptide (NT-proBNP). 
Natriuretic peptides are secreted by cardiomyocytes when the heart is diseased or the load 
on any chamber is increased. Increased BNP levels have been shown to be strong indicators 
for poor prognosis, but also to be of value in guiding therapy to treat heart failure. Evidence 
suggest a strong link between the endocrine function of the heart and the immune system, 
in which cytokines upregulate BNP expression while BNP has immunomodulatory functions 
which can induce pro-inflammatory cytokines.13 
Many studies have shown that CRT induces a significant decrease in BNP,7-12 but the 
evidence on inflammatory markers like C-reactive protein (CRP), IL-6, TNFα, and soluble TNF 
receptors 1 and 2 (sTNFr1, sTNFr2) is inconclusive. The majority of studies report a decrease 
in IL-62, 10, 12, 14-15 and CRP7, 14 3 months to 1 year after CRT implantation, but only two studies 
showed a decrease in TNFα and the soluble TNF receptors.2, 16 Tarquini et al. observed no 
reduction in any of the inflammatory markers after CRT implantation at 1 year follow-up.17  
In addition, most of the evidence regarding these inflammatory markers is based on studies 
with a small number of patients, missing pre-implantation data, a short follow-up duration, 
and a lack of adjustment for pertinent clinical or socio-demographic covariates in the 
analyses. 
In addition, it is not clear whether changes in the plasma levels of BNP and 
inflammatory markers are associated with response to CRT. The CRT-response can be 
assessed using various objective and subjective criteria. Objective response criteria are 
echocardiographic parameters that detect left ventricular reverse remodeling, indicating an 
improvement of the pump function of the heart. A subjective response criterion is patient-
reported health status which has proven to be of important prognostic value in CRT 









nonresponders. The few studies that examined BNP and inflammatory markers in relation to 
CRT-response have shown mixed results,1, 17, 19-29 and most of these studies defined CRT-
response only using echocardiographic measures. As there is only a moderate association 
between the objective and subjective response criteria, it is possible that clinically relevant 
changes in health status can occur in the absence of changes in echocardiographic 
parameters.18, 30 Hence, the question is to which extent the results on inflammatory markers 
also relate to subjective CRT-response. No study to date has examined the association 
between changes in subjectively reported patient-reported health status after CRT and 
changes in levels of BNP or inflammatory markers, and compared these to response 
according to objective echocardiographic parameters. For both the objective and subjective 
CRT response criteria, the expectation is that responders will have a stronger decrease in 
BNP and cytokine levels compared to non-responders.   
Hence, the aim of this study was to (1) further explore the profile of BNP and 
inflammatory markers from pre-CRT implantation until 14 months follow-up in CRT-
responders and nonresponders, defined by echocardiography as well as patient-reported 
health status, and (2) to additionally explore the contribution of socio-demographic, clinical 
and lifestyle factors to the association between BNP or inflammatory markers and the 
response to CRT therapy. 
 
METHODS 
Study design and participants 
The sample comprised HF patients receiving a first-time CRT implantation according to the 
guidelines (NYHA functional class ≥ II despite optimal pharmacological therapy, LV ejection 
fraction (LVEF) ≤35%, QRS≥120ms) between January 2009 and August 2011 at the University 
Medical Center Utrecht, the Netherlands. All patients received a CRT device with defibrillator 
function (CRT-D). Patients participated in the ‘The influence of PSYchological factors on 
health outcomes in HEART failure patients treated with Cardiac Resynchronisation Therapy: 
A prospective, single-center, observational study’ (PSYHEART-CRT). PSYHEART-CRT was 
primarily designed to examine whether psychological factors moderate the effect of the 
objectively assessed response to CRT implantation patient-reported outcomes in patients 
with HF. Patients were not eligible for inclusion when aged <18 or >85 years; having 
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according to Simpson’s biplane method. Echocardiographic response to CRT was defined by 
a ≥15% relative reduction in LVESV, indicating reverse remodeling. This cut-off of 15% was 
based on previously performed studies,31-32 and has shown to be a good predictor of long-
term survival after CRT implantation.33-34 
 
Subjective CRT-response according to disease-specific health status 
The Kansas City Cardiomyopathy Questionnaire (KCCQ) was used to assess HF-specific health 
status.35 The KCCQ is a 23-item, self-report questionnaire that quantifies physical limitation, 
symptoms, social function, and quality of life of patients with HF. These four health status 
subscales can be combined into a single overall summary score. Scores are transformed into 
a score from 0 to 100, with higher scores representing better health status. The validity and 
reliability of the KCCQ have previously been established and the measure was shown to be 
highly sensitive to clinical change in HF patients over a 6-12 week period.35-37 In the current 
study, the absolute difference between baseline and 6-month KCCQ overall summary scores 
was calculated and dichotomized, with an improvement of ≥10 points indicating a ‘health 
status response’. An improvement of ≥10 points represents a moderately large difference in 
patient health status.37  A previous study in CRT patients using the same cut-off showed that 
health status responders had a 76% lower subsequent risk of dying of any cause in the first 
18 months after implantation.38 Poor health status was defined as a KCCQ score <50 points. 
 
BNP and inflammatory markers   
Levels of BNP and CRP were obtained using a standard hospital protocol. BNP was analyzed 
on a DxI 800 (Beckman Coulter) using a two-step chemiluminescence (sandwich) assay (Alere, 
San Diego, United States of America), and CRP was analyzed using a Nefelometer (BN 
Prospec).  Interleukin (IL)-6, tumor necrosis factor (TNF-α), and soluble TNF receptors 1 and 
2 (sTNFr1 & sTNFr2) were assessed in serum. Venous blood samples were allowed to clot at 
room temperature for at least 20 minutes and centrifuged at 4oC. Aliquots of serum were 
stored at -80°C until batchwise analysis of cytokine levels. Concentrations of IL-6 (sensitivity: 
0.156-10 pg/ml), TNFα (sensitivity: 0.5-32 pg/ml) and soluble tumor necrosis factor receptors 
(sTNFR1 and sTNFR2; sensitivity for both: 7.8-500 pg/ml) were measured using a 
quantitative enzyme-linked immunosorbent assay (R&D Systems, Abingdon, United 




The sensitivity of all tests was calculated as the mean of six zero-values plus three SDs 
extrapolated on the standard curve. The intra-assay variation was less than 10%, and the 
inter-assay variation was less than 10.5%. TNF-α levels were below the level of detection in 
67 (22.9%) samples; IL-6 levels were below the level of detection in 4 (1.4%) samples. These 
values were imputed using the lower detection limit/2.39  
 
Statistical analyses 
To compare the demographic and clinical characteristics between CRT-responders and 
nonresponders, t tests, Mann-Whitney U tests, or χ2-tests were used depending on the 
measure and variable distribution. Prior to analyses, BNP, CRP and the inflammatory markers 
were tested for normality, after which they were transformed using log10 to obtain normal 
distributions. Time-course analyses of the biomarkers of the responders and nonresponders 
over time were done using analysis for repeated measurements on the log transformed data. 
The medians and interquartile ranges or the non-transformed levels of BNP, CRP and the 
inflammatory markers over time are given.  
For the multivariable analyses we used the linear mixed model procedure (covariance 
model: unstructured, maximum likelihood (ML) estimate) in SPSS version 17.0. Separate 
analyses were run for BNP, CRP, IL-6, TNFα, sTNFr1 and sTNFr2 that were measured at 
baseline, 2 months and 14 months. Data from all available time points was used, thereby 
limiting bias and preserving statistical power. BNP and markers of inflammation were 
examined by CRT-response and covariates in five consecutive models. The first model 
(Model 1) is the base model in which CRT-response was entered together with age, gender 
and time. In the second model (Model 2: Disease severity), the first model was 
complemented by markers of disease severity; NYHA functional class, etiology, LVEF and QRS. 
In the third model (Model 3: Medication), medication use which could have affected the 
inflammatory makers  (ACE/ARB’s, amiodarone, statins and aspirin) were added to the first 
model. In the fourth model (Model 4: Co-morbidity), the co-morbidities COPD, renal failure 
and diabetes were added, and in the fifth model (Model 5: Lifestyle) the lifestyle variables 
and socio-economic variables BMI, smoking en educational level were added to the model. 
The choice of covariates was based on theoretical evidence of possible confounders of 
inflammation. CRT-response (at 6 months) and other covariates were entered into the 









(variance of) the averaged level of BNP and inflammatory markers over time. Furthermore, 
in a secondary analysis the interaction term time*CRT-response was also entered into the 
model. The interaction term was constructed to examine whether the level of inflammatory 
markers differed over time between CRT-responders and CRT-nonresponders. The results of 
this analysis is merely outlined in the results and not included in Table 3. 
The results of multivariable analysis of the association between BNP, inflammatory 
markers and CRT-response are indicated by symbols ranging from p<.10 (weak association), 
to p<.05 (significant association) and p<.01 (strongly significant association). 
No post-hoc corrections were made for multiple comparisons due to the high 
probability of finding small effect sizes, the moderate to high correlation between the 




Of 105 patients included in the PSYHEART-CRT study blood was drawn at baseline, 2 months 
and 14 months follow-up. The mean age of the study sample was 65.4±10.1 years and 71 
(68%) patients were male. The underlying HF etiology was ischemic in 51 (48.6%) patients 
and 84 (80.0%) patients were in NYHA functional class III/IV (with only 2 patients being in 
NYHA functional class IV). The pre-implantation electrocardiogram showed a sinus rhythm in 
81 (77.6%) patients and a LBBB in 58 patients (55.0%), the mean QRS duration was 
160.7±25.5ms. Medication included ACE-inhibitors/angiotensin receptor blocker (92.4%), 
betablockers (78.1%), diuretics (87.6 %) and statins (59.0%). The patient sample had severely 
depressed LV function with a mean LVEF of 24.5±8.2%, mean LVESV of 171.0±68.6 mL and 
mean LVEDV of 225.4±75.9 mL. A transvenous LV lead placement via the coronary sinus was 
successfully performed in all but one patient. In this patient, who was a subjective and 
objective CRT-responder, an epicardial LV lead placement via video assisted thoracoscopy 
was required. In the majority of patients the LV lead position was posterolateral (85%).  
During the 14 months follow-up, 14 (13.3%) of the patients had a major adverse cardiac 
event including hospitalization for HF, implantation of a left ventricular assist device, CRT-
explantation or death. This percentage is  in accordance with randomized controlled trials on 
the effect of CRT-D on prognosis.40-41 The mean baseline KCCQ score was 56.2±22.9, with 37 




Complete information on the demographic and clinical characteristics of the patients, 
stratified by CRT (LVESV and KCCQ) response, is shown in Table 1.  
 
Based on a relative reduction in LVESV of ≥15% from baseline to 6 months follow-up, 47 
patients were labeled as objective CRT-responder and 42 as CRT-nonresponder. Information 
on the LVESV change was missing for 17 patients, and these patients were not included in 
the analyses regarding objective CRT-response. Objective responders and nonresponders did 
not differ on demographic and clinical variables (p≥.05, Table 1). Based on an improvement 
of ≥10 points on the KCCQ, 58 patients were labeled as subjective CRT-responder and 47 as 
CRT-nonresponder. Subjective responders and nonresponders did not differ on demographic 
and clinical variables, except for a difference in pre-implantation QRS duration (165.7±25.4 
in responders vs. 154.3±24.4 in nonresponders, p=.03 respectively, Table 1).  Of note, there 
was a large discrepancy between objective and subjective CRT-response, with half of the 
patients showing discordant responses (kappa=-.021, p=.83).  
 
CRT-response and inflammatory markers 
Baseline concentrations of BNP and inflammatory markers did not differ between the 
objective CRT-responders and nonresponders (p>.05,Table 2a). BNP levels decreased 
significantly from baseline to 2 months and from baseline to 14 months for the objective 
responders (p<.001), while there was only a marginal decrease in BNP levels from baseline to 
2 months (p=.05) and no difference from baseline to 14 months (p>.05) follow-up for the 
nonresponders. Both objective CRT-responders and nonresponders showed a significant 
decrease in TNFα levels from baseline to 14 months follow-up (p<.001). The levels of CRP, IL-
6, TNFr1 and TNFr2 did not change significantly over time in both groups (Table 2a). 
The subjective CRT-responders had significantly lower baseline TNFα levels compared 
to nonresponders (p=.05, Table 2b). In addition, subjective responders showed a significant 
decrease in BNP (p<.001), TNFα (p<.001) and sTNFr1 (p=.05) levels from baseline to 14 
months follow-up. In the subjective nonresponders, there was a (marginal) significant 
decrease in BNP and TNFα levels over time (p=.06 and p<.001, respectively), but an increase 
























































































































































































































































































































































































   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   




















































































































































































































































































































































































































































   
   
   
   
   
   
   























































































































































































































































































































































































































































































































Using mixed multivariable modeling, the averaged level of BNP and inflammatory markers 
over time was examined for CRT-responders versus nonresponders (Table 3). Being an 
objective CRT-responder was significantly associated with significantly lower BNP levels over 
time after correction for age, sex and time (F=27.31, p<.001), but also after adjustment for 
disease severity (F=18.15, p<.001), medication (F=20.68, p=<.001), co-morbidity (F=19.20, 
p<.001) and lifestyle and socio-economic variables (F=7.30, p=.009). Objective CRT-response 
was not significantly associated with the overall levels of CRP, IL-6, TNFα, sTNFR1 or sTNFR2 
after adjustment for age, sex and time (all ps>.05). Adjustment for disease severity, 
medication, co-morbidity and lifestyle confounders did not alter these findings.   
KCCQ subjective CRT-response showed a significant association with lower levels of 
TNFα over time after correction for age, gender and time (F=5.67, p=.019) (Table 3). These 
findings remained after adjustment for disease severity (F=4.54, p=.036), medication (F=5.20, 
p=.021), co-morbidity (F=7.56, p=.007) and lifestyle variables (F=6.28, p=.014).  As in 22.9% 
of the cases TNFα levels were below the detection limit and substituted by the lower 
detection limit divided by 2, we performed a sensitivity analysis in which these cases were 
excluded to see if this would change our results. The association between the subjective 
CRT-response and TNFα remained significant for all the models after the exclusion of 
patients having TNFα below the detection limit. There was no association between 
subjective CRT-response and BNP, CRP, IL-6, sTNFr1 and sTNFr2, except for a marginal 
significant higher level of BNP after correction for lifestyle covariates (F=3.01, p=.086) for 
responders compared to nonresponders.  
 In secondary analyses, the interaction term time*CRT-response was added to the 
model, to see whether changes in BNP and inflammatory markers over time differed 
between responders and nonresponders. There was only a significant interaction effect for 
BNP, sTNFr1 and sTNFr2 levels over time in relation to subjective CRT-response (FBNP=3.59, 
p=.03; FsTNFr1=3.43, p=.04; FsTNFr2=3.80, p=.03), whereby the level of BNP, sTNR1 and sTNFr2 
slightly decreased for responders and increased for nonresponders leading to an intersection 
between 2 and 14 months follow-up (results not shown). The significant main effect between 
BNP levels over time and objective responders and nonresponders did not change after 
adding the interaction effect, nor did the significant main effect change between TNFα levels 
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The contribution of socio-demographic, clinical and lifestyle factors to the association 
between BNP or inflammatory markers and the response to CRT therapy is shown in 
Supplementary Tables 1a and b. The covariates in the first model included 
objective/subjective CRT-response, age, gender and time. Older age was significantly 
associated with higher BNP, IL-6, sTNR1 and sTNFr2 levels (p<.05). In relation to the potential 
clinical confounders, patients with NYHA class III/IV showed significantly higher levels of BNP, 
CRP, IL-6, TNFα and sTNFr1 over time (p<.10). A lower LVEF and ischemic etiology were 
associated with a higher level of BNP (p<.05), while a shorter QRS duration at baseline was 
associated with higher CRP and TNFα levels (p<.10). The levels of sTNFr2 were significantly 
higher for CRT patients who used ACE/ARBs (p<.05), but lower for patients using aspirin 
(p<.05). The model adding co-morbidity showed that patients with co-morbid COPD had 
significantly higher levels of IL-6 and TNFα (p<.05). Patients with diabetes had higher levels 
of sTNFr1 and 2, whereas renal failure was significantly associated with higher levels of all 
inflammatory markers (all ps<.10). The lifestyle confounders BMI and smoking were 
associated with higher levels of IL-6 (p<.05), and a higher educational level was associated 
with an overall reduction in inflammatory markers over time (all ps<.10). 
 
DISCUSSION 
The aim of this study was to investigate the levels of BNP and markers of inflammation in 
relation to CRT-response, defined by a significant improvement on an echocardiographic 
(objective) or a patient-reported health status (subjective) indicator. Several hypotheses 
could explain the relation between inflammatory markers and the response to CRT. An 
increase on the load of the heart chambers, myocardial injury and underperfusion of 
peripheral tissues is found to increase the secretion of cytokines from mononuclear cells and 
the myocardium.  As CRT helps to reduce the load on the heart failure chambers and restore 
left ventricular systolic function by correcting the electro-mechanical dyssynchrony, this 
could result in a decrease in BNP and pro-inflammatory cytokine  levels.5    
  In the current sample, 53% of the patients were objective CRT-responders and 55% 
were subjective CRT-responders, which is in line with previous studies using various 
response criteria.18 Multivariable mixed modeling showed that objective CRT-responders 
had significantly lower overall levels of BNP over time compared to LVESV nonresponders 




The relation was attenuated after correction for lifestyle and socio-economic variables. No 
differences were found between objective CRT-responders versus nonresponders in CRP, IL6, 
TNFα, sTNFr1 and sTNFr1 levels over time. Subjective CRT-responders showed significantly 
lower levels of TNFα over time compared to nonresponders, also after adjusting for socio-
demographic and clinical variables, medication, co-morbidity, and lifestyle variables. The 
average levels of BNP and the other inflammatory markers did not differ over time between 
subjective CRT- responders and nonresponders. However, there was a significant interaction 
effect for BNP, sTNFr1 and sTNFr2 levels over time in relation to subjective CRT-response, 
with levels slightly decreasing for responders and increasing for nonresponders.  
There are several studies describing levels of BNP and inflammatory markers after 
CRT implantation, but only few of these studies examined the association with CRT-response 
and most focused only on BNP.9,19,21-24,29,42 Studies which did differentiate between CRT-
responders and nonresponders reported mixed results, and examined (objective) 
echocardiographic CRT-response only. Most of these studies reported that the reduction in 
BNP was significantly larger or limited to responders over time,9,19,21-24,27-28 whereas two 
studies reported no difference in the reduction in BNP over time after CRT implantation 
between responders and nonresponders.25,29  
 Only Osmancik et al. examined the association between CRT-response, based on a 
combination of echocardiographic and clinical criteria, and TNFα levels. Results showed no 
significant differences between responders and nonresponders on baseline TNFα and a 
significant decrease in TNFα levels in responders only.26 In our study, we showed an overall 
lower level of TNFα in subjective CRT-responders versus nonresponders during the 14-
month follow-up period. Besides BNP and TNFα, the current study found no evidence for an 
association between CRT-response and CRP, IL-6, sTNFr1 and sTNFr2 levels over time. These 
findings for CRP were similar to those found by Pryzbyla et al.,15 but in contrast to two other 
studies that did find a significant reduction in CRP for CRT-responders only.27-28 Likewise, 
only two out of the five studies on IL-62, 10,15,26-27  found a significant reduction in IL-6 levels 
after CRT implantation in CRT-responders only.26-27 Interestingly, the levels of IL-6 in the 
current sample were considerably lower compared to the other studies, indicating possible 
differences in patient characteristics (i.e., higher age, higher percentage NYHA III-IV in other 









The findings on the association between BNP and inflammatory markers and the 
socio-demographic, disease severity, medication, co-morbidity and lifestyle covariates were 
consistent with literature. Age, NYHA functional class, COPD, renal failure, diabetes, BMI, 
low educational level and smoking, were associated with higher levels of BNP or 
inflammatory markers, while aspirin use was associated with lower averaged inflammatory 
markers. The interaction effect of time by CRT-response differed between the inflammatory 
markers. 
Overall, there was a large discrepancy in the association between BNP, TNFα and 
CRT-response based on the type of response measurement (objective vs. subjective). This 
could be explained by the poor agreement between CRT-response indicators,18 as was 
confirmed in the current study with half of the patients showing discordant responses. 
 A number of limitations of this study should be acknowledged. First, although the 
present study included a larger group of patients compared to the majority of previous 
research in relation to this topic, the sample size of the current study was relatively small. 
Therefore, we had to combine patients with stable and deteriorated LVESV or health status 
as nonresponders. Large scale studies are needed to confirm our results. Furthermore, there 
are many confounders that could exert some effects in a complex field such as heart failure 
that could not all be taken into account in this observational study. Information on the 
presence of an acute infection at follow-up was missing, yet such infections could have 
influenced the values of the inflammatory markers. The percentage of women in this study 
was relatively low, which affects the generalizability of the results to women with HF. About 
20% of the study patients were not included in the analyses due to missed follow-up visits or 
missing values in the inflammatory markers, but they did not differ systematically on 
baseline characteristics nor CRT-response versus nonresponse.  
 
CONCLUSION 
Objective echocardiographic CRT -response was associated with lower BNP levels in the first 
14 months after implantation, while subjective patient-reported health status CRT-response 
was associated with lower TNFα over time. However, the differences were small and there 
were no associations between CRT-response and other inflammatory markers. Hence, based 
on our and previous results, it does not seem feasible to formulate any conclusions 




Large-scale studies are warranted to confirm our results and to further examine whether 
inflammatory markers have a role to play as an indicator of CRT-response. 
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Supplementary Table 1a; mixed multivariable modeling - significant covariates 
LVES response 
LVESV response BNP CRP IL-6 TNFα sTNFr1 sTNFr2
Model 1 Older age +++ O ++ O +++ +++
Male gender O O O O O O
Time 2 vs. time 1













Model 2 NYHA class III/IV +++ O + O O O
EF -- O O O O O
Ischemic etiology ++ O O O O O
QRS O -- O - O O
Model 3 ACE/ARB O O O O O ++
Amiodarone O O O O O O
Statins - O O O O O
Aspirin O O O O O O
Model 4 COPD O O + +++ O O
Renal failure O O O + +++ +++
Diabetes O O O O +++ +
Model 5 BMI - O +++ O O O
Smoking O O +++ O ++ O
Educational level -- -- O O -- ---
O= no association, p >.10 
− = negative association, p <.10; −− = nega�ve associa�on, p <.05;  −−− = nega�ve associa�on, p<.01
+ = positive association, p <.10; ++ = positive association, p < .05; +++ = positive association. P < .01
ACE=angiotensin converting enzyme inhibitor; ARB=angiotensin receptor blocker; COPD= chronic  








BNP CRP      IL-6 TNFα sTNFr1 sTNFr2 
       
Model 1 Older age +++ O ++ O +++ +++ 
Male gender O O O O 
 
O O 
 Time 2 vs. time 1 




















Model 2 NYHA III/IV +++ + +++ + ++ O 
 EF -- O O O O O 
 Ischemic etiology +++ O O O O O 
 QRS O -- O O O O 
Model 3 ACE/ARB O O O O O ++ 
 Amiodarone O O + O O O 
 Statins -- O O O O O 
 Aspirin O O - O - -- 
Model 4 COPD O O + ++ O O 
 Renal failure + ++ + +++ +++ +++ 
 Diabetes O O O O +++ + 
Model 5 BMI O O +++ O O O 
 Smoking O - ++ O O O 
 Educational level -- - O -- --- --- 
O= no association, p >.10  
− = negative association, p <.10; −− = nega�ve associa�on, p <.05;  −−− = nega�ve associa�on, p<.01 
+ = positive association, p <.10; ++ = positive association, p < .05; +++ = positive association. P < .01 
ACE=angiotensin converting enzyme inhibitor; ARB=angiotensin receptor blocker; COPD= chronic 




























Summary and General Discussion
 
 
SUMMARY OF THE RESULTS 
Several treatment options are available for patients with heart failure in order to improve 
their physical functioning and increase survival. These include the implantable cardioverter 
defibrillator (ICD), the biventricular pacemaker (CRT), the ICD combined with CRT (CRT-D), 
and the left ventricular assist device (LVAD), which are state-of-the-art cardiovascular 
implantable electronic devices. This dissertation focused on the influence of these innovative 
technologies on survival and patient well-being. Findings from studies on several heart 
failure samples from the Netherlands and Denmark were presented. In the current chapter, 
these findings are summarized, discussed and their implications for clinical practice and 
future research are outlined. 
 
Health status and psychological distress in patients with heart failure 
The first aim of this dissertation was to examine the health status and level of psychological 
distress in patients who are genetically predisposed to heart failure or implanted with an 
LVAD due to end-stage heart failure. Before conducting the study on LVAD patients, current 
knowledge on health status and psychological distress in LVAD patients was summarized in a 
systematic review, as presented in Chapter 2. The results from this review indicate that 
LVAD patients experience an improvement in health status over time, independent of device 
type and setting. However, while their physical disability becomes less prominent post 
implantation, many patients experience difficulties with psychological adjustment. Extensive 
information on patient-reported outcomes in LVAD patients is limited, with many of the 
existing studies having methodological shortcomings. Therefore, in order to advance the 
field of LVAD research and to optimize the care of LVAD patients, more well designed large-
scale studies are needed to further elucidate the impact of LVAD therapy on patient-
reported outcomes.  
Chapters 3 and 4 reported on the results of a prospective multi-center LVAD study 
that examined the impact of LVAD implantation on Dutch and Canadian heart failure 
patients and their partners. The findings of the study indicate that the majority of LVAD 
patients experience a clinically relevant improvement in health status between LVAD 
implantation and 12 months follow-up. However, there were large differences in individual 
health status score trajectories, which are only partially explained by measures of disease 




patients and their partners experienced significant levels of psychological distress after LVAD 
implantation which slowly abated over time. Partners of LVAD patients may fare worse than 
LVAD patients with respect to psychological distress. At baseline, partners were more likely 
to be anxious than patients, and there was a trend towards a higher prevalence of 
depression in partners.          
 Chapter 5 examined the differential burden related to having a genetic condition 
versus experiencing cardiac symptoms in patients with non-compaction cardiomyopathy. 
The health status and psychological distress of patients with non-compaction 
cardiomyopathy was compared with age- and gender-matched controls with acquired 
dilated cardiomyopathy and familial hypercholesterolemia. The results showed that cardiac 
symptoms are mainly responsible for the observed poor health status and elevated anxiety 
and depression in patients with non-compaction cardiomyopathy rather than the genetic 
nature of the disease. This was also found in previous studies on patients with long QT 
syndrome and hypertrophic cardiomyopathy,1-3 and indicates that the majority of patients 
with a genetic cardiovascular condition are able to cope with their diagnosis and may not 
need additional psychological care support compared to patients with a non-genetic 
cardiovascular condition. 
 
Psychological distress and clinical outcomes of heart failure 
Current evidence suggests that psychological distress in heart failure patients may influence 
the progression of disease and patients’ survival. The second aim of this dissertation was to 
examine the existing literature on the relation between psychological distress and adverse 
clinical outcomes, and to elaborate on possible mechanisms which could be responsible for 
this association. Chapter 6 reports on the results of the use of anti-depressants and its 
relation with mortality in a large sample of heart failure patients extracted from the Danish 
National Patient Registry. Results of this study showed that use of anti-depressants after 
hospital discharge was significantly associated with a higher all-cause mortality risk, 
irrespective of a diagnosis of clinical depression and also after correction for socio-
demographic and clinical risk factors. In Chapter 7 evidence was found for a relation 
between psychological distress and an increased risk of ventricular tachyarrhythmia’s and 
mortality in patients implanted with an ICD, independent of traditional risk factors. However, 









whether they exert indirect effects via various physiological and behavioral pathways such as 
a decrease in heart rate variability, inflammation, HPA axis dysfunction, low physical 
inactivity, smoking and poor medication adherence.  
 
Health status and psychological distress - the link with inflammation and cardiac hormones 
The third aim of this dissertation was to examine the role of cardiac hormones and 
inflammation as potential mechanisms between psychological distress and heart failure 
prognosis. In Chapter 8 no relationship was found between psychological distress (i.e. 
anxiety, depression and Type D personality) and NT-proBNP levels in a sample of systolic 
heart failure patients using a prospective study design. These results suggest that 
psychological distress is not confounded by disease severity markers and is therefore an 
independent risk marker for heart failure prognosis. Other evidence from the literature on 
the relation between psychological distress and BNP/NT-proBNP is mixed which could be 
due to large differences in the sample size across studies, the severity of distress and the 
large intra-individual differences in levels of BNP and NT-proBNP.  
Chapter 9 reported on the results of a study that examined the relative importance 
of inflammation, disease severity and psychological vulnerability as the underlying etiological 
factors of depression in heart failure patients. Personality factors (i.e. Type D personality and 
loneliness) predicted depressive symptoms beyond inflammation and disease severity 
markers, even after correcting for potential socio-demographic confounders. Hence, it 
seems that inflammation is not the underlying cause of depressive symptoms or perhaps 
only in a small subset of patients suffering from a heightened systemic inflammatory state. 
These results suggest the need for more research on the differences in etiology of 
depression in heart failure patients and the exploration of a broader range of psychological 
and lifestyle variables. 
Apart from the detrimental effects of psychological distress, Chapter 10 focused on 
positive affect, which is increasingly recognized for its beneficial effect on prognosis in 
cardiac patients through its involvement in neuroendocrine, autonomic, immune and 
inflammatory pathways. The results suggest that positive affect is associated with reduced 
inflammation in patients with heart failure, also after correction for socio-demographic, 




positive affect and inflammation did depend on the type of positive affect measure that was 
used.  
Chapter 11 examined the relation between inflammation and the objective and 
subjective response to CRT implantation, as measured by echocardiography and health 
status, respectively. Results showed that the objective echocardiographic CRT-response was 
only associated with lower BNP levels, while subjective patient-reported health status CRT-
response was associated with lower TNFα in the first 14 months after implantation. This 
indicates that response to CRT is not automatically related to an overall decrease in 
inflammation, and the role of inflammatory markers as an indicator of CRT-response 
therefore remains uncertain. 
 
METHODOLOGICAL AND CLINICAL CONSIDERATIONS 
Study design 
Except for the two systematic reviews (Chapter 2 and 7), all studies included in this 
dissertation were based on cross-sectional (Chapter 4), longitudinal (Chapter 6) or 
prospective observational data (Chapter 3, 4, 8, 10 and 11). An important limitation 
inextricably linked to observational research is the limited potential for drawing causal 
inferences. Although prospective studies may give more insight into certain relations over 
time, they still do not provide conclusive results on causality. However, as research on the 
psychological impact of genetically predisposed heart failure and LVAD therapy is still in its 
infancy, it is appropriate first to further elucidate this topic using data from observational 
studies. The prospective studies with long-term follow-ups (i.e. 12-14 months) reported on 
in this dissertation provide the possibility to examine changes in clinical and psychological 
factors over time. The findings of these studies may set the stage for future research in the 
field of heart failure, and also point to important targets for intervention and the 
optimization of the quality of patient care in clinical practice.   
 
Heart failure samples 
This dissertation reports on different samples of heart failure patients which differ in terms 
of site of recruitment, type of treatment (i.e. CRT-D vs. LVAD), underlying etiology, disease 
severity and age. Due to the low prevalence of non-compaction cardiomyopathy, the low 









complications in LVAD patients, the sample sizes reported on in Chapters 3, 4 and 5 are 
relatively small. This might have impinged on the results, as we were not able to stratify the 
samples by age, type of device or site. As the clinical and psychological care of LVAD patients 
might slightly differ between the sites this could have lead to an unknown bias in the 
prevalence of psychological distress.        
 The limitations in Chapters 8, 9 and 10 included the relatively young age of the 
patients and the fact that most patients were NYHA class I-II, thereby possibly affecting the 
association with inflammatory markers. Overall, there was a low prevalence of female 
participants in the heart failure samples included in this dissertation, therefore caution has 
to be taken in generalizing these results to female patients. Furthermore, patients and 
partners who refused to participate in the study might have suffered from more 
psychological distress, with the possibility that the prevalence of psychological distress in 
this dissertation could be an underestimation of the actual situation. 
 
Measurements and statistical analyses 
Throughout this dissertation multiple constructs were used to measure psychological 
distress. Except for Chapter 6, which used a clinical diagnosis of depression, all other studies 
used self-report questionnaires. Although even minimal symptoms of distress have been 
related to prognosis in cardiac populations4 and the instruments we used have been 
validated in cardiac samples, their sensitivity and specificity are still lower compared to a 
clinical diagnosis of psychological disorders.5, 6 Also, the items in these instruments do not 
tap into the subtypes of psychological disorders and do not inquire about the duration of 
symptoms. In addition, the different instruments used for measuring depression and positive 
affect assess slightly different aspects of the same constructs (Chapter 8 and 10). 
 The clinical data gathered for all studies were not self-reported but extracted from 
the patients’ medical records. Although medical records a more reliable than self-reported 
clinical data, researchers are still dependent on the quality of the diagnostics and 
registration inherent to the systems used in the hospitals. Using the medical records, 
extensive information could be gathered on the anamneses and etiology of the patients’ 
heart failure, echocardiography, electrocardiogram, blood tests, complications, 
hospitalizations and medication. The cytokine measurements, which were used for the 




an high quality assays. However, due to missing blood samples or detection limits, missing a 
small percentage of cytokine data was inevitable. The missing cytokine data were imputed, 
thereby taking into account the detection range of the assays (Chapters 9, 10 and 11).  
In the present dissertation, a variety of statistical analyses was used, including 
survival analysis, logistic and linear regression, mixed linear modeling, multilevel analysis and 
univariate and multivariate analysis of covariance, to examine predictors of binary and 
continuous outcomes or time-to-event data. Based on current theoretical evidence, we 
adjusted the analyses for potential clinical, psycho-social and socio-demographic 
confounders. However, there is always residual confounding caused by the fact that 
information on potential confounders were lacking or poorly assessed. Furthermore, except 
for Chapter 6, the sample size in some of the studies did not allow for the addition of many 
predictors in order to prevent overfitting of the models, which may yield overly optimistic 
results.7 To avoid or minimize overfitting the optimal statistical strategy for each study was 
carefully considered. By using mixed linear modeling and multilevel analyses all available 
time points were used for each patient thereby limiting bias and preserving statistical power 
(Chapters 3, 4, 10, 11). Furthermore, if possible the number of predictor variables in the 
models was reduced by combining predictors (i.e. Charlson Comorbidity Index) into a single 
composite measure (Chapters 3, 4 and 5). While this approach preserves degrees of 
freedom in the model, this comes at a trade-off, as specific information about the individual 
components of the composite measure is lost.7 Hence, while it appears our studies did not 
violate any guidelines regarding overfitting, caution was maintained in formulating any 
strong conclusions where appropriate.8 
 
PRACTICAL AND CLINICAL IMPLICATIONS 
Use of patient-reported outcomes to improve patient care 
During the last few years, there has been growing interest in the patient perspective by 
policy makers, physicians and other health care professionals. The American Institute of 
Medicine, American College of Cardiology and the European Society of Cardiology have 
stipulated that future medical treatment should fulfill the key aspects of being safe, effective, 
timely, equitable, efficient and patient-centered.9 The patient perspective should guide 
clinical trials and patient care in order to provide the most optimal health care system of the 









asking patients to rate their own health, can aid with the identification of high risk patients 
and clinical decision making, but also in optimizing clinician-patient communication and 
removing barriers to patient self-management. Information on the patient perspective 
provides the opportunity to take into account patients’ needs, preferences and psychological 
make-up in addition to their clinical profile and may provide evidence-based information for 
patients who want to make informed treatment options.10     
In this dissertation, we evaluated the patient perspective by means of standardized 
and validated questionnaires that tap into psychological distress and health status. Findings 
from the current dissertation (Chapter 3, 4) and previous research (Chapter 2) indicate that 
the prevalence of anxiety, depression and PTSD in LVAD patients and their partners shortly 
after LVAD implantation is between 23-48%.11, 12 A small number of LVAD patients seem to 
suffer from chronic levels of distress, and these patients seem to have more difficulty 
adjusting to life post LVAD implantation and are at high risk of poor self-care behavior. 
Patients implanted with a LVAD experience an increase in health status scores post 
implantation, which is consistent with those found in other large scale trials,13-17 indicating 
that the consequences of LVAD therapy are similar across sites and countries. However, our 
findings also showed that LVAD patients still have decreased health status compared to the 
Dutch normative population and patients who have undergone heart transplantation.18-20 
Hence, although LVADs may solve the problem of donor scarcity, it is important not to lose 
sight of the impact of treatment on patients and thus continue to seek ways that may help 
improve their well-being and quality of life.    
Although Chapters 2-5 do not examine the relation between psychological distress 
and cardiovascular outcomes, Chapters 6 and 7 and previous literature show that poor 
health status and psychological distress are independent risk factors for mortality and 
hospital readmissions in various cardiac populations.21 This relation can partially be 
explained by behavioral factors such as lack of adoption of secondary prevention behaviors 
(i.e. smoking cessation, physical activity) and an increase in inflammation. As shown in 
Chapters 10 and 11, this effect on inflammation can be counteracted by an increase in 
health status and positive affect.         
 Overall, the high prevalence of psychological distress in heart failure patients should 
gain more awareness in order to prevent adverse outcomes. As psychological guidance or 




anti-depressants when presenting with psychological distress.22 However, Chapter 7 shows 
that caution should be used when prescribing anti-depressants, as they do not guarantee a 
reduction in cardiovascular events and might even increase the risk for heart failure 
mortality through unknown pharmacological, physiological or behavioral mechanisms,23, 24 
depending on the type of anti-depressant and duration of use.  
 
Challenges of using patient-reported outcomes in clinical practice 
Despite their clear benefits, the use of patient-reported outcomes is also associated with 
considerable challenges.25 Hence, when choosing a measure to assess patient-reported 
outcomes, it is important to make a well informed decision. With respect to health status, 
generic measures, such as the Short-Form Health Survey (SF-12 or SF-36), are suitable for all 
populations and can therefore be used to compare heart failure patients with a normative 
population or patients with other conditions.26 However, as these measures may not be 
sufficiently sensitive to tap into treatment-related changes the use of disease-specific 
measures is often preferred.27 The Minnesota Living with Heart Failure Questionnaire 
(MLHFQ)28, 29 and the Kansas City Cardiomyopathy Questionnaire (KCCQ)30 (Chapters 2, 4, 11) 
have been developed for use in heart failure patients and include questions on functional 
limitations and symptoms specific to heart failure. Both measures are subject to copyright 
but are easy to administer and have proven to be psychometrically sound and predict heart 
failure prognosis.31,32 It is important to consider that for LVAD patients the MLHFQ and KCCQ 
may still be too time-, or energy-consuming just before or after LVAD implantation. 
Furthermore, a recent study found that baseline KCCQ levels were not predictive of survival 
after LVAD implantation.33 It is possible that change in health status over time rather than 
pre-implantation health status is a more valuable predictor of clinical outcome, as we 
examined in Chapter 4.  
With respect to the assessment of psychological distress, such as anxiety and 
depression, a large number of scales are available, but they cannot necessarily be used 
interchangeably due to differences in prevalence rates.6,34 Besides the Hospital Anxiety and 
Depression Scale, Beck Depression Inventory and the Center for Epidemiological Studies 
Depression Scale, the more recent Patient Health Questionnaire (PHQ-9) and Generalized 
Anxiety Disorder (GAD-7) (Chapter 5) are considered reliable measures that are free of 









has been an increased interest in the assessment of positive emotions, such as positive 
affect, optimism, and self-esteem (Chapter 10). Given that positive and negative affect are 
not merely the opposite of a continuum,38, 39 and that both types of affect can be present 
simultaneously, their assessment might contribute to a fuller understanding of the 
contribution of psychological factors in heart failure patients.    
 In addition to the choice of measure used, there are important challenges associated 
with the analysis and interpretation of scores. First, in order to evaluate the efficacy of a 
treatment, as in Chapters 4 and 11, it is important to know which change in scores 
represents a clinically significant change (e.g. 5 points on the KCCQ).31 Second, for most 
measures of psychological distress a continuous and dichotomous score can be calculated, 
the latter being based on a cut-off score with the highest sensitivity and specificity for 
detecting the psychological disorder. Using a dichotomous score may enhance the clinical 
interpretability while creating a potential loss of important information. Third, instead of 
analyzing only between-person differences in scores over time there should be an increased 
focus on within-person differences in scores over time and the predictors of these changes. 
Such information may help to identify patients at high-risk for a difficult post-treatment 
course and adverse health outcomes (Chapter 4). 
In addition to the choice of measure and the analytical strategies used, there are 
important practical, methodological and attitudinal barriers for implementing measures on 
health status and psychological distress in clinical practice. Lack of financial and human 
resources and especially the perceived relevance by health care providers are preventing the 
large scale use of these measures in heart failure care.40,41 Future studies in heart failure 
patients are therefore warranted to make the measures more actionable, efficient and user-
friendly, but also more easy to interpret.25  
 
Patient-reported outcomes, heart failure and health outcomes: How are they tied together? 
Several mechanisms have been proposed that may explain the association between 
psychological distress and adverse health outcomes, such as hypothalamic-pituitary-adrenal 
(HPA) axis dysfunction, autonomic nervous system imbalance, platelet activation, adverse 
health behaviors and inflammation.42-45 Chapters 9-11 of this dissertation focused on the 
association between patient well-being and inflammation in different samples of heart 




psychological distress and inflammation is considered to be bidirectional,46 with 
inflammation preceding distress while distress may also precede inflammation. Various 
hypotheses have been formulated which suggest that pro-inflammatory cytokines are able 
to induce depression through HPA-axis hyperactivity and serotonin shortage.47-51 However, 
studies examining these hypotheses found mixed results.52-58 Chapter 9 of this dissertation 
adds to this body of evidence, as we found no association between inflammation and 
depressive symptoms in patients with heart failure.     
Alternatively, evidence suggests that the immune system can respond to 
psychological distress in an immunopathological manner which results in chronic 
inflammation. The results presented in Chapters 10 and 11 showed that this effect on 
inflammation may be reversed by the presence or increase in patient well-being, suggesting 
that positive emotions may represent unique components of psychobiological resilience.59  
Interestingly, while there is strong evidence for a link between patient well-being and 
inflammation, Chapters 8 and 11 found no association between psychological distress, 
health status and BNP or NT-proBNP, indicating that these cardiac markers may be more 
closely related to disease severity than to psychological distress.     
 The association between psychological distress and inflammation seem to be strongly 
dependent on the sample composition, sampling method (i.e. clinical vs. community) and 
methodology. For example, a clinical diagnosis of depression seems to be more strongly 
related to inflammation than depressive symptoms, as measured by self-reported 
questionnaires.46 Furthermore, evidence on depression and anxiety suggest that the type of 
symptoms, clinical subtype of the disorder, and onset of the disorder may influence the 
relation with inflammation.60,61 The association between psychological distress and 
inflammation may mainly be driven by somatic symptoms of depression and anxiety rather 
than by cognitive symptoms.53 For depression, three clinical subtypes have been identified 
(i.e. catatonic, melancholic and atypical). The atypical depression subtype, which is marked 
by hypersomnia, fatigue and weight gain, seems to induce metabolic syndrome (i.e. elevated 
blood pressure, abdominal obesity) and higher levels of inflammation.62-64 Melancholic 
depression, which is marked by psychomotor disturbance, insomnia and weight loss, induces 
hypercortisolemia.65 The association between major depressive disorder, dysthymia and 
inflammation (i.e. IL-1β, IL-6, TNFα) show inconclusive results.66 These subtypes of 









and suggest that there may be a dose-response relationship between psychological distress 
and inflammation. In relation to the onset of depression, current evidence indicates that the 
association between depression and inflammation is more apparent in those who suffer 
from recurrent depression than in patients with a single episode of depression.67, 68 Contrary 
to acute stress, cortisol released through the HPA-axis response in chronic stress induces an 
upregulation of inflammation and the sympathetic nervous system.69    
       
To gain more insight into the psycho-neuro-immunological mechanisms linking psychological 
distress and health outcomes in patients with heart failure, more large-scale studies should 
address the heterogeneity of psychological distress. Furthermore, studies should examine 
the relation between different types of psychiatric disorders (generalized anxiety disorder, 
major depressive disorder, dysthymia, atypical depression, new-onset vs. recurrent 
depression) and their relation with inflammatory markers, behavioral factors and disease 
progression, thereby taking into account socio-demographic, socio-economic and 
personality factors. This will give us insight into the physiological distinction between heart 
failure patients suffering from psychological distress, resulting in the ability to better predict 
heart failure disease trajectories and to provide more effective psychological treatment 
options resulting in better treatment outcomes.  
 
Management and treatment of distressed heart failure patients 
Based on the current literature, monitoring psychological distress might not be beneficial 
due to a trade-off between the sensitivity and specificity of the screening instruments.6 
Furthermore, only a paucity of studies has evaluated psychological and pharmacological 
interventions in heart failure patients. The efficacy of interventions using education, 
telemonitoring and telephone support to improve patient-well being are mixed,70-73 as are 
interventions using cognitive behavioral therapy (i.e. identifying and challenging negative 
automatic cognitions and behaviors) as mainstay.74 By contrast in studies on ICD patients - 
that also include heart failure patients - cognitive behavioral therapy has shown to be 
effective in reducing psychological distress and improving health status.75-77 Interventions 
using exercise training showed a positive effect on quality of life in heart failure patients but 
not on anxiety or depression,78-80 while relaxation and mindfulness showed only short-term 




not alter these findings.83, 84 A recent multi-model intervention in LVAD patients, consisting 
of nutrition management, exercise training and psychosocial support, also found no impact 
on health status, anxiety and depression compared to a control group.85 Overall, various 
factors may be responsible for the small effect sizes of intervention studies such as 
competing priorities of the patients, the stigma of psychological distress, the financial and 
resource-intensive design of the interventions and by incorrectly addressing psychological 
distress (e.g. depression) as a homogeneous disorder.     
 Also pharmacological studies have found only small positive effects on depression in 
patients post myocardial infarction or with stable coronary heart disease.86-90 However, two 
seminal studies on patients with heart failure did not find an effect of citalopram or 
sertraline on depression nor any effects on cardiovascular outcomes.91, 92 Hence, based on 
this evidence and the results from Chapter 6, the value of psychopharmacological therapy in 
patients with heart failure remains uncertain, and psychotropic medication should only be 
administered after careful evaluation by a heart failure specialist. One has to keep in mind 
that different antidepressants can have a differential impact on inflammation and metabolic 
dysregulation,93 while inflammation and metabolic dysregulation may also impact on the 
efficacy of antidepressant use.60 Furthermore, it is important to discuss patients’ preferences 
for psychological versus pharmacological treatment when offering a treatment in order to 
enhance patient compliance.   
In order to provide effective treatment for heart failure patients suffering from 
psychological distress in the future, it is important to address the heterogeneity of 
psychological distress, to integrate needs and preferences of the individual patient and use a 
collaborative care approach in which primary care providers, cardiologists, heart failure 
nurses, and mental health professionals work together to provide optimal care and monitor 
patients’ progress. As addressed in Chapter 3 of this dissertation it is also very important to 
involve the partner in these interventions, as they may also suffer from severe distress which 
can have adverse effects on the health of the patient. Furthermore, getting patients involved 
regarding their own treatment by means of shared decision making is essential, as the 
efficacy of an intervention is greatly dependent on the motivation of the patient. A stepped 
care approach, in which patients can receive different types and intensities of services, might 
also help in providing the patient different alternatives depending on their own preferences 










This dissertation extends previous research on health status and psychological distress in 
patients with an ICD, CRT-D or LVAD. Including measures on the patient perspective is 
paramount in order to optimize patient-centered care and to bridge the gap between 
research and clinical practice. However, there is still much ground to be gained, with 
recommendations for future research and clinical practice outlined in Table 1. 
First, future research should enhance the knowledge on the well-being of LVAD 
patients using large scale prospective observational studies. LVAD therapy provides patients 
with end-stage heart failure a chance of survival and a better quality of life while waiting for 
a donor heart. However, dealing with device-, driveline- and medication related aspects of a 
LVAD remains challenging. The impact of LVAD therapy on patients’ lives is reflected in the 
citations below. 
 
Man (59 years) “Slowly I start to feel myself again and once in a while I even forget I have a 
LVAD. However, I do realize my life hangs by a thread (literally and figurative)”.  
 
Man (41 years) “My LVAD was implanted in an emergency care setting, I was therefore not 
able to choose whether I would want a LVAD. However, if they would have asked me again 
today I would have said YES”. 
 
Female (53 years) “Since I got the LVAD I can lead a normal life again. I am happy with my 
LVAD, it has become a part of me. However, I do look forward to having a heart transplant so 
that I no longer have any restrictions with playing sports, showering and swimming”. 
 
The success of LVAD therapy has generated debate about the severity of heart failure that 
should prompt implantation of the device, thereby increasing the group of patients who may 
benefit from this treatment.94 To deal with this growing group of patients it is crucial to gain 
insight into the complex nature of psychological distress associated with having an LVAD, 
including information on illness perceptions, personality, coping and social support but also 
on factors that may enhance adjustment such as optimism. Furthermore, research should 
shift its focus from presenting mean group changes of patient well-being scores to 




individual health status score trajectories which are only partially explained by measures of 
disease severity pre-LVAD, comorbidity and psychological distress. Identifying the predictors 
of these trajectories is crucial in order to better predict the post-implantation course, 
enhance the quality of care and improve the outcomes after LVAD therapy. Furthermore, 
LVAD patients and their partners who show chronic levels of anxiety and depression should 
be closely monitored and offered additional care.    
Second, in order to develop more efficient psychological interventions for heart 
failure patients it is important to enhance our understanding of the behavioral and biological 
pathways underlying the relationship between patient well-being and health outcomes. 
Research should focus on whether heart failure patients with different profiles of 
psychological distress show different pathophysiological characteristics, disease trajectories 
and outcomes (i.e., mortality, hospitalization) and arguably need different treatment options. 
This will provide the opportunity to tailor interventions to patients’ needs and increase the 
quality of care.            
Third, to increase the feasibility of measuring patient well-being and providing 
additional psychological care to heart failure patients, several issues have to be tackled. To 
save time and human resources it is important to examine rapid and efficient ways to 
administer, score and interpret scores on patient-well being. This can be done using new 
technologies (i.e. computerized assessment and scoring, mobile phone applications) that 
enables patients to complete measures at home or while they are waiting at the outpatient 
clinic. Although the current generation of heart failure patients might not yet be sufficiently 
acquainted with this technology, this will be an option in the near future. For the small group 
of heart failure patients who show signs of chronic distress, additional care or interventions 
should be in place to prevent adverse health outcomes. It is important to discuss with the 
patient the options for psychological treatment within or outside the hospital and start by 
providing additional care using a stepped-care approach (i.e. (web-based) educational 
session or relaxation therapy). The challenge will be to keep such patient care feasible in 
terms of human and financial resources in order to enhance the possibility that such 
interventions will become an integrative part of the clinical care of heart failure patients.
 Hopefully, the new insights from this dissertation and the recommendations for 
future research and clinical practice will help shed light on the pathophysiological processes 







development of effective multi-disciplinary interventions that will enhance survival and 
improve patient well-being.  
Table 1: Recommendations for future research and clinical practice
Future research Clinical practice 
 Examine rapid and efficient ways to
administer, score and interpret outcomes on
patient well-being in clinical practice
 Use (computerized) serial assessments
 Use outcomes on patient well-being as
primary outcomes in large-scale, well-
designed clinical trials
 Examine behavioral and biological
mechanisms underlying the relationship
between psychological distress and adverse
clinical outcomes
 Address the heterogeneity of psychological
distress in heart failure patients
 Examine the most appropriate timing of
psychological interventions and relative
efficacy of different interventions which
focus on:
 including exercise training and
mindfulness components
 patient tailored interventions using a
stepped-care approach
 including the patient’s family (partner,
children)
 web-based interventions
 Use disease-specific health status and
distress questionnaires to measure patient
well-being in heart failure samples.
 Create awareness of the importance of
patient-wellbeing in relation to clinical
outcomes, treatment expectations, self-
management and patient-physician
communication
 Provide additional (psychological) care to
patients whose health status and
psychological distress do not improve after
treatment
 Provide patient-centered care as much as
possible
 Include a mental health professional in the
multi-disciplinary heart failure team who has
sufficient knowledge of heart disease and
device therapy; if this is not possible refer to
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Hartfalen is een chronische aandoening waarbij het hart niet meer in staat is om voldoende 
bloed rond te pompen om aan de behoefte van de weefsels te voldoen, en wordt 
gekenmerkt door vermoeidheid en kortademigheid bij geringe inspanning. Oorzaken van 
hartfalen zijn een hartinfarct, hoge bloeddruk, een defect aan de hartkleppen, een 
hartritmestoornis of cardiomyopathie (‘hartspierziekte’). Cardiomyopathie kan verworven 
zijn (bijv. door alcoholgebruik of een infectie) of genetisch van aard zijn. Hartfalen is een 
veelvoorkomende aandoening met een hoge mortaliteit.      
 Er bestaan verschillende behandelopties voor hartfalen afhankelijk van de ernst van 
de aandoening, zoals medicatie, een implanteerbare cardioverter defibrillator (ICD), 
eventueel met resynchronisatie therapie (CRT-D), of een linker ventrikel assist device (LVAD). 
Een ICD registreert continue informatie over het hartritme en beëindigt eventuele 
hartritmestoornissen met snelle elektrische pulsen of een krachtige elektrische schok. Een 
CRT-D kan naast het beëindigen van hartritmestoornissen ook de pompfunctie van het hart 
verbeteren door met elektrische impulsen de linker- en rechterventrikel weer synchroon te 
laten samentrekken. Een LVAD zorgt voor een mechanische ondersteuning bij eindstadium 
hartfalen en dient als (tijdelijke) vervanging van harttransplantatie.    
 Hartfalen kan een enorme invloed hebben op het fysieke, sociale en psychologische 
welbevinden van patiënten. Hierdoor hebben patiënten met hartfalen vaak een lagere 
kwaliteit van leven en lijden ze vaker aan psychische klachten zoals angst en depressie. 
Eerder onderzoek heeft aangetoond dat het ervaren van psychische klachten kan leiden tot 
een hogere mortaliteit, meer ziekenhuisopnames en een lagere therapietrouw. De link 
tussen psychische klachten en slechtere gezondheidsuitkomsten kan gezocht worden in 
gedragsmatige en fysiologische factoren zoals het niet naleven van medicatie en levensstijl 
voorschriften (bijv. minder alcoholgebruik en meer lichaamsbeweging) en een verhoogde 
inflammatie. Inflammatie is een biologische reactie van het lichaam op stress, waarbij 
moleculen (cytokines) vrijkomen die het hartfalen kunnen verergeren.    
 Als gevolg van deze bevindingen zijn naast klinische factoren ook 
patiëntgerapporteerde uitkomsten (bijv. kwaliteit van leven) van steeds groter belang. 
Patiëntgerapporteerde uitkomsten zijn uitkomsten van vragenlijsten die door patiënten zelf 
worden ingevuld. Deze lijsten gaan bijvoorbeeld over de symptomen die patiënten ervaren, 




beleving van de patiënt ten opzichte van hun ziekte en/ of behandeling. Deze uitkomsten 
kunnen leiden tot een hogere kwaliteit van zorg doordat hiermee patiënten beter 
geïnformeerd kunnen worden over de gevolgen van een behandeling, en patiënten met 
langdurige of ernstige psychische klachten op tijd geïdentificeerd en geholpen kunnen 
worden. Bovendien kunnen de uitkomsten gebruikt worden om de effectiviteit van 
behandelingen te vergeleken en biedt het de mogelijkheid tot een meer individuele 
patiëntenbenadering.  
      
DOEL VAN DIT PROEFSCHRIFT 
In dit proefschrift is onderzoek gedaan naar de psychosociale aspecten van het leven met 
hartfalen (na een implantatie van een CRT-D of LVAD), de relatie tussen psychische klachten, 
inflammatie en mortaliteit en de determinanten van psychische klachten bij hartfalen 
patiënten. Om een beter beeld te krijgen van de psychosociale aspecten ligt de focus van dit 
proefschrift op patiëntgerapporteerde uitkomsten.     
 In deel 1 (Hoofdstuk 2-5) van dit proefschrift wordt een literatuuroverzicht gegeven 
van de gezondheidstoestand en psychische klachten van patiënten met een LVAD. Ook 
worden hierin de resultaten beschreven van een prospectief onderzoek onder LVAD 
patiënten en hun partners waarbij naar het verloop van gezondheidsstatus en psychische 
klachten wordt gekeken over de tijd, en de determinanten hiervan. Daarnaast wordt en in 
dit deel gekeken naar het aandeel van symptomen versus genetische belasting op 
gezondheidsstatus en psychische klachten bij patiënten met genetisch hartfalen (non-
compaction cardiomyopathie).          
 In deel 2 (Hoofdstuk 6 en 7) wordt met een literatuurstudie en een grote Deense 
patiënten dataset gekeken naar het verband tussen psychische klachten, het gebruik van 
antidepressiva en morbiditeit en mortaliteit.       
 In deel 3 (Hoofdstuk 8-11) wordt gekeken naar de relatie tussen gezondheidsstatus, 
psychische klachten en inflammatie bij verschillende groepen hartfalen patiënten. Hierbij 
wordt onderzocht in welke mate psychische klachten onafhankelijk zijn van de mate van 
ziekte ernst, of inflammatie een etiologische factor is in het ontstaan van depressie bij 
hartfalen patiënten, en of een verbetering in gezondheidsstatus en psychische klachten ook 










VOORNAAMSTE BEVINDINGEN VAN DIT PROEFSCHRIFT 
LVAD therapie wordt pas sinds enkele jaren op grote schaal toegepast als vervanging van 
harttransplantatie of brug-naar-transplantatie bij hartfalen patiënten. Hierdoor is er nog 
relatief weinig bekend over de psychosociale gevolgen van deze behandeling. Uit de 
bestaande literatuur (Hoofdstuk 2) en de ervaringen uit de dagelijkse praktijk (Hoofdstuk 3 
en 4) blijkt dat LVAD patiënten een sterke verbetering laten zien in gezondheidsstatus na de 
implantatie, onafhankelijk van het type LVAD en de implantatie strategie (urgent of semi-
selectief). Echter lijkt de gezondheidsstatus van de patiënten wel te stabiliseren na 3 tot 6 
maanden, en is er een grote mate van verschil tussen patiënten in het beloop van de scores 
welke maar deels werd verklaard door de ernst van de ziekte, co-morbiditeit en psychische 
klachten. Bovendien lijkt een deel van de LVAD patiënten psychische klachten zoals angst, 
depressie en post-traumatische stress (PTSD) te hebben, vooral kort na implantatie. Deze 
klachten lijken vaak het gevolg te zijn van complicaties, langdurige ziekenhuisopnames en 
vereiste LVAD trainingen. Ook de partners van de LVAD patiënten blijken een hoge mate van 
psychische klachten te ervaren, welke soms zelfs hoger zijn dan bij de LVAD patiënten zelf.
 Het welzijn van patiënten met non-compaction cardiomyopathie, welke in Hoofdstuk 
5 in beeld wordt gebracht, is tevens nauwelijks eerder onderzocht. Uit Hoofdstuk 5 blijkt dat 
de score op gezondheidsstatus en mate van psychische klachten bij non-compaction 
cardiomyopathie patiënten (NCCM) voornamelijk afhankelijk zijn van de symptomen van 
hartfalen en de daaruit voortvloeiende beperkingen en behandelingen (bijwerkingen van 
medicatie) en niet gerelateerd zijn aan de genetische belasting van de aandoening. Deze 
resultaten lijken aan te geven dat genetische screening voor hartfalen een geringe negatieve 
invloed heeft op het leven van patiënten, maar dat het wel van belang is nog meer 
onderzoek te doen naar de eventuele effecten van psychische klachten op het beloop van 
NCCM en andere erfelijke hartaandoeningen.      
 Het belang van het identificeren van een slechte gezondheidsstatus en psychische 
klachten blijkt uit de resultaten van Hoofdstuk 6 en 7 waarin een relatie wordt gevonden 
tussen psychische klachten, het gebruik van antidepressiva en een slechtere prognose en 
overleving. Hieruit blijkt verder dat men voorzichtig moet zijn met het voorschrijven van 
antidepressiva, vooral bij subklinische depressie, totdat er meer bekend is over de 
farmacologische, fysiologische en gedragsmatige mechanismen die verantwoordelijk zijn 




 Een van de mechanismen die in Hoofdstuk 9-11 verder is onderzocht is inflammatie. 
In de literatuur wordt vaak gesproken over een bi-directionele relatie tussen inflammatie en 
depressie, waarbij inflammatie depressie veroorzaakt en depressie leidt tot een hogere 
inflammatie. In Hoofdstuk 9 is onderzocht in welke mate depressie bij hartfalen patiënten 
geassocieerd is met inflammatie, ziekte ernst en persoonlijkheidsfactoren (Type D 
persoonlijkheid). Hieruit blijkt dat Type D persoonlijkheid een sterkere voorspeller was van 
depressie dan inflammatie en ziekte ernst. Het kan dus zo zijn dat slechts in een deel van de 
hartfalen patiënten inflammatie leidt tot depressie, of dat depressie eerder inflammatie 
voorspelt dan andersom. Verder is het van belang het onderzoek te herhalen met een 
uitgebreider scala aan psychosociale en gedragsmatige factoren.     
 Uit de assumptie dat depressie een negatieve invloed heeft op inflammatie vloeit 
voort dat wellicht positieve emoties, zoals optimisme en een betere gezondheidsstatus ook 
inflammatie zouden kunnen verlagen. In Hoofdstuk 10 blijkt inderdaad dat het ervaren van 
meer positieve emoties significant geassocieerd is met een lagere inflammatie (sTNFr2, TNFα, 
IL-6). Wel was de relatie tussen positieve emoties en inflammatie afhankelijk van het type 
instrument dat werd gebruikt om positieve emoties te meten. Dit geeft aan dat de positieve 
emoties die deze instrumenten meten niet identiek zijn.      
Hoofdstuk 11 laat zien dat patiënten die na een CRT-D implantatie verbetering 
ervaren in gezondheidsstatus ook een daling laat zien in de inflammatoire marker TNFα 
maar niet bij de andere markers. Verder bleek gezondheidsstatus niet geassocieerd te zijn 
met het cardiale hormoon brain natriuretic peptide (BNP). Het ontbreken van een relatie 
tussen objectieve parameters voor de ernst van hartfalen en patiënt-gerapporteerde 
uitkomsten werd al eerder gevonden in Hoofdstuk 8. Patiëntgerapporteerde uitkomsten 
lijken dus onafhankelijk te zijn van de ziekte ernst en moeten daardoor beschouwd worden 
als belangrijke risicofactoren voor de prognose van hartfalen. Uit Hoofdstuk 11 blijkt 
bovendien dat er een grote discrepantie zit tussen de verbetering van patiënten op 
gezondheidsstatus en de verbetering op de echocardiografie. Zo zijn er patiënten bij wie het 
hartfalen volgens de resultaten van de echo is verbeterd, maar die zelf geen verbetering 
ervaren, en andersom. Een verbetering op de echocardiografie was niet geassocieerd met 
inflammatie maar wel met het cardiale hormoon brain natriuretic peptide (BNP), waarvan de 










CONCLUSIES EN AANBEVELINGEN 
De bevindingen in dit proefschrift bevestigen het belang van patiëntgerapporteerde 
uitkomsten in hartfalen. De vooruitstrevende behandelmethoden van deze tijd maken het 
mogelijk een stijgend aantal patiënten met hartfalen in leven te houden en hun kwaliteit van 
leven te verbeteren. Hoewel het merendeel van de patiënten goed omgaat met een ICD, 
CRT-D of LVAD rapporteert een subgroep (≈25%) van deze patiënten psychische klachten 
(angst, depressie) welke kunnen leiden tot een slechtere prognose en vroegtijdig overlijden. 
Om dit te voorkomen is het van belang om patiëntgerapporteerde uitkomsten mee te 
nemen in de dagelijkse zorg van hartfalen patiënten om zo alert te zijn op eventuele 
psychische problemen en deze op tijd te behandelen. Verder is het meten van 
patiëntgerapporteerde uitkomsten ook een meerwaarde voor de kwaliteit van de zorg 
omdat het patiënten perspectief niet is af te leiden uit het medische dossier maar wel van 
groot belang kan zijn voor de arts-patiënt communicatie en het voorspellen van 
behandeluitkomsten. Verder biedt het meten van deze uitkomsten de mogelijkheid tot een 
patiënten benadering waarbij een arts het patiënt perspectief en de wensen en voorkeuren 
van een patiënt kan afwegen tegen de risico’s van verschillende behandelopties.  
 Het implementeren van patiëntgerapporteerde uitkomsten in de dagelijkse zorg van 
hartfalen patiënten is echter niet eenvoudig, vooral vanwege praktische aspecten zoals 
financiële middelen, de tijd en arbeidskracht die nodig is om de gegevens te verzamelen en 
te analyseren. Het is dus van belang dat toekomstig onderzoek zich richt op hoe patiënt 
gerapporteerde uitkomsten zo eenvoudig en efficiënt mogelijk kunnen worden toegepast 
(web-interventies, digitale testafnames). Ook moeten er meer onderzoek gedaan worden 
naar interventies voor hartfalen patiënten met psychische klachten waarbij rekening 
gehouden wordt met de heterogeniteit van de psychische klachten en de wensen van de 
patiënt. De heterogeniteit van psychische klachten kan namelijk samenhangen met 
specifieke biologische (inflammatie) en gedragsmatige mechanismen en ziekte beloop, 
waarvoor verschillende behandelopties nodig kunnen zijn. Verder is het van belang om te 
streven naar een multidisciplinair behandelteam waarbij patiënten met psychische klachten 
hulp kunnen krijgen van een maatschappelijk werkster of een psycholoog die voldoende 
kennis heeft van de specifieke problemen geassocieerd met het hebben van een ICD, CRT-D 
of LVAD. Hierbij is het aan te bevelen om ook de partners en andere familieleden van de 




negatieve invloed zouden kunnen hebben op de gezondheid van de patiënt.   
 Bij het gebruik van patiëntgerapporteerde uitkomsten dient een breed scala aan 
constructen meegenomen te worden om zo de complexiteit van psychische klachten in 
hartfalen patiënten te kunnen doorgronden. De keuze voor een bepaalde vragenlijst moet 
hierbij zorgvuldig worden afgewogen, afhankelijk van het doel (screening, kost-effectiviteit 
of behandeluitkomsten meten) en het gebruiksgemak (aantal subschalen, interpretatie 
scores). Vooral persoonlijkheid, coping, sociale steun, optimisme en levensstijl factoren 
(bewegen, roken, drinken) zijn hierbij van belang. In plaats van het bekijken van 
groepsgemiddelden op patiëntgerapporteerde uitkomsten is het van belang individuele 
score verloop te bekijken, en te zien hoe deze worden beïnvloedt.   
 Hopelijk zullen de inzichten van dit proefschrift en de aanbevelingen voor toekomstig 
onderzoek en praktijk helpen om de mechanismen tussen psychische klachten, biologische 
en gedragsmatige factoren en overleving te ontrafelen, patiënten met een hoog risico op 
psychische klachten op tijd te identificeren en succesvolle interventies te ontwikkelen die de 

























Toen ik vier jaar geleden na mijn studie begon met werken bij Medische en Klinische 
Psychologie op de Universiteit van Tilburg was het even wennen. Ik wist relatief weinig van 
psychologie maar toch waren mijn (destijds) toekomstige promotoren ervan overtuigd dat ik 
goed zou passen bij het onderzoek en het departement. Uiteindelijk kijk in terug op hele 
leerzame, inspirerende en gezellige jaren in Tilburg. Bij dezen wil ik graag een aantal mensen 
bedanken die een belangrijke rol hebben gespeeld in het tot stand komen van dit 
proefschrift.  
 
Allereerst wil ik heel graag de patiënten bedanken die hebben meegeholpen aan mijn 
onderzoek, zonder hun bijdrage was dit proefschrift er niet geweest. Een speciale dank gaat 
uit naar de LVAD patiënten, die ondanks de zware strijd die zij moesten leveren bereid 
waren om bij te willen dragen aan het onderzoek zodat wij meer inzicht hebben kunnen 
krijgen hoe het is om te leven met een LVAD. De persoonlijke verhalen, beproevingen maar 
ook de positiviteit van deze patiënten zullen me voor altijd bijblijven.  
 
Graag dank ik ook mijn promotoren: Prof. Dr. Susanne S. Pedersen en Prof. Dr. Johan 
Denollet voor het vertrouwen dat jullie in mij hebben gesteld maar ook vanwege de prettige 
samenwerking over de jaren. Jullie enthousiasme, inspiratie, betrokkenheid, eindeloze 
kennis en optimisme hebben mij ontzettend geholpen mijzelf verder te ontwikkelen, en te 
motiveren als ik mijn onderzoek even niet meer zag zitten of als een van mijn artikelen voor 
de zoveelste keer was afgewezen (When the going gets though, the though gets going ). 
Verder kijk ik met veel plezier terug op de interessante en leuke congresbezoeken met jullie 
naar Athene (American Pscyhosomatic Society -2012) en Madrid (Europace -2011), en ben ik 
dankbaar voor het mogelijk maken van mijn werkbezoek aan Kopenhagen en Bern waar ik 
ontzettend veel heb geleerd en genoten van de Danish pastries, fijne sfeer en mooie natuur.  
 
Beste Nicolaas en Kadir, bedankt voor jullie medewerking, belangrijke inzichten en hulp die 
het mogelijk hebben gemaakt om het LVAD project tot een goed einde te brengen. Ik heb 
ontzettend veel ontzag voor de manier waarop jullie in het UMC Utrecht en het Erasmus MC 
de zorg van de LVAD patiënten vormgeven en de patiënten weer de hulp en het vertrouwen 




andere cardiologen, Alina Constantinescu en Olivier Manintveld, en andere personen van 
het hartfalenteam, Ymkje, Marijtje, Nelienke, Ben, Hanneke, Nan en Albert ontzettend 
bedanken voor hun betrokkenheid bij de patiënten inclusie en/of artikelen. Naast het 
hartfalenteam wil ik graag ook Mathias, Linda, Cornelie, Marjolein en Thea van de afdeling 
Elektrofysiologie van het UMCU bedanken voor hun samenwerking, advies en gezellige 
momenten op het secretariaat en bij de kerstborrels . 
 
Dear Quincy, Colleen, Annemarie and Jennifer, thank you for the collaboration on the LVAD 
project. Your expertise, commitment and input helped making our project and publications a 
success, hopefully the knowledge gained from our study can help future research and clinical 
practice to improve the lives of LVAD patients.  
 
Dear Gunnar and Stefan, thank you for giving me the opportunity to visit Gentofte Hospital 
and work on the Danish patient registries. It has been a wonderful experience to work with 
you and your group. Tak og tage sig! 
 
Ook wil ik graag de leden van mijn promotiecommissie bedanken. Prof. Dr. Felix Zijlstra,  
Dr. Johan Brügemann, Prof. Dr. Brenda Penninx, Prof. Dr. Anne Roukema, Prof. Dr. Ad 
Vingerhoets en Prof. Dr. Frans Pouwer. Hartelijk dank voor de tijd en moeite die jullie 
besteed hebben aan het lezen van mijn proefschrift.  
 
Natuurlijk wil ik ook alle UvT (ex)collega’s bedanken voor alle gezellige momenten, hulp en 
advies over de laatste jaren. Wijo, Ivan, Nina en Paula, bedankt voor de leerzame 
samenwerking op enkele van mijn artikelen in dit proefschrift. Wobbe, door jouw geduld en 
enthousiasme voor statistiek is het gelukkig elke keer weer goed gekomen met alle analyses, 
heel fijn dat we altijd bij je terecht kunnen!  
 
Henneke, Mirela, Madelein, Mirjam en Nikki, oftewel het ‘Device-clubje’, jullie zijn 
onmisbaar geweest in de fijne werksfeer die ik in Tilburg heb mogen ervaren. Ik heb met 
veel plezier met jullie samengewerkt aan het opzetten van de Device Conference en ik heb 
ontzettend genoten van onze congressen, vooral de stapavonden in Madrid en Belgrado zal 









nachts !). Henneke, ik ben blij dat we de PSYHEART studie samen goed hebben kunnen 
afronden en dat ons artikel een mooi ‘thuis’ heeft gekregen, bedankt voor de fijne 
gesprekken en dat ik altijd bij je terecht kon als stief-co-promoter. Mijn kamergenootje 
Mirela, you are one of a kind, wat heb ik vaak moeten lachen om je verhalen en wat fijn we 
elkaar hadden om altijd positief te blijven en onze proefschriften tot een goed einde te 
brengen.  
 
Dan mijn lieve vrienden Linda, Eline, Marjolein, Priscilla, Eva, Vincent en Pieter. Bedankt voor 
jullie interesse, steun en advies al die jaren en het aanhoren van mijn (soms iets te 
enthousiaste) verhalen. Ik ben blij en dankbaar dat ik altijd bij jullie terecht kan en ik hoop 
dat we nog heel veel jaren samen kunnen genieten onder het genot van heerlijke theetjes, 
etentjes of (paar) flesjes wijn.  
 
Papa en mama, met jullie onvoorwaardelijke steun en liefde kan ik de wereld aan, het voelt 
goed om te weten dat jullie altijd achter me staan. Bedankt voor alles, ik hou van jullie! 
 
Lieve grote zus, vriendin en reismaatje, Esther, jij zorgt er altijd voor dat ik alles positief moet 
blijven bekijken en motiveert mij om er altijd op te vertrouwen dat alles goed komt, bedankt 
daarvoor. Samen hebben we behoorlijk wat grappige, spannende en mooie momenten 
beleefd op vakantie en daarbuiten die ik mij altijd zal herinneren, ik kan me geen betere zus 
wensen ! 
 
En ja, lieve Roland, wat ben ik blij met jou! Ik weet dan mijn eigenwijsheid, ‘druzigheid’, 
gekke buien en ongeduld niet altijd even makkelijk zijn om mee om te gaan, maar dat je 
ondanks dat houdt van wie ik ben. Dankjewel voor de liefde, steun en rust die je mij geeft, 
me helpt als het even tegenzit en in mij gelooft. Ik hoop dat we samen nog van vele mooie 
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